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Abstract 
 
Eukaryotic initiation factor 4E (eIF4E) is a key focus in cancer research due to 
its central role in controlling the translation of tumour-associated proteins that 
drive an aggressive migratory phenotype. eIF4E activity, modulated via its 
availability and phosphorylation are regulated by the PI3K/AKT/mTOR and 
mitogen-activated protein kinase interacting protein kinases (MNK1/2). The 
latter phosphorylates eIF4E on Ser209 whereas mTORC1 phosphorylates and 
de-activates the eIF4E inhibitor, 4E-BP1, to release translational repression. 
The work presented here describes the synthesis and characterisation of 4-((4-
fluoro-2-isopropoxyphenyl)amino)-5-methyl thieno[2,3-d] pyrimidine-6- carboylic 
acid, known as compound 1, a MNK1/2 inhibitor.  
 
Further analysis of compound 1 in combination with mTORC1/2 inhibitors show 
that inhibiting these pathways simultaneously effectively slows the rate of cell 
migration in MDA-MB-231 triple negative breast cancer (TNBC) cells. As an 
alternative approach, novel, cleavable dual MNK1/2 and PI3K/mTOR inhibiting 
hybrids were synthesised and characterised in MDA-MB-231 cells. These were 
found to be less effective at slowing cell migration than the combination of 
individual inhibitors. Molecular modelling of compound 1 revealed a large 
hydrophobic pocket which was exploited with a bulkier ferrocene group. Two 
novel ferrocene-containing compounds based upon compound 1 were 
synthesised and screened for MNK1/2 inhibition.  
 
To target migration more specifically, work was also carried out with an 
alternative translational protein, DDX3X. Both genetic knockdown and 
pharmacological inhibition alone and in combination with compound 1 reveal its 
potential as an anti-cancer target. 
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1 Introduction 
 
1.1 Introduction to Translational Control 
1.1.1 Cap-dependent Translation Initiation 
 
Translation can be divided into three phases: initiation, elongation and 
termination. Translation initiation begins with the formation of a complex on the 
mRNA, the large ribosomal subunit binds to the complex causing the release of 
initiation factors. The large subunit of the ribosome has three sites to which 
mRNA and tRNA molecules can bind to, these are the A site, P site and E site 
(Figure 1-1) (Clancy & Brown, 2008).  
 
Gene expression is regulated at both the transcriptional and post-translational 
levels. Translational control is critical for maintaining protein levels within the 
cell and achieving homeostasis. The majority of mRNA is translated by the cap-
dependent mechanism. This is primarily regulated at the level of the initiation 
phase and involves eukaryotic initiation factors (eIFs) and accessory proteins 
(summarised in Figure 1-2, Table 1-1 and reviewed in Sonenberg & 
Hinnebusch, 2009). Initiation factors coordinate vital checkpoints during this 
process and determine both whether a specific mRNA is translated, therefore, 
contributing to the total abundance of specific protein within the cell (Ruggero, 
2013).  
 
Prior to translation initiation, eIF3 binds to the 40S ribosomal subunit and 
contributes to the rate of association of the 40S and 60S subunits (Sonenberg & 
Hinnebusch, 2009). This allows the 40S ribosomal subunit to bind to eIF1A and 
the ternary complex, eukaryotic initiation factor 2 (eIF2)-GTP-methionyl tRNAi 
(eIF2-GTP-Met tRNAi). Additional factors such as eIF5 and eIF1 join to form a 
multifactorial complex (MFC) and lead to the construction of the 43S pre-
initiation complex (43S PIC). The 43S PIC then binds to the mRNA, together 
with the cap-binding complex eIF4F (eIF4E, eIF4G and eIF4A) at the 5’end of 
the mRNA (Ruggero, 2013). 
 
20 
 
Circularisation of the mRNA occurs when eIF4G binds to poly(A)-binding protein 
PABP, bringing together the 5’ and 3’ ends of the mRNA (Wells et al., 1998). 
eIF4B also binds to PABP (Bushell et al., 2001). eIF4G contains a binding site 
for eIF3, specifically interacting with the eIF3c, eIF3d, and eIF3e subunits, 
which also circularises the mRNA (Villa et al., 2013). Upon recognition of the 
correct start codon by ribosomal scanning, eIF5, a GTPase activating protein, 
induces the hydrolysis of eIF2-GTP. This triggers its release from the 48S 
complex along with other eIFs (Das & Maitra, 2001). 
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Figure 1-1. The large ribosomal subunit binds to the complex causing the release of 
initiation factors. The A (amino acid) site is where the aminoacyl-tRNA anticodon base pairs 
with the mRNA codon. The P (polypeptide) site holds the amino acid which is transferred from 
the tRNA to the growing polypeptide chain. The E (exit) site holds the tRNA without the amino 
acid, before it is subsequently released back into the cytoplasm. The elongation phase 
describes the process of the ribosome translocating from one codon to the next along the 
mRNA molecule in a 5’ to 3’ direction. The charged tRNA molecule that occupies the A site is 
shifted to the P site, where it is added to the growing polypeptide chain. The “empty” A site 
receives the next charged tRNA molecule and the process repeats itself until all of the codons in 
the mRNA have been read by the tRNA molecules. Termination occurs when a termination 
codon (UAA, UAG or UGA) is found in the protein-coding sequence. Adapted from Clancy & 
Brown, 2008. 
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Figure 1-2. Eukaryotic cap-dependent translation initiation. Eukaryotic initiation factors 
(eIFs) such as eIF1, eIF1A and eIF3 form a 43S pre-initiation complex (PIC), together with the 
ternary complex (eIF2-GTP-Met tRNAi), and the 40S subunit. After binding of the ternary 
complex to the 40S subunit, eIF5 interacts with eIF2. The mRNA is activated by the binding of 
the eIF4F complex (eIF4A, eIF4E and eIF4G) to the cap and PABP to the poly(A) tail, 
circularising the mRNA. The interaction of eIF3/eIF5 with eIF4G facilitates the binding of the 
43S PIC near the cap, forming the 48S initiation complex. This 48S initiation complex scans the 
5’leader for the AUG codon in an ATP-dependent reaction, partial hydrolysis of eIF2-GTP to 
eIF2-GDP also occurs. Upon start codon recognition, eIF1/eIF1A dissociates, allowing the 
release of eIF2-GDP +Pi. The joining of the 60S ribosomal subunit is promoted by eIF5B, along 
23 
 
with the release of other eIFs to yield the final 80S initiation complex and translation can then 
begin. eIF2B, a guanine nucleotide exchange factor, converts the inactive eIF2-GDP to the 
active eIF2-GTP allowing the ternary complex to be reformed. 
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Initiation 
Factor 
Subunits Function 
eIF1 Monomer 
Necessary for scanning and involved in initiation site selection. 
Promotes the assembly of 48S ribosomal complexes at the initiation 
codon. 
eIF1A Monomer 
Required for maximal rate of protein biosynthesis. Enhances ribosome 
dissociation into subunits and stabilises the binding of the initiator Met-
tRNA to 40S ribosomal subunits. 
eIF2 α, β, γ 
Functions in the early steps of protein synthesis by forming a ternary 
complex with GTP and initiator tRNA.  
eIF2B α, β, γ, δ, ε Catalyses the exchange of eIF2-bound GDP for GTP. 
eIF3 Multimeric 
RNA-binding component of the eIF3 complex, which is required for 
several steps in translation initiation. The eIF3 complex associates with 
the 40S ribosome and facilitates the recruitment of eIF1, eIF1A, eIF2-
GTP-methionyl-tRNAi and eIF5 to form the 43S pre-initiation complex 
(43S PIC).  
eIF4A Trimer 
ATP-dependent RNA helicase, which is a subunit of the eIF4F complex. 
Involved in cap recognition and required for mRNA binding to the 
ribosome. eIF4A unwinds RNA secondary structures in the 5'-UTR of 
mRNAs which is necessary to allow efficient binding of the small 
ribosomal subunit, and subsequent scanning. 
eIF4B Monomer 
Required for the binding of mRNA to ribosomes. A subunit of the eIF4F 
complex and functions in close association with eIF4A. Binds near the 
5'-terminal cap of mRNA and promotes the ATPase activity and the 
ATP-dependent RNA unwinding activity of eIF4A. 
eIF4E Monomer 
Recognises and binds the 7-methylguanosine mRNA cap during 
translation initiation and facilitates ribosome binding by inducing the 
unwinding of the mRNAs secondary structures. Component of the 
CYFIP1-eIF4E-FMRP1 complex which binds to the mRNA cap and 
mediates translational repression.  
eIF4E2 Monomer 
Recognises and binds the 7-methylguanosine-containing mRNA cap 
during an early step in the initiation. Acts as a repressor of translation 
initiation. In contrast to eIF4E, it is unable to bind eIF4G (eIF4G1, 
eIF4G2 or eIF4G3), suggesting that it acts by competing with eIF4E and 
block assembly of eIF4F at the cap. 
eIF4G1 Monomer 
Component of eIF4F complex. It is a multi-domain phosphoprotein that 
contains binding sites for eIF4E, eIF4A, MNK1/2 and poly(A)-binding 
protein (PABP). 
eIF4G2 Monomer 
Appears to play a role in the switch from cap-dependent to IRES-
mediated translation during mitosis, apoptosis and viral infection.  
eIF4G3 Monomer 
Probable component of the eIF4F complex and thought to be a 
functional homolog of eIF4G1. 
eIF4H Monomer 
Stimulates the RNA helicase activity of eIF4A in the translation initiation 
complex.  
eIF5 Monomer 
Catalyses the hydrolysis of GTP bound to the 40S ribosomal initiation 
complex, with the subsequent joining of a 60S ribosomal subunit. 
eIF5B Monomer 
GTPase that catalyses the joining of the 40S and 60S subunits to form 
the 80S initiation complex, with the initiator methionine-tRNA in the P-
site.  
eIF6 Monomer 
Binds to the 60S ribosomal subunit and prevents its association with the 
40S ribosomal subunit to form the 80S initiation complex in the 
cytoplasm.  Associates with pre-60S subunits in the nucleus and is 
involved in its nuclear export. Involved in miRNA-mediated gene 
silencing by the RNA-induced silencing complex (RISC).  
 
Table 1-1. Initiation factors and their role in translation. Data compiled using the UniProt 
database (www.uniprot.org/).
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eIF2B, a guanine nucleotide exchange factor, recycles eIF2-GDP back to its 
active form, eIF2-GTP (Webb & Proud, 1997). The formation of the 80S 
ribosomal complex is promoted by the dissociation of these factors and eIF5B, 
which regulates the association of the 40S and 60S ribosomal subunits 
(Pestova et al., 2000). The process of peptide bond synthesis can then begin 
(Klann & Dever, 2004, Sonenberg & Hinnebusch, 2009).  
 
1.1.1.1 The Roles of Specific eIFs 
 
eIF1 is a highly conserved protein that plays several roles in the regulation of 
translation initiation (Nanda et al., 2009). eIF1 cooperates with eIF1A in the 
MFC to promote ribosome scanning by stabilising the open conformation of the 
PIC, allowing the mRNA to pass through the complex (Passmore et al., 2007). 
Upon AUG codon recognition, eIF1 dissociates from the complex triggering a 
conformational change from an open form to a closed formation (Maag et al., 
2005). The dissociation of eIF1 is necessary to elicit downstream events in 
translation initiation, including the release of phosphate from eIF2 (Nanda et al., 
2009). Mutations in eIF1 weaken the binding of eIF1 to the PIC, leading to the 
release of eIF1 at non-cognate AUG codons, and alternative initiation codon 
selection (Nanda et al., 2009). 
 
eIF3 is the largest of the translation initiation factors and is composed of 13 
subunits (eIF3a-eIF3m) (Cate, 2017). Cryo-EM reconstructions have shown that 
eIF3 has a five-lobed structure, with highly flexible regions outside of its core 
(Querol-Audi et al., 2013, Siridechadilok et al., 2005) (Figure 1-3A). Genetic 
evidence has revealed multiple roles for eIF3. eIF3 wraps around the 40S 
subunit, preventing its association with the 60S subunit and also forms a 
scaffold for the assembly of other translation initiation factors (Figure 1-3B). In 
addition to its role in canonical cap-dependent translation, eIF3 also drives 
specialised translation (Lee et al., 2015). Recent work has discovered a novel 
translation pathway driven by the interaction of eIF3 with an internal RNA stem 
loop structure in a subset of mRNAs (Lee et al., 2016). eIF3 was found to both 
activate and repress translation in a transcript-specific manner, through the 
direct binding of a RNA stem loop in the 5’UTR (Lee et al., 2015).  
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Figure 1-3. The structure and roles of eIF3. A. Cryo-EM reconstruction of the core subunits of human eIF3 taken from Querol-Audi et al., 2013. B. eIF3 
(red) binds to the 40S ribosomal subunit (yellow). The ternary complex (TC) is also bound to the 40S subunit, forming the 43S pre-initiation complex. Taken 
from Cate, 2017. C. Mechanism of eIF3 binding to the m7GTP cap of c-jun mRNA. Adapted from Lee et al., 2016. The eIF3d subunit of eIF3 binds to the 
m7GTP cap to promote translation, following the recruitment of eIF3 to the stem loop in the 5’UTR of c-jun mRNA. An RNA element in the 5’UTR also prevents 
eIF4F recruitment to the m7GTP cap of c-jun mRNA.  
  
A. 
B. 
C. 
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For example, the translation of c-jun mRNA is activated by the recruitment of 
eIF3 to the 5’UTR. The eIF3d subunit recognises and binds to the cap (m7GTP) 
on the mRNA (Figure 1-3C). This mechanism allows specific mRNAs to be 
translated in conditions where eIF4F complex components are sparse. 
Interestingly, c-jun mRNA translation initiation complexes are depleted of the 
eIF4F complex and it has been hypothesised that c-jun mRNA contains an RNA 
element which blocks the recruitment of eIF4F (Lee et al., 2016). Additionally, 
eIF3 has been shown to directly bind to mRNAs containing N6-methyladenosine 
(m6A) in their 5’UTR. This post-translational modification is abundant under 
conditions of cell stress. The binding of eIF3 to m6A recruits the 43S pre-
initiation complex, promoting translation of the mRNA in the absence of eIF4E 
(Meyer et al., 2015). 
 
eIF4E recognises the 5’cap necessary for the start of cap-dependent translation 
initiation. Structural studies of eIF4E in complex with m7GTP/m7GpppA have 
elucidated a well conserved core structure of eIF4E, with highly flexible N- and 
C-terminal regions (Tomoo et al., 2002). Model studies by Ishida et al (1998) 
showed that the m7G moiety of the cap structure is sandwiched between the 
two aromatic side chains of Trp56 and Trp102 (Figure 1-4) (Ishida et al., 1988, 
Ishida et al., 1991). Two hydrogen bonds between the cap m7G amines and the 
oxygen in the carboxy group of Glu103 stabilise the stacking interaction. The 
first and second phosphate groups of the m7GpppA complex form direct or 
water-mediated hydrogen bonds with basic amino acids situated in the cap-
binding pocket (Arg112, Arg157 and Lys162). The third phosphate group of the 
m7GpppA complex forms a water-mediated hydrogen bond with the side chain 
of Arg112. The adenosine nucleoside of the m7GpppA complex is located in the 
C-terminal loop region of eIF4E, and forms water-mediated hydrogen bonds 
with Thr205 and Thr211. Van der Waals forces between the adenosine and 
Ser207 (and neighbouring residues) stabilise the interaction (Tomoo et al., 
2002). The adenosine is thought to be important for regulating the flexibility and 
orientation of the C-terminal loop region. 
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Figure 1-4. eIF4E in complex with m7GpppA (PDB code: 1IPB). A. The m7G moiety of the cap structure (grey) is sandwiched between the two aromatic 
side chains of Trp56 and Trp102 (purple).  B. Structure of the m7GpppA. The 5′ guanosine is methylated at the N7 position and is linked to the first nucleoside 
of the mRNA chain, adenosine, via an inverted 5′-5′ triphosphate bridge. C. eIF4E in complex with m7GpppA showing Ser209 orientated away from the cap-
binding region. Molecular graphics and analyses were performed with the UCSF Chimera package (Pettersen et al., 2004). 
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Biophysical studies on eIF4E-m7GTP complex suggest a probable two-step 
mechanism for binding. The negatively charged phosphate groups in the cap 
are thought to act as a molecular anchor, interacting with the basic residues of 
the cap-binding pocket, enabling the further formation of intermolecular 
interactions (Niedzwiecka et al., 2002).  It has been reported previously, that the 
formation of a competent interaction between the cap and the protein results 
from the recruitment of water molecules in the binding interface (Niedzwiecka et 
al., 2002). These water molecules are thought to be critical in the selectivity of 
the mRNA cap analogues (Lama et al., 2017).  
 
The structure of eIF4E resembles a cupped hand; the concave surface of eIF4E 
binds to the cap and the convex surface interacts with eIF4G (Morley et al., 
2005, Tomoo et al., 2002). Crystal structures of eIF4E in complex with eIF4G 
revealed an extensive, conserved eIF4E-eIF4G interface (Gruner et al., 2016). 
eIF4G was observed binding to the lateral surface of eIF4E in addition to the 
known dorsal aspect. The availability of eIF4E is regulated by eIF4E binding 
proteins (4E-BPs); these are discussed in detail below (Section 1.1.5.1) 
(Sonenberg & Dever, 2003, Sonenberg & Hinnebusch, 2009, Van Der Kelen et 
al., 2009). Both eIF4G and 4E-BPs compete for eIF4E binding, and the lateral 
surface of eIF4E is no longer exclusive to 4E-BPs (Gruner et al., 2016). This 
recent observation of an extended eIF4E-eIF4G interaction offers the 
opportunity to develop translational inhibitors with increased potency. 
 
The presence of the cap structure on eukaryotic mRNA facilitates the 
recruitment of eukaryotic initiation factors to allow ribosome binding and 
initiation at the correct start site (Morley et al., 2005). eIF4G functions as a 
scaffold protein, necessary for the coordinated attachment of translation 
initiation machinery and the ribosome to the 5’end of the mRNA (Sonenberg & 
Hinnebusch, 2009). It is a multi-domain phosphoprotein that contains binding 
sites for eIF4E, eIF4A, MNK1/2 and poly(A)-binding protein (PABP) (Mamane et 
al., 2006).  
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1.1.1.2 DEAD-box Helicases 
 
DEAD-box RNA helicases are ATP-dependent RNA-binding proteins, 
associated with the remodelling of RNA structures and RNA-protein complexes 
(Linder & Jankowsky, 2011). RNA helicases are characterised by two linked 
RecA-like domains (domains 1 and 2) that contain seven to eight conserved 
motifs (Figure 7.1), classified into superfamily 1 (SF1) or superfamily 2 (SF2) 
depending on their primary sequence (Soto-Rifo & Ohlmann, 2013). The DEAD-
box family of helicases belong to the SF2 superfamily and typically have the 
sequence Asp-Glu-Ala-Asp (DEAD) in motif II (Fairman-Williams et al., 2010).  
 
eIF4A, a member of the DEAD box RNA helicase family (Parsyan et al., 2011), 
is an abundant eIF and is present as part of the eIF4F complex. eIF4A is 
negatively regulated by pdcd4. The phosphorylation of pdcd4 by p70S6K results 
in its ubiquitination and subsequent degradation, permitting eIF4A to participate 
in the eIF4F complex (Yang et al., 2003). There are three isoforms of eIF4A; 
eIF4AI, eIF4AII and eIF4AIII. eIF4AI and eIF4AII have roles in protein synthesis, 
whereas eIF4AIII has been identified as a component of the exon junction 
complex (EJC) (Table 1-1) (Chan et al., 2004). 
 
eIF4A is brought to the 5’end of the mRNA where it directly interacts with eIF4E. 
eIF4A possesses weak bidirectional RNA-dependent ATPase helicase activity, 
stimulated by eIF4B, eIF4F and eIF4H (Grifo et al., 1984, Richter-Cook et al., 
1998, Rogers et al., 2001). Experiments showed ATP-dependent structural 
changes induced by the unwinding activity of eIF4A (Ray et al., 1985, Rozen et 
al., 1990). eIF4A resolves complex secondary structure in the 5’ untranslated 
regions (UTR) and facilitates scanning of the 43 initiation complex. eIF4A has 
the ability resolve most 5’UTR regions. Although, it has been observed that 
additional helicases are required to support cap-dependent translation in the 
case of 5’UTRs with multiple stem loops and a highly complex structure 
(Heerma van Voss et al., 2017). DDX3, another DEAD box helicase has been 
found to have potent unwinding activity and is involved in facilitating translation 
initiation by resolving complex structures in the 5’UTR (Marsden et al., 2006). 
Secondary structures, such as G-quadruplexes were found to be significantly 
31 
 
higher among (proto) oncogenes than tumour suppressor genes. Cancer cells 
rely heavily on RNA helicases to meet increased protein demand. These 
oncogenes have a greater dependency on RNA helicase activity in order to be 
expressed (Eddy & Maizels, 2006, Pickering & Willis, 2005). DDX3 was found to 
be required for the translation of several oncogenes with complex 5’UTRs, 
including cyclin E1 (Lai et al., 2010) and RAC1 (Chen et al., 2015). There is 
evidence for several roles of DDX3 in translation, although the exact 
mechanisms are yet to be fully investigated (see Figure 1-5).   
 
DDX3X is universally expressed in all tissues. Similar enzyme activity is 
observed with the Saccharomyces cerevisiae orthologue, Ded1p (Sharma & 
Jankowsky, 2014). DDX3X shares 92% sequence similarity with its human 
homologue, DDX3Y, which is specifically expressed in spermatocytes and 
associated with spermatogenesis (Ditton et al., 2004). Crystallographic studies 
of DDX3X have revealed a two-domain structure, with an N-terminal DEAD-box 
domain linked to a C-terminal helicase domain (Figure 1-6B and 1-7) (Hogbom 
et al., 2007). Sequence alignments have identified nine conserved motifs in the 
helicase core of DEAD-box proteins. Motifs Q, I (Walker A), II (Walker B) III, V 
and VI are involved in ATP binding and hydrolysis, whereas Motifs Ia, Ib, IV are 
involved in RNA binding (Figures 1-6B and 1-7) (Chang et al., 2006).  A specific 
DDX3 insertion between motifs I and Ia was recently found to be important for 
RNA interaction (Figures 1-6B and 1-7) (Garbelli et al., 2011). 
 
DDX3X demonstrates both nuclear and cytoplasmic function and recent work 
has identified DDX3X as a candidate for anti-viral therapy, due to its role in 
promoting viral replication (Garbelli et al., 2011). DDX3X is essential for the 
translation of HIV mRNA and was found to directly bind to the 5’UTR of HIV 
mRNA and interact with eIF4G and PABP. It was also observed that 
cytoplasmic DDX3X could be retained on an m7GTP affinity matrix 
independently of eIF4E.  
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Figure 1-5. DDX3 mediates cap-dependent translation. A. DDX3 facilitates the translation of 
complex secondary structure in mRNAs such as cyclin E1 and RAC1. B. DDX3 resolves 
complex structures in mRNAs within the vicinity of the m7GTP cap. C. DDX3 has an alternative 
role as a translational repressor through sequestration of eIF4E. 
  
A. 
B. 
C. 
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Figure 1-6. DDX3X gene and protein structure. A. Schematic representation of the DDX3X gene, with the 17 exons coloured in pink (not to scale). B. 
Schematic representation of the DDX3X protein showing the domain structure and conserved motifs. 
  
A. 
B. 
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Figure 1-7. Overall structure of DDX3X showing the two domains and the consensus motifs (PDB: 2I4I). The disordered linker region is depicted by 
dashed lines connecting the helicase domain and DEAD domain.
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This indicated that cytoplasmic DDX3X could assemble a pre-initiation complex 
on the HIV mRNA in the absence of eIF4E (Soto-Rifo et al., 2012, Soto-Rifo et 
al., 2013). The helicase activity of DDX3X has been proposed to enable the 
threading of HIV mRNA through the nuclear pore and into the cytoplasm, 
instigating a surge in the development of small molecule inhibitors which inhibit 
this interaction (Brai et al., 2016).  
 
DDX3X has been reported to be involved in many cellular processes, including 
miRNA biogenesis, transcriptional control, mRNA splicing and export of mRNA 
from the nucleus (Botlagunta et al., 2008; Zhao et al., 2016; Garbelli et al., 
2011; Soto-Rifo et al., 2013). However, one of the most extensively studied 
functions of DDX3X is in translational control. Direct interactions have been 
observed between DDX3X and eIF4E, and DDX3X and eIF4G (Shih et al., 
2008, Soto-Rifo et al., 2012). As with 4E-BP1, DDX3X physically interacts with 
eIF4E and contains a consensus eIF4E-binding motif (YIPPHLR). DDX3X traps 
eIF4E in a translationally inactive complex by blocking interaction with eIF4G; in 
this context, DDX3X appears to have a tumour suppressor role (Shih et al., 
2008). The role of DDX3X in translation appears to be heavily context 
dependent, reflecting its properties as both an oncogene and a tumour 
suppressor under different cellular conditions. DDX3X has been found to 
promote the translation of specific mRNAs containing highly structured 
sequences in their 5’UTRs, including cyclin E1, which facilitates G1/S transition 
and cell proliferation (Lai et al., 2008, Soto-Rifo et al., 2012). DDX3X also 
modulates efficient expression of RAC1, thereby regulating actin dynamics (Lai 
et al., 2010) and contributing to cell adhesion and motility (Gungabissoon et al., 
2003). The oncogenic properties of DDX3X are further supported by its role in 
the inhibition of apoptosis. DDX3X blocks tumour necrosis factor-related 
apoptosis-inducing ligand (TRAIL) mediated apoptosis by associating with the 
TRAIL receptor 2 and prevents apoptotic signalling (Li et al., 2006, Sun et al., 
2008). Overexpression of DDX3X in MCF10A cells also induces an epithelial-
mesenchymal transition (EMT) and promotes an aggressive cellular phenotype 
(Botlagunta et al., 2008).  
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DDX3X is known to contribute to the formation of cytoplasmic stress granules 
(Chen et al., 2015), which sequester mRNAs in response to exogenous or 
endogenous stress and, with the exception of some stress-related mRNAs, 
halts their translation (Anderson et al., 2009; Shih et al., 2012) . It can also 
inhibit influenza viral mRNA translation by binding to eIF4E-viral mRNP 
complexes, trapping them in a translationally inactive state and thereby 
sequestering the eIF4E–viral mRNPs into stress granules (Buchan et al., 2009). 
 
The role of DDX3X in cancer is controversial; DDX3X is a “double-edged sword” 
gene that can play a tumour suppressive or oncogenic role depending on the 
type of cancer (Zhao et al., 2016). DDX3X is frequently mutated in cancers such 
as chronic lymphocytic leukaemia (Ojha et al., 2015), lymphoma (Jiang et al., 
2015), head and neck squamous cell carcinoma (Stransky et al., 2011), breast 
(Botlagunta et al., 2008) and lung cancer (Bol et al., 2015). It is also one of the 
most frequently amplified genes in prostate cancer (Xie et al., 2016). Whole 
exome sequence analysis identified DDX3X amplification in 22% of 114 cases 
of prostrate cancer (Beltran et al., 2016), where it has the ability to promote cell 
migration and metastasis 
  
With so many potential regulatory roles in RNA metabolism, it is unsurprising 
that DDX3X has been a focus for the development of small molecule inhibitors. 
A ring-expanded nucleoside analogue (REN), NZ51, was originally trialled as an 
anti-viral agent for the treatment of HIV (Figure 1-8A). NZ51 was reported to 
inhibit DDX3X helicase activity and molecular modelling supported the 
hypothesis that NZ51 bound to the ATP-binding site of DDX3X (Xie et al., 
2015). NZ51 was investigated as an anti-cancer compound in vitro and showed 
promising activity. However, when NZ51 was trialled in the mouse model it 
showed no reduction in tumour size in comparison to untreated mice (Xie et al., 
2015). It is possible that structural features of NZ51 may be responsible for poor 
solubility and hence reduced distribution in vivo. More recently, a derivative of 
NZ51, with a third ring added to the 7-membered ring was synthesised. This 
tricyclic diimidazodiazepine analogue, termed RK-33 (Figure 1-8B), was 
reported to induce apoptosis, cause G1 cell cycle arrest, and also promote 
radiation sensitisation in DDX3X over-expressing cells. In addition, tumour 
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regression was demonstrated in pre-clinical mouse models when RK-33 was 
given in combination with radiation therapy (Bol et al., 2015).  
 
 
 
 
Figure 1-8. Chemical structures of DDX3X inhibitors. A. NZ51, B. RK-33. 
 
1.1.1.3 Alternative Mechanisms for Cap-dependent Translation Initiation 
 
In most eukaryotic mRNA’s, translation is initiated at the first AUG codon 
nearest the 5’end. However, there are several alternative mechanisms for cap-
dependent translation initiation. These include processes such as leaky 
scanning, termination re-initiation and ribosomal shunting.  
 
Leaky scanning may occur if the first AUG codon is found in a suboptimal 
context. For example, the canonical scanning model states that the 40S 
ribosomal subunit recognises and binds to the first AUG codon that occurs in 
the Kozak sequence (Kozak, 1995). The Kozak sequence has the consensus 
sequence gccGCCACCAUGG, and forms a favourable context for the 40S 
ribosomal subunit to initiate at the AUG site (Kozak, 1987). However, mutations 
to critical positions in the consensus sequence provide a suboptimal context for 
initiation. This often leads to the 40S ribosome bypassing the first AUG codon 
and initiating at a downstream site (Kozak, 1989).  
  
NZ51 RK-33 
A. B. 
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Termination re-initiation describes the process of ribosomal re-initiation at an 
internal downstream AUG codon, following termination of translation of an 
upstream reading frame. Ribosomes remain associated with the mRNA and are 
able to re-initiate downstream (Peabody & Berg, 1986). 
 
Ribosomal shunting is an alternative mechanism of cap-dependent translation 
often employed by viruses. Ribosomes bind to the 5’cap and physically bypass 
parts of the 5’UTR to reach the initiator codon. This allows the translation of 
downstream open reading frames in polycistronic mRNAs (Pooggin & Ryabova, 
2018). Ribosomal shunting supports the translation of specific mRNAs under 
conditions of stress, as it is less dependent on the scanning-mediated process 
mediated by eIF4F (Ryabova et al., 2002).   
 
1.1.2 Cap-independent Translation Initiation 
 
An alternate mode of translation initiation in eukaryotic cells bypasses the 
requirement for cap-dependent scanning. This allows the 40S ribosomal subunit 
to directly bind to sites on the mRNA, known as internal ribosome entry sites 
(IRES). The vast majority of IRES elements are located within the 5’ UTR 
immediately upstream of the initiation codon (Komar & Hatzoglou, 2011).  
 
Under normal cellular conditions the majority of mRNA translation initiation 
occurs by the cap-dependent mechanism, although cellular IRES support low 
levels of translation initiation of mRNAs containing cellular IRES with highly 
structured 5’ UTR that are incompatible with efficient scanning (Komar & 
Hatzoglou, 2011). However, under a variety of physiological and stress 
conditions, cap-dependent translation is compromised and translation initiation 
occurs largely via an IRES element. Cellular IRES sequences offer a cell the 
flexibility to switch to cap-independent translation initiation. For example, 
hypoxia inhibits cap-dependent protein synthesis but leads to translation of 
growth factors that promote blood vessel formation, including IRES-driven 
proteins such as the alpha subunit of hypoxia-inducible factor-1 (HIF-1) and 
fibroblast growth factor 2 (Jackson, 2013, Niepmann, 2009). 
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In silico analyses estimates that up to 10% of cellular mRNAs may contain an 
IRES element. This allows their translation to be maintained under conditions in 
which cap-dependent translation is inhibited, such as mitosis or physiological 
stress (Spriggs et al., 2008). Cap-independent translation generally has a 
reduced requirement for canonical translation initiation factors, such as eIF4E 
and eIF4G. In contrast, IRES trans-acting factors (ITAFs) have been identified 
for their role in modulating internal initiation (Komar & Hatzoglou, 2011). 
Although their mechanism of action remains unclear, ITAFs have several roles 
in modulating the translation of IRES-containing mRNAs. They may act as RNA 
chaperones, by stabilising the secondary structure of the IRES or by recruiting 
other proteins to the IRES element (Stoneley & Willis, 2004). IRES elements 
have differing requirements for specific initiation factors and ITAFs. The activity 
of a given IRES is cell-line dependent, due to the difference in the availability of 
ITAFs. For example, the c-myc IRES was found to be 20-fold more active in 
HeLa cells than in MCF7 cells (Stoneley et al., 2000). One of the most studied 
ITAFs, polypyrimidine-tract-binding protein (PTB), is an RNA binding protein 
that is required for most IRESs to function. ITAFs such as PTB may be positive 
or negative regulators of IRES activity (Cho et al., 2005, Kim et al., 2000). 
ITAFs have also been implicated in cancer; mutated IRES elements can alter 
the binding affinity of ITAFs, which in turn can lead to the dysregulation of 
cellular processes (Cobbold et al., 2008, Cobbold et al., 2010). 
 
1.1.3 eIF4E and its Role in Cancer 
 
eIF4E is a critical component of the eIF4F complex (eIF4E, eIF4A and eIF4G) 
and the level of eIF4E expression is an important determinant in the translation 
of mRNAs (Truitt et al., 2015). Although translation initiation is considered to be 
the rate-limiting step of protein synthesis and the primary level of modulation, 
recent work has found that substantial regulation also occurs at the elongation 
stage (Faller et al., 2015, Truitt & Ruggero, 2017). Cellular mRNAs differ in the 
amount of eIF4E required for their translation, and protein homeostasis is 
achieved by maintaining the translation of essential mRNAs and limiting the 
translation of proto-oncogenes. eIF4E is a general translation factor but has the 
potential to selectively enhance the translation of mRNAs that lead to the 
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production of malignancy-associated proteins (Hou et al., 2012). In addition to 
its cap-binding ability, eIF4E possesses a second function in translation 
initiation by strongly stimulating eIF4A helicase function (Feoktistova et al., 
2013). The generation of an eIF4E-haplo-insufficient mouse has challenged the 
dogma that eIF4E dose is limiting for normal development. Truitt et al (2015) 
found that a 50% reduction in eIF4E expression was compatible with regular 
development and global protein synthesis, revealing that eIF4E is present at 
levels exceeding those required for normal translational control. Interestingly, 
these mice were physiologically normal but resistant to neoplastic 
transformation. eIF4E appears to be limiting for the expression of oncogenic 
proteins and further enforces the importance of eIF4E in cancer development 
(Truitt et al., 2015, Truitt & Ruggero, 2017, Yanagiya et al., 2012). 
 
The overexpression of eIF4E leads to an increase in the translation of a subset 
of mRNAs that favour oncogenesis, in particular those with highly structured 5’ 
UTRs (Graff et al., 2008). Housekeeping mRNAs, for example, those encoding 
cytoskeleton proteins, require a low level of eIF4E, whereas proto-oncogenic 
and pro-survival proteins such as c-myc, cyclin D1, PIM1, survivin, BCL-2, 
VEGF, fibroblast growth factor 2 (FGF-2) and matrix metalloprotease -9 (MMP-
9) have a much higher dependency on eIF4E for translation (Grzmil et al., 2014, 
Lu et al., 2016). These mRNAs are termed “weak mRNAs” and are greatly 
influenced by an increase in eIF4E levels, observed in 30% of human cancers 
(Asimomytis et al., 2016, Feoktistova et al., 2013, Liu et al., 2016).  
 
A study proposed the mechanism by which eIF4E promotes the translation of 
specific mRNAs is by increasing their cytoplasmic levels and therefore the 
capacity of these mRNAs to associate and form the eIF4F complex. eIF4E 
stimulates the nuclear transport of mRNAs housing an eIF4E-sensitivity element 
(4E-SE), a ~50 nucleotide structurally conserved element in the 3’ UTR. This 
structural motif was found to consist of two adjacent stem loop pairs (SLP) 
(Culjkovic et al., 2006). Notably, mRNAs containing this motif encode proteins 
associated with growth and malignancy (Thumma et al., 2015). For example, 
eIF4E promotes the nuclear export of cyclin D1 mRNAs via an element in the 3' 
UTR of the target mRNA (Culjkovic et al., 2005). It has been proposed that 
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either eIF4E by itself binds both the mRNA cap and 4E-SE or that some other 
factors mediate 4E-SE sensitivity in the nucleus. eIF4E also regulates the 
expression of E3 ubiquitin-protein ligase (MDM2), an important negative 
regulator of p53 by promoting the export of the mRNA encoding MDM2 into the 
cytoplasm in a MNK1-dependent manner (Garcia-Recio et al., 2016, Phillips & 
Blaydes, 2008). 
 
The oncogenic potential of eIF4E has been recapitulated both in vitro and in 
vivo. A number of studies have found that high levels of eIF4E phosphorylation 
coincided with poor clinical outcome in human cancers (Bhat et al., 2015, Li et 
al., 2017, Mamane et al., 2007). One possible explanation for this is that the 
phosphorylation of eIF4E promotes expression of mesenchymal markers such 
as N-cadherin, fibronectin and vimentin, along with the acquisition of invasive 
properties (Robichaud et al., 2015). Additional studies found that eIF4E 
phosphorylation enhanced the nuclear export of cyclin D1 and Hdm2 mRNAs, 
subsequently increasing their concentration in the cytoplasm (Phillips & 
Blaydes, 2008, Topisirovic et al., 2004). It has been known for many years that 
overexpression of eIF4E leads to the transformation of immortalised murine 
fibroblasts and human epithelial cells in culture (Avdulov et al., 2004, Lazaris-
Karatzas et al., 1990, Ruggero, 2013). In one study, eIF4E overexpression was 
associated with an increase in cyclin D1 expression and a subsequent rise in 
cell proliferation (Rosenwald et al., 1993). Multiple studies have shown a link 
between increased eIF4E availability and tumourigenesis (Graff et al., 2007, 
Ruggero et al., 2004, Wendel et al., 2004, Wendel et al., 2007). High levels of 
eIF4E expression were also shown to promote the aberrant expression of 
tumour related proteins by positively regulating the expression of VEGF in a 
head and neck squamous cell carcinoma (HNSCC) cell line. Low levels of 
eIF4E were found to downregulate VEGF and MMP-2 and MMP-9 
simultaneously in colon cancer. MMP-2 promotes tumour invasiveness by 
degrading type IV collagen, a vital component of the basement membrane. The 
increase in expression frequency of eIF4E, VEGF-C, N-cadherin and MMP-2 
was associated with the depth of tumour invasion, lymph node metastasis and 
clinical stage in colorectal cancer (Gao et al., 2016).  
 
42 
 
1.1.4 Mechanisms for Regulating Translation 
 
Translational control of mRNA is critical for maintaining cellular homeostasis 
and for modulating rapid changes in the cellular concentrations of proteins. The 
majority of regulation occurs at the initiation stage of translation, summarised in 
Figure 1-9. Key mechanisms governing translation regulation include 
translational control via the cap-recognition process and a more selective 
process of translational control by microRNAs (miRNAs) (Sonenberg & 
Hinnebusch, 2009); reviewed in Eulalio (Eulalio et al., 2008). 
 
1.1.4.1 eIF4E-4E-BP1 
  
An extensively used mechanism to control the rate of translation initiation 
involves the mRNA 5′-cap recognition process by eIF4F. eIF4E-binding proteins 
(4E-BPs) inhibit the interaction between eIF4G and eIF4E in the eIF4F complex. 
4E-BP1 competes with eIF4G for a shared binding site on eIF4E (Figure 1-10) 
(Peter et al., 2015). The interaction strength of 4E-BP1 binding to eIF4E 
depends on the phosphorylation status of 4E-BP1 (Merrick, 2015). Hypo-
phosphorylated 4E-BP1 binds strongly to eIF4E whereas hyper-phosphorylated 
4E-BP1 weakens its interaction with eIF4E (Gingras et al., 2001, Hsieh & 
Ruggero, 2010, Sonenberg & Hinnebusch, 2009, Van Der Kelen et al., 2009).  
 
4E-BP1 contains at least seven sites of phosphorylation, of which four (T37, 
T46, S65, T70) are known to be regulated by mTORC1 and associated 
signalling pathways (Beugnet et al., 2003, Hsieh & Ruggero, 2010) (Figure 1-
11). Activated mTORC1 remains at the mRNA 5’ cap where it can promote cap-
dependent mRNA translation by phosphorylating and inactivating 4E-BP1, 
activating p70S6K and increasing overall protein synthesis by stimulating rRNA 
transcription and ribosome biogenesis (Laplante & Sabatini, 2012, Qin et al., 
2016).  
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Figure 1-9. Key components of major signalling pathways affecting protein translation. 
Growth factors bind to receptors including Receptor Tyrosine Kinases (RTKs) in the cell 
membrane, stimulating a cascade of signals. The activated RTK is phosphorylated on its 
tyrosine residues, GRB2 docks the phosphotyrosine residues via its SH2 domain and 
subsequently binds the guanine nucleotide exchange factor, SOS, by its SH3 domains. 
Activated SOS promotes the release of GDP from RAS, enabling the binding of GTP to form 
RAS-GTP. Activated RAS recruits RAF to the plasma membrane, where it phosphorylates and 
activates MEK1/2, which in turn activates ERK. ERK phosphorylates and activates many 
proteins including MNK1/2 and p90RSK. In addition, ERK phosphorylates and inactivates TSC2. 
MNK1/2 lie at the convergence point of both the p38MAPK pathway and ERK pathways and 
upon activation, phosphorylate eIF4E. Class I PI3 kinases are activated by RTKs resulting in the 
conversion of PIP2 to PIP3, a secondary messenger that is essential for AKT translocation to 
the plasma membrane. The level of PIP3 is negatively regulated by the tumour suppressor, 
PTEN. AKT is partially activated by PDK1 and becomes fully activated upon phosphorylation at 
Ser473, a process that can be catalysed by multiple proteins. mTOR forms two distinct 
multiprotein complexes, mTORC1 and mTORC2. mTORC1 comprises mTOR, regulatory-
associated protein of mTOR (RAPTOR), mammalian lethal with SEC13 protein 8 (mLST8), DEP 
domain containing mTOR-interacting protein (DEPTOR), proline-rich AKT substrate 40kDa 
(PRAS40) and the TTI1/TEL2 complex. mTORC2 comprises mTOR, mammalian lethal with 
SEC13 protein 8 (mLST8),  DEP domain containing mTOR-interacting protein (DEPTOR), the 
TTI1/TEL2 complex, rapamycin-insensitive companion of mTOR (RICTOR), mammalian stress-
activated map kinase-interacting protein 1 (SIN1) and protein observed with RICTOR 
(PROTOR). In response to stimulation, activated AKT phosphorylates and inactivates the TSC1-
TSC2 complex, which allows RHEB-GTP to activate mTORC1 on the lysosome. Activated 
mTORC1 complex stimulates protein translation by phosphorylating 4E-BP1 on several 
residues, releasing eIF4E allowing it to participate in translation initiation. In addition to 
phosphorylating other translational targets, mTORC1 also phosphorylates p70S6 kinase 
(p70S6K), which becomes fully activated following PDK1-mediated phosphorylation. p70S6K 
targets a number of proteins that control protein translation, including ribosomal protein S6, 
eIF4B and pdcd4. Low glucose levels and hypoxic conditions result in high AMP levels and lead 
to AMPK activation and subsequent mTORC1 inhibition. mTORC2 promotes cell survival 
through the phosphorylation of AKT on Ser473 and modulates the cytoskeleton following 
stimulation of cell growth. 
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Figure 1-10. Schematic of eIF4E bound to 4E-BP1 and eIF4G. A. 4E-BP1 interacts with 
eIF4E through a conserved motif, termed the canonical 4E-binding motif. 4E-BP1 also contains 
non-canonical 4E-binding motifs that bind to the lateral surface of eIF4E (PDB: 4UED). B. 
eIF4G contains the canonical 4E-binding motif and competes with 4E-BP1 for binding to the 
same site on the dorsal surface of eIF4E (PDB: 4UEC). Taken from Peter et al., 2015.
A. 
B. 
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Figure 1-11.  Schematic representation of the control of 4E-BP1 phosphorylation by growth factor-activated kinases. A. mTORC1 promotes the 
hierarchical phosphorylation of 4E-BP1. Hyper-phosphorylated 4E-BP1 is released from eIF4E, thereby allowing eIF4E to bind to eIF4G. B. The RAIP and 
TOS motifs present in 4E-BP1 are important for the phosphorylation of the protein. The N-terminal RAIP motif is required for the phosphorylation of T37, T46, 
S65 and T70, whereas the TOS motif binds to RAPTOR and regulates the phosphorylation of S65, T70 and the rapamycin in-sensitive S101 site (see text for 
details).
A. 
B. 
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1.1.4.2 CYFIP1-FMRP 
 
In addition to its role in cancer, translational control has also been implicated in 
neuropsychiatric disorders such as fragile X mental retardation (FMR) 
syndrome (Sonenberg & Hinnebusch, 2009) and autism (Bramham et al., 
2016). This is caused by mutated or reduced expression of fragile X mental 
retardation protein (FMRP), an RNA-binding protein that normally inhibits the 
translation of specific mRNAs. The loss of FMRP results in excessive synaptic 
plasticity and has been linked to intellectual defects, anxiety and repetitive 
behaviours. FMR syndrome is the most frequent monogenic cause of autism 
(Bramham et al., 2016). 
 
It has been reported that FMRP binds to eIF4E via CYFIP1 (cytoplasmic FMRP 
interacting protein 1), repressing the translation of specific mRNAs by displacing 
eIF4G (Figure 1-12) (Abekhoukh & Bardoni, 2014, Bramham et al., 2016, Napoli 
et al., 2008). CYFIP1 is best known for being a component of the Wiskott-
Aldrich syndrome family Verprolin homologous proteins (WAVE) regulatory 
complex (WRC), which is involved in actin remodelling (Bramham et al., 2016). 
However, in the context of eIF4E, CYFIP1 acts as a translational repressor with 
binding surfaces overlapping that found in common with eIF4G and 4E-BP1 
(Figure 1-10). 
 
In recent work, the MNK proteins, which phosphorylate eIF4E, have been 
implicated in the regulation of the CYFIP1-FMRP translational repressor 
complex in neuronal cells (Genheden et al., 2015, Panja et al., 2014). MNK1 
was found to be required for the activation of protein synthesis in response to 
brain-derived neutrophic factor (BDNF) and metabotropic glutamate receptor 
(mGluR) signalling in mouse cortical neurons (Genheden et al., 2015). MNK1 
activation promoted the release of CYFIP1/ FMRP from eIF4E, allowing the 
formation of the eIF4F complex and the subsequent translation of mRNA 
(Genheden et al., 2015, Panja et al., 2014). However, it is not known whether 
this reflected a conformational change in eIF4E following phosphorylation on 
Ser209 or direct phosphorylation of CYFIP1/FMRP by MNK proteins. 
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Figure 1-12. CYFIP1-FMRP translational repression. A. CYFIP1 in complex with FMRP binds 
to and inhibits the formation of the eIF4F complex and halts translation. B. MNK1/2 signalling 
phosphorylates eIF4E, stimulating the release of CYFIP1. eIF4E is free to participate in the 
eIF4F complex and translation begins (Adapted from Bramham et al., 2016).  
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1.1.4.3 eIF2 
 
eIF2 is a multimeric protein complex consisting of three subunits termed α, β 
and . The smallest subunit, eIF2α, contains a phosphorylation site on Ser51; 
four different protein kinases can phosphorylate this specific site leading to the 
blockage of guanine nucleotide exchange (Pavitt & Ron, 2012). The four protein 
kinases; HRI, PKR, GCN2 and PERK all phosphorylate this residue and elicit 
the same response involving the down regulation of general translation and the 
translational induction of specific transcription factor mRNAs (Jackson et al., 
2010, Wek, 2018). eIF2β contains phosphorylation sites for CK-II, PKC and 
PKA. The C-terminal portion contains a binding domain for the guanine 
nucleotide exchange factor, eIF2B. Both eIF5 and eIF2B compete for binding to 
eIF2β. eIF2B promotes eIF2 activity by exchanging GTP for GDP where as eIF5 
functions as both a GAP (GTPase activating protein) and a GDI (guanine 
nucleotide exchange inhibitor) by preventing nucleotide exchange. eIF2 binds 
GTP which is essential for binding Met-tRNAi to form the ternary complex 
(Hinnebusch & Lorsch, 2012, Pavitt & Ron, 2012). 
 
eIF2/GTP localises Met-tRNAi to the multifactor complex associated with the 
40S ribosomal subunit. As eIF2 is released from the ribosome as an eIF2/GDP 
complex, and eIF2 has a higher affinity for GDP than GTP, GDP bound to eIF2 
must be exchanged for GTP (Hinnebusch, 2005). This reaction is catalysed by 
eIF2B which is present in cells in limiting amounts relative to eIF2 levels. 
Phosphorylation of Ser51 of eIF2α increases the binding affinity of eIF2B to 
eIF2 and eIF2-GDP acts as a competitive inhibitor of the guanine nucleotide 
exchange reaction. This leads to the formation of an inactive eIF2-eIF2B 
complex; as eIF2B is present in limited amounts compared to eIF2, no ternary 
complex is formed and translation initiation is inhibited (Hinnebusch & Lorsch, 
2012, Pestova et al., 2001). Hence, a small increase in phosphorylation of 
eIF2α can have a large impact on protein synthesis initiation. For example, in 
amino acid starvation, free tRNAs accumulate, activating the kinase GCN2. 
GCN2 phosphorylates eIF2α, which inhibits the eIF2B-dependent GDP 
exchange and subsequent translation initiation (Harding et al., 2000, 
Hinnebusch, 2005).  
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1.2 The MAP Kinase-Interacting Kinases (MNKs) 
 
1.2.1 Overview 
 
The MAPK-interacting kinases 1 and 2 (MNKs) were first discovered in mice in 
1997 (Waskiewicz et al., 1997). The MNKs are serine/threonine protein kinases 
that lie downstream of both p38MAPK and ERK pathways (Figure 1-6), which 
are often subject to upregulation in tumour cells (Hou et al., 2012). These 
upstream kinases activate mouse MNK1 via phosphorylation on Thr197/202 
(Joshi & Platanias, 2014). The MNKs associate with the C-terminus of eIF4G, a 
vital interaction that brings the kinase into close enough proximity to 
phosphorylate eIF4E on Ser209 (Figure 1-4C) (Buxade et al., 2008, Mamane et 
al., 2006, Pyronnet et al., 1999). Serine/threonine-protein kinase PAK 2 (PAK2) 
can interfere with the MNK1/2-eIF4G interaction by phosphorylating the MNKs 
on specific threonine and serine residues resulting in decreased affinity for 
eIF4G (Orton et al., 2004). The phosphorylation of eIF4E enhances translation 
of specific mRNAs involved in cell survival (Beggs et al., 2015). A number of 
studies using a mouse lymphoma model have demonstrated that the 
phosphorylated form of eIF4E is required for the translation of a subset of 
mRNAs that oppose apoptosis and favour tumourigenesis (Bianchini et al., 
2008, Feoktistova et al., 2013, Furic et al., 2010, Grzmil et al., 2011, Joshi & 
Platanias, 2014, Wendel et al., 2007). The role of the MNKs has now been 
linked to the pathogenesis of many cancers (Diab et al., 2016, Kosciuczuk et 
al., 2016).  
 
1.2.2 Isoforms and Subcellular Distribution 
 
There are four human MNK isoforms; each MNK gene produces both a long 
isoform and a short isoform through variation in splicing (Figure 1-13) 
(O'Loghlen et al., 2004, Slentz-Kesler et al., 2000). The N-termini of all four 
isoforms are similar; each one containing a nuclear localization signal (NLS) 
and an eIF4G-binding site. The central region houses a kinase domain (Hou et 
al., 2012). The C-terminal region of the isoforms differs; the longer isoforms 
51 
 
(MNK1a and MNK2a) contain a MAPK binding site, which is lacking in the 
shorter isoforms 
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Figure 1-13. Schematic of the four human MNK isoforms. (NLS: nuclear localisation signal, 
NES: nuclear export signal). 
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(MNK1b and MNK2b) (O'Loghlen et al., 2004, Slentz-Kesler et al., 2000). The 
MNK1a MAPK binding domain interacts with both p38MAPK and ERK1/2, 
whereas the MNK2a MAPK-binding domain only binds to ERK1/2. This variation 
is reflected in a single amino acid change in the MAPK binding site and 
determines the difference observed in their regulation (Scheper et al., 2001). 
MNK1a has low basal activity, and is activated and tightly regulated by ERK and 
p38 kinases in response to mitogens and stress (Beggs et al., 2015, Ueda et 
al., 2004). MNK2 displays high basal activity and is predominantly regulated by 
ERK1/2, although MNK2a is regulated by mTORC1 through at least one site in 
its C-terminal region (Diab et al., 2014, Stead & Proud, 2013). 
 
There is speculation as to why mammalian cells possess two kinases that 
perform the same function but show a variation in basal activity. Knockout 
mouse studies have revealed that MNK2 maintains a basal level of eIF4E 
phosphorylation under conditions of starvation, where MNK1 is inactive, and 
ensures the synthesis of housekeeping proteins. Data show that changes in the 
phosphorylation status of eIF4E in response to growth factors and stress are 
MNK1-dependent (Cargnello & Roux, 2011, Scheper et al., 2001, Ueda et al., 
2004). MNK1a is primarily responsible for inducible activity as MNK1b lacks a 
MAPK binding site (O'Loghlen et al., 2004). The subcellular location of MNK 
isoforms likewise differs; MNK1 is predominantly localised in the cytoplasm. 
MNK1a contains a CRM1-dependent nuclear export signal (NES) in its C-
terminus, allowing its transport to the cytoplasm (Parra-Palau et al., 2003). 
MNK1b lacks a nuclear export signal, and is localised both in the nucleus and 
cytoplasm. MNK2a and MNK2b are predominantly nuclear (Bramham et al., 
2016, Garcia-Recio et al., 2016). MNK2b has been associated with eIF4E and 
nuclear bodies, implying that MNK2b is responsible for eIF4E phosphorylation 
in the nucleus (Scheper et al., 2003). Both MNK1 and MNK2 mRNAs have been 
found ubiquitously expressed in a variety of tissues by Northern blot analysis. 
Fan et al. (2016) recently observed a considerably higher percentage of active 
phospho-MNK in astrocytomas, further endorsing the role of active MNK in 
cancer (Fan et al., 2016, Scheper et al., 2001). High levels of phosphorylated 
MNK1 are also observed in HER-2 positive breast cancer and in glioblastoma 
multiforme primary tumours. Silencing of MNK1 through the transfection of a 
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U87MG glioma cell line with a small hairpin RNA attenuated eIF4E 
phosphorylation and reduced proliferation (Astanehe et al., 2012, Diab et al., 
2014). 
 
1.2.3 MNK Structure 
 
The crystal structures of MNK1 and MNK2 are available in the DFD-out (Asp-
Phe-Asp) conformation (Figure 1-14). Their catalytic domains share 78% 
sequence identity and the active sites are highly conserved (Beggs et al., 2015, 
Oyarzabal et al., 2010). MNK1 and MNK2 display the canonical bilobal 
arrangement of the ATP-binding cleft sandwiched in between the C-terminal 
and N-terminal lobes. The C-terminal lobe is predominantly α-helical and is 
composed of the activation segment, the P-loop and the catalytic loop; elements 
required for substrate binding and phosphate transfer. Kinase activation occurs 
when the activation loop is phosphorylated, resulting in a conformational 
change. The P-loop enables the optimal alignment of the phosphoryl groups of 
ATP, while the catalytic loop encompasses highly conserved residues vital for 
phosphotransfer. The N-terminal lobe comprises five β-strands and the 
regulatory αC-helix. The αC-helix is misaligned in inactive kinases and its 
correct alignment is required for ATP binding, and hence kinase activity 
(Kannan et al., 2015, Sebolt-Leopold & English, 2006). The conserved DFD 
motif marks the beginning of the activation loop (Hou, Teo et al., 2013, Kannan 
et al., 2015). The DFD motif (Asp191-Phe192-Asp193 in MNK1 and Asp226-
Phe227-Asp228 in MNK2) has less affinity for ATP than the equivalent DFG 
motif present in other kinases. This is due to a 180° rotation relative to the DFG 
motif, which locks the kinase in the DFD-out conformation. This unique structure 
coupled with specific regions of the catalytic domain (insertions 1-3) 
distinguishes the MNKs from other kinases and provide an opportunity to design 
specific MNK inhibitors (Figure 1-15) (Di Tommaso et al., 2011, Hou et al., 
2012, Jauch et al., 2005). 
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Figure 1-14. Apo-form of MNK1 in inactive conformation DFD-Out conformation (PDB ID: 2HW6). Structural elements coloured accordingly: N-terminal 
lobe (purple), C-terminal lobe (cyan), αC-helix (pink), hinge region (green), catalytic loop (orange), DFD-motif (grey), activation segment (red) and p-loop 
(gold). Auto-inhibition due to Phe230 in the activation segment pushing out Phe192 away from DFD towards the ATP binding site, obstructing the ATP binding 
pocket. Molecular graphics and analyses were performed with the UCSF (University of California) Chimera package (Pettersen et al., 2004). 
 
A. B. 
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Figure 1-15. Multiple sequence alignment of MNK1 and MNK2. The alignment was made 
with T-Coffee (Tommaso et al., 2011) and edited manually. A darker background indicates a 
higher conservation. Functional elements are colour-coded and labelled: αC-helix- pink; hinge 
region- green; catalytic loop- orange; DFD motif- grey; activation segment- red. Insertions that 
are specific for MNKs (I1–I3) are outlined.  
 
 
  
αC-helix 
Catalytic loop DFD Activation segment 
Hinge region 
I1 
I2 I3 
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1.2.4 Regulation of MNK Activity 
 
1.2.4.1 Upstream Signalling Pathways 
 
The MNKs bind to eIF4G, which brings them into close enough proximity to 
phosphorylate eIF4E (Shveygert et al., 2010). The MNKs lie at the convergence 
point of major intracellular signalling pathways (Figure 1-9). Depending on the 
isoform, MNKs can be activated by either ERK1/2 or ERK1/2 and p38MAPK 
(Cargnello & Roux, 2011). In mammalian cells p38MAPK isoforms are activated 
by environmental stresses or inflammatory cytokines (Cuadrado & Nebreda, 
2010). In addition activation can occur by the Rho family GTPases, RAC1 and 
CDC42, linked into cell architecture (Bagrodia et al., 1995). 
 
1.2.4.1.1 RAS-RAF-MEK1/2-ERK1/2 Pathway 
 
The RAS-RAF-MEK1/2-ERK1/2 pathway is a key intracellular pathway that 
regulates a breadth of cellular functions, including cell proliferation, cell survival 
and cell migration (Friday & Adjei, 2008). The importance of this pathway in 
numerous cellular processes and its implication in oncogenesis has made it a 
focus for therapeutic targeting. Multiple receptors are capable of activating the 
pathway, hence, a wide range of stimuli can initiate a cellular response. The 
canonical activation pathway is initiated by growth factors binding receptor 
tyrosine kinases at the cell surface and culminates in gene transcription in the 
nucleus (Yarden & Sliwkowski, 2001). Although the pathway is described as 
linear, considerable cross-talk occurs between numerous signalling cascades. 
The epidermal growth factor receptor (EGFR) pathway serves as a model for 
studying the RAS-RAF-MEK1/2-ERK1/2 signalling cascade, and is described 
below (Figure 1-16). 
 
Epidermal growth factor binds to the extracellular domain of EGFR. A 
conformational change leads to the dimerisation of the receptor and subsequent 
autophosphorylation of specific tyrosine residues leads to activation of the 
intracellular tyrosine kinase (Zhang et al., 2006). Adaptor proteins such as 
GRB2 connect RAS to the tyrosine kinase receptor.  
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Figure 1-16. The RAS-RAF-MEK1/2-ERK1/2 pathway. Epidermal growth factor (EGF) binds to 
receptor tyrosine kinase (RTK) at the cell membrane and activates the downstream signalling 
cascade. GRB2 docks the phosphotyrosine residues on the activated RTK via its SH2 domain 
and subsequently binds the guanine nucleotide exchange factor, SOS, by its SH3 domains. 
Activated SOS promotes the release of GDP from RAS, enabling the binding of GTP to form 
RAS-GTP. Activated RAS recruits RAF to the plasma membrane, where it phosphorylates and 
activates MEK1/2, which in turn activates ERK1/2.  
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GRB2 contains a SH-2 domain, which binds to the phosphotyrosine residue on 
the activated tyrosine kinase receptor. GRB2 interacts with RAS via guanine 
nucleotide exchange factors, such as SOS1 using two SH3 domains in the latter 
(Yamazaki et al., 2002). The RAS family of proteins are small G proteins with 
discrete domains for localisation of RAS to the membrane and regions for 
GDP/GTP binding. RAS has intrinsic GTPase activity, which switches the 
protein off, reverting it back to its inactive state. This activity is stimulated by a 
family of proteins, RAS-GAPs (GTPase activating protein). RAS is activated by 
guanine nucleotide exchange factors (GEF) which promote the exchange of 
GDP for GTP (Hallberg et al., 1994).  
 
RAS-GTP binds to and activates the serine/ threonine kinase, RAF, by 
recruiting it to the membrane where it is phosphorylated by an array of protein 
kinases. RAF activation also involves the release of an auto-inhibitory 
mechanism (Song et al., 2001, Tzivion et al., 2001). The binding of RAS-GTP to 
Arg89 of RAF is necessary for its activation by RAS-GTP (Fabian et al., 1994); 
activated RAF, functioning as a dimeric signal transducer propagates the signal 
away from the membrane by phosphorylating MEK1/2, dual tyrosine and serine/ 
threonine kinases. MEK1/2 go on to phosphorylate and activate their only 
known substrates, ERK1 and ERK2 (Cox et al., 2014).  
 
ERK1/2 are serine/threonine kinases that link the cytoplasmic signal to the 
regulation of gene expression. The signal to the nucleus occurs by a variety of 
mechanisms, including the direct translocation of ERK1/2. ERK1/2 is able to 
phosphorylate and activate transcription factors that regulate specific genes 
required for cell growth (Berti & Seger, 2017). The AP-1 transcription factor is 
one such target of ERK1/2. AP-1 is composed of jun and fos gene products, the 
expression of which are regulated by ERK1/2 (Glauser & Schlegel, 2007). 
Increased expression of both jun and fos genes result in an increase of AP-1 
activity, leading to an increase in activation of AP-1 target, cyclin D1, a crucial 
regulator of the cell cycle (Vartanian et al., 2011). 
 
ERK1/2 cytoplasmic targets include MNK1/2, (as discussed in Section 1.2.2) 
and p90RSK. Activated ERK docks with p90RSK at the C-terminus, where it 
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phosphorylates p90RSK on Thr365, Ser369 and Thr577 to activate the C-
terminal kinase domain. This phosphorylates Ser386 and generates a binding 
site for PDK1. PDK1 phosphorylates Ser277 in the N-terminal kinase domain 
resulting in activation (Cargnello & Roux, 2011). Upon activation, p90RSK 
phosphorylates multiple substrates and regulates many biological responses. 
The four isoforms of p90RSK have roles in nuclear signalling, cell cycle, cell 
proliferation, cell growth, cell survival and protein synthesis (Cargnello & Roux, 
2011). p90RSK isoforms have been found to phosphorylate rpS6 on Ser235 
and Ser236 in vivo, in response to RAS-RAF-MEK1/2-ERK1/2 stimulation. This 
facilitated the assembly of the pre-initiation complex and increased cap-
dependent translation (Roux et al., 2007). In addition, other substrates of 
p90RSK include TSC2 (Ma, Chen et al., 2005), RAPTOR (Carriere et al., 2008), 
eEF2 kinase (Wang et al., 2001) and eIF4B (Shahbazian et al., 2006), 
implicating the importance of p90RSK in mRNA translation. Recent work also 
shows that MNK1 can also be phosphorylated by p90RSK in a mechanism that 
confers trastuzumab resistance in HER-2 positive breast cancers (Astanehe et 
al., 2012). 
 
1.2.4.2 MNK substrates 
 
Whilst the MNK kinases phosphorylate multiple downstream targets, the only 
fully validated substrate is the cap-binding protein, eIF4E, discussed in Section 
1.1.1.1 MNK1 was also found to phosphorylate eIF4GI and eIF4GII in vitro 
(Pyronnet et al., 1999) but the functional consequences of this, if any, are not 
known. The following sections describe proteins that have also been identified 
as MNK substrates.  
 
1.2.4.2.1 Sprouty 2 
 
Sprouty2 (Spry2) acts as a negative feedback modulator of tyrosine kinase 
pathways. MNK1 was reported to phosphorylate Spry2 on conserved serine 
residues, Ser112 and Ser121, leading to an accumulation of Spry2 and its 
stabilisation (DaSilva et al., 2006). Spry2 activity can be rapidly modified 
through ERK signalling, since MNK1 activity is regulated by ERK1/2. A more 
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recent publication contradicts this finding, showing that MNK2 dependent 
phosphorylation of Sprouty2 promotes its degradation by the binding of Nedd4, 
a HECT domain family E3 ubiquitin ligase (Edwin et al., 2010). 
 
1.2.4.2.2 hnRNP A1 
 
The MNK kinases regulate tumour necrosis factor (TNF) α production, through 
the phosphorylation of AU-rich element binding proteins (ARE-BPs), such as 
heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) that bind to the 3’UTR 
of the TNFα mRNA and repress translation (Guil et al., 2006). hnRNP A1 is 
phosphorylated at two sites in vitro and in vivo by the MNKs in response to T 
cell activation, decreasing its binding to the TNFα mRNA (Buxade et al., 2005). 
hnRNP A1 is an abundant nuclear protein, involved in alternative splicing. 
hnRNP A1 shuttles continuously between the nucleus and the cytoplasm, and in 
addition to its role in splicing, is involved in mRNA export and regulation of 
mRNA stability.  
 
hnRNP A1 was also found to be present in stress granules. Stress granules are 
cytoplasmic aggregations that contain translationally stalled mRNAs, which 
accumulate in cells exposed to stress (Guil et al., 2006). Stress-induced 
phosphorylation of hnRNP A1 prevented its interaction with the import 
transporter, transportin, leading to its cytoplasmic accumulation (Allemand et 
al., 2005). In the cytoplasm, mRNA-bound hnRNP A1 is phosphorylated by the 
MNK kinases in response to stress stimuli, resulting in the recruitment of the 
mRNA-bound hnRNP A1 to the stress granule and its translational repression 
(Guil et al., 2006). 
 
1.2.4.2.3 cPLA2 
 
Cytoplasmic phospholipase A2 (cPLA2) catalyses the hydrolysis of arachidonic 
acid from membrane phospholipids. Arachidonic acid is involved in signalling 
processes, such as inflammation, and also provides a precursor for 
eicosanoids (Six & Dennis, 2000). There is evidence that MNK1 is responsible 
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for Ser727 phosphorylation of cPLA2 in thrombin- and collagen-stimulated 
platelets, enhancing its activity (Hefner et al., 2000). 
 
1.2.4.2.4 PSF 
 
In addition to the MNK kinases phosphorylating the ARE-binding protein, 
hnRNP A1, one study found that MNK2 phosphorylated another ARE-binding 
protein, polypyrimidine tract-binding protein-associated splicing factor (PSF) on 
Ser8 and Ser283 in vitro. MNK2-mediated phosphorylation of PSF was found to 
enhance its binding to the AREs in the 3’ UTR TNFα mRNA, inhibiting 
translation and providing further evidence for a regulatory role of the MNKs in 
inflammation (Buxade et al., 2008). 
 
1.2.5 MNKs in Cancer 
 
MNK1/2 present an attractive potential therapeutic target as they act at the 
convergence point of two critical signalling pathways, (the p38MAPK and ERK 
pathways). The MNK1/2 substrate, eIF4E, is also regulated by the mTORC1 
pathway, which is activated in about 70% of cancers (Hou et al., 2012, Joshi & 
Platanias, 2014, Ueda et al., 2010, Wendel et al., 2007). Mice with a targeted 
deletion of MNK1 and MNK2 exhibit a total lack of eIF4E phosphorylation and 
do not display developmental or reproductive defects (Grzmil et al., 2011, Joshi 
& Platanias, 2014, Ueda et al., 2004). Additionally, knock-in mice expressing a 
mutant form of eIF4E (S209A), which is unable to be phosphorylated by 
MNK1/2, show resistance to neoplastic transformation by c-myc, constitutively 
active RAS and PTEN loss-induced prostate cancer. These mice also exhibit a 
reduction in VEGF and MMP3 associated with tumour invasiveness (Furic et al., 
2010). Clinical development of MNK inhibitors may provide a means to 
selectively target cancer cells, as MNKs are dispensable for normal 
development. The treatment of acute myeloid leukaemia (AML) cell lines with 
MNK inhibitor, cercosporamide (Figure 1-17B) resulted in suppression of MNK 
kinase activity and leukemic progenitor cell growth. In addition, anti-leukemic 
effects were amplified when cercosporamide was used in conjunction with 
mTORC1/2 inhibitor, rapamycin (Figure 1-20A) (Altman et al., 2013). 
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                                                    Figure 1-17. Chemical structure of MNK inhibitors. 
 
A. B. C. 
64 
 
 
Recent findings indicate that MNK kinases act as negative feedback regulators 
in response to chemotherapy and hence, contribute to chemoresistance. The 
level of eIF4E phosphorylation significantly increased in cancer patients during 
treatment with doxorubicin and cyclophosphamide, the standard treatment for 
advanced stage breast cancer. The siRNA knockdown or pharmacological 
inhibition of MNK1/2 was found to enhance the chemotherapeutic response in 
both AML and advanced stage breast cancer cell lines (Altman et al., 2013, Li et 
al., 2017). 
 
1.2.6 MNK Inhibitors 
 
Until recently, there has been little progress made since the discovery of 
CGP57380 (Figure 1-17A), which exhibits low micromolar MNK inhibition (Teo 
et al., 2015a). CGP57380 inhibits both MNK1 and MNK2 and has subsequently 
been used in a number of studies (Bianchini et al., 2008, Chrestensen et al., 
2007, Grzmil et al., 2011, Knauf et al., 2001). Cercosporamide (Figure 1-17B), a 
natural anti-fungal agent, was found to be a potent inhibitor of MNK1/2, in the 
nanomolar range. However, its off-target effects limit its uses as an effective 
treatment as it also inhibits a number of other kinases, including Jak3 (Janus 
kinase 3), GSK3β (Glycogen synthase kinase 3β), ALK4 (Activin receptor-like 
kinase 4) and PIM1 (Serine/threonine-protein kinase pim-1) at low micromolar 
potency (Hou et al., 2012, Konicek et al., 2011, Liu et al., 2016). Both 
compounds have mainly served as pharmacological tools for MNK target 
validation due to the low potency of CGP57380 and the lack of specificity of 
cercosporamide. 
 
It is important to note that at this time there are no FDA approved drugs which 
specifically act on MNK kinases. However, recently two compounds have 
entered clinical trials. A small molecule MNK1 inhibitor, BAY 1143269 (structure 
unavailable), showed potent and selective activity against its target MNK1 (IC50: 
40 nM) and against cancer models both in vitro and in vivo (Santag et al., 
2017). A phase I dose escalation and expansion of oral BAY 1143269 in 
combination with intravenous docetaxel (a microtubule stabilising agent) trial 
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was undertaken; however, it was terminated early. eFT508 (Figure 1-17C), an 
orally bioavailable MNK1/2 inhibitor with an IC50 of 1-2 nM against both MNK 
isoforms in cell-free assays, is currently being investigated in several clinical 
trials (Reich et al., 2018). Following full characterisation in non-clinical safety 
pharmacology and toxicology studies, eFT508 is being evaluated in subjects 
with advanced triple negative breast cancer (TNBC), hepatocellular carcinoma 
(HCC) (Clinical trial ID: NCT03318562) and haematological malignancies 
(Clinical trial ID: NCT02937675). In addition, an on-going clinical trial is 
investigating eFT508 alone and in combination with Avelumab (a monoclonal 
antibody targeting the programmed death-1 (PD-1) receptor) in patients with 
microsatellite stable (MSS) colorectal cancer (Clinical trial ID: NCT03258398). 
eFT508 holds much promise for  targeting dysregulated translation in the 
clinical setting. 
 
1.3 mTOR 
 
1.3.1 mTOR Overview 
 
The mechanistic (formerly mammalian) target of rapamycin (mTOR) was 
identified in 1994 as the direct target of the rapamycin-FKBP12 complex in 
mammals (Sabatini et al., 1994). The mTOR pathway is highly conserved as a 
major growth regulator in eukaryotes. mTOR is a Ser/Thr protein kinase that lies 
downstream in the PI3K/AKT signalling pathway and coordinates cellular growth 
in response to nutrients and extracellular signals (Figures 1-9 and 1-18) (Saxton 
& Sabatini, 2017). mTOR belongs to the phosphatidylinositol 3-kinase (PI3K) 
family, and forms the catalytic subunit of two multiprotein complexes; mTORC1 
and mTORC2. mTORC1 is defined by the regulatory-associated protein of 
mTOR (RAPTOR) whereas mTORC2 is defined by the rapamycin-insensitive 
companion of mTOR (RICTOR) (see Figure 1-9) (Wang et al., 2013). 
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Figure 1-18. Schematic showing the signalling inputs sensed by mTORC1 and mTORC2 
and the processes they regulate to control growth and proliferation. 
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1.3.2 mTORC1 
 
1.3.2.1 Upstream of mTORC1 
 
mTORC1 is activated in nutrient rich conditions to stimulate cell growth and 
energy storage (Sabatini, 2017). mTORC1 is regulated by multiple upstream 
pathways, most of which signal through the tuberous sclerosis (TSC) proteins 1 
and 2, a tumour suppressor complex that inhibits RAS homolog enriched in 
brain (RHEB) by stimulating its GTPase activity. RHEB, in its GTP-bound form, 
binds directly to mTORC1 and is required for its activation (Figure 1-9) (Hay & 
Sonenberg, 2004). Proteins in these upstream pathways are commonly mutated 
in cancer and allow oncogenic signalling through mTORC1 (Saxton & Sabatini, 
2017). The activity of mTORC1 is coupled with amino acid concentration and 
the availability of growth factors (reviewed in Sabatini, 2017). In simple terms, 
mTORC1 regulation by amino acids involves Rag GTPases, heterodimeric 
proteins that are tethered to the lysosomal membrane. A high concentration of 
amino acids converts Rag GTPases into their active GTP-bound form, which 
enables them to bind to the regulatory protein, RAPTOR. mTORC1 is then 
recruited to the lysosomal membrane by RAPTOR where it localises with 
RHEB/GTP. mTORC1 signalling requires both Rag and RHEB GTPases for 
activation, ensuring mTORC1 is only active when nutrients and growth factors 
are available (Sancak et al., 2008, Saxton & Sabatini, 2017). Growth factor 
signalling through mTORC1 is primarily mediated by the PI3K/AKT pathway. 
Tyrosine kinase receptors at the cell membrane transduce the signal initiated by 
the binding of growth factors and hormones, such as insulin, leading to PI3K 
activation. PI3K stimulates AKT, which phosphorylates and inhibits TSC2, 
dissociating it from the lysosomal membrane and preventing its interaction with 
RHEB and its tumour suppressor function (Manning et al., 2002, Menon et al., 
2014).  
 
mTORC1 is also activated through RAS signalling, via ERK1/2 and p90RSK, 
both of which phosphorylate and inhibit TSC2, preserving RHEB/GTP levels 
(Ma et al., 2005, Roux et al., 2004). Additionally, the Wnt pathway and 
inflammatory cytokine, TNFα, both activate mTORC1 by inhibition of the 
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TSC1/2 complex (Inoki et al., 2006, Lee et al., 2007). Intracellular and 
extracellular stresses such as low levels of ATP, hypoxia or DNA damage elicits 
an inhibitory response from mTORC1, through the activation of AMPK (Figure 
1-6) (Saxton & Sabatini, 2017). mTORC1 is both directly inhibited by AMPK 
through the phosphorylation of adaptor protein, RAPTOR, and indirectly by the 
phosphorylation of TSC2; the latter activates TCS2 and reduces levels of 
RHEB/GTP (Gwinn et al., 2008, Inoki et al., 2003). Hypoxic conditions also 
induce the expression of protein regulated in development and DNA damage 
response 1 (REDD1), a protein that modulates TSC2 activity, leading to 
inhibition of mTORC1 (Morita et al., 2015). In response to DNA damage, DNA 
damage response (DDR) pathways induce the expression of P53 target genes, 
such as TSC2, AMPKβ and PTEN, all of which increase TSC1/2 complex 
activity and inhibit mTORC1 through regulation of RHEB/GTP levels (Feng et 
al., 2007).  
 
Signalling pathways involving mTORC1 are complex, and there are many 
negative loops which add a further level of regulation (summarised in Figure 1-
19). One such loop involves the phosphorylation of insulin receptor substrate 1 
(IRS1), either directly by activated mTORC1 or via mTORC1-activated p70S6K. 
This leads to its degradation and results in a decrease in PI3K/AKT signalling 
and subsequently a downregulation of mTORC1 activity (Cope et al., 2014, 
Rozengurt et al., 2014).  
 
1.3.2.2 Downstream of mTORC1 
 
In order to regulate cell growth, mTORC1 controls the balance between 
anabolic and catabolic processes. Cancer cells often hijack the 
PI3K/AKT/mTOR pathway in order to meet the demands of increased growth 
rate, as observed in patients with AML (Jhanwar-Uniyal et al., 2017, Showkat et 
al., 2014, Zhang et al., 2015). This involves an increase in protein, lipid and 
nucleotide synthesis and the suppression of autophagy. mTORC1 has a central 
role in stimulating protein synthesis through the phosphorylation of two key 
substrates, 4E-BP1 and p70S6K (Figure 1-9) (Hsieh et al., 2012, Morita et al., 
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2015). The interaction between eIF4G and eIF4E in the eIF4F complex is 
inhibited by 4E-BPs. 
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Figure 1-19. Negative feedback loops in the PI3K-mTOR and RAS-RAF-MEK1/2-ERK1/2 
pathways. Intrinsic negative loops stem from distal components of the same pathway, whereas 
extrinsic feedback loops originate from components of alternate pathways. Both intrinsic and 
extrinsic feedback loops inhibit upstream signalling nodes (coloured and numbered in red). 
Feedback loop (1): activated mTORC1 and p70S6K inhibits IRS1. Feedback loop (2): activated 
mTORC1/p70S6K disrupts mTORC2 via phosphorylation of SIN1, and subsequent dissociation 
from mTORC2 complex. Feedback loop (3): mTORC2 negatively feeds back to inhibit IRS1. 
Feedback loop (4): GRB10, is phosphorylated and activated by sustained mTORC1 activity, 
which potentiates its inhibitory effect on IGF receptor signalling. Adapted from Liu et al., 2015 
and Rozengurt et al., 2014). 
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4E-BP1 competes with eIF4G for a shared binding site on eIF4E, preventing the 
assembly of the eIF4F complex (Figure 1-11). The interaction strength of 4E-
BP1 binding to eIF4E depends on the phosphorylation status of 4E-BP1 
(Merrick, 2015). Hypo-phosphorylated 4E-BP1 binds strongly to eIF4E whereas 
hyper-phosphorylated 4E-BP1 weakens its interaction with eIF4E (Hsieh & 
Ruggero, 2010, Sonenberg & Hinnebusch, 2009, Van Der Kelen et al., 2009). 
4E-BP1 contains at least seven sites of phosphorylation, of which four (T37, 
T46, S65, T70) are known to be regulated by mTORC1 and associated 
signalling pathways (Figure 1-11A) (Hsieh & Ruggero, 2010). mTORC1 
phosphorylates p70S6K; a subsequent phosphorylation by PDK1 leads to its full 
activation and its release from eIF3 (Holz et al., 2005, Showkat et al., 2014). 
Active p70S6K subsequently phosphorylates several positive regulators of 
translation; ribosome protein S6 (rpS6), eIF4G and eIF4B. Additionally, p70S6k 
phosphorylates and promotes degradation of pdcd4, an inhibitor of eIF4A and 
fragile X mental retardation protein (FMRP), an mRNA binding protein (Guertin 
& Sabatini, 2007, Wang et al., 2012).  
 
In order to meet the demands of an increased growth rate, mTORC1 promotes 
nucleotide synthesis, required for DNA replication and increases overall protein 
synthesis by stimulating rRNA transcription and ribosome biogenesis (Laplante 
& Sabatini, 2012, Qin et al., 2016). mTORC1 also has a prominent role in lipid 
synthesis by promoting sterol responsive binding protein (SREBP) transcription 
factors, responsible for the expression of genes involved in fatty acid and 
cholesterol synthesis (Saxton & Sabatini, 2017). De novo lipid synthesis is 
required for the generation of cellular membrane during proliferation (Laplante & 
Sabatini, 2012).   
 
mTORC1 is a negative regulator of autophagy, an important cellular process in 
which damaged organelles and intracellular pathogens are degraded inside 
lysosomes (Showkat et al., 2014). mTORC1 on lysosomes phosphorylates unc-
51 like autophagy activated kinase (ULK1) and its positive regulator, autophagy-
related protein 13 (ATG13), inhibiting autophagosome formation (Chiarini et al., 
2015, Cope et al., 2014, Laplante & Sabatini, 2012). The phosphorylation of 
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ULK1 prevents its activation by AMPK, an important activator of autophagy 
(Saxton & Sabatini, 2017). 
 
1.3.3 mTORC2 
 
1.3.3.1 Upstream of mTORC2 
 
mTORC2 is an effector of the insulin/PI3K pathway, it responds to growth 
factors such as EGF (Figure 1-18). mTORC2 activity is stimulated by a mutation 
in EGFR in glioblastoma (GBM), leading to uncontrolled growth via the 
activation of NF-κB (Tanaka et al., 2011). Recent cryo-electron microscopy of 
mTORC2 has revealed distinct similarities and differences in comparison to 
mTORC1. The common regulatory proteins interact with mTOR in the same 
way for both complexes (mTORC1 and mTORC2). However, there are 
differences in the way that the other accessory proteins are arranged, which 
accounts for the variation in the roles of the mTOR complexes (Stuttfeld et al., 
2018). One such mTORC2 protein, mSin1, contains a phosphoinositide-binding 
PH domain that inhibits mTORC2 in the absence of insulin. This auto-inhibition 
is released by the binding of PIP3, the product of PI3K signalling, at the plasma 
membrane. This allows mTORC2 to partially activate AKT in a PI3K-dependent 
manner, discussed in the following section (Liu et al., 2015).  
 
mTORC2 signalling is also regulated by negative feedback loops involving 
mTORC1, which leads to an inhibition of the PI3K/AKT/mTORC1 pathway (Liu 
& Liu, 2014). An endogenous negative regulator of the insulin/insulin-like growth 
factor pathway, GRB10, is phosphorylated and activated by sustained mTORC1 
activity (Figure 1-19). GRB10 phosphorylation leads to its interaction with 
RAPTOR, an activator of mTORC1. GRB10 prevents RAPTOR binding to 
mTORC1 and suppresses mTORC1 signalling (Hsu et al., 2011). The 
downstream target of mTORC1, p70S6K, phosphorylates insulin receptor 
substrate 1 (IRS1), promoting its degradation and the suppression of mTORC2 
signalling (Shah et al., 2004). These negative feedback loops involving 
mTORC1 have repercussions for the therapeutic targeting of mTOR (Figure 1-
19). 
73 
 
 
1.3.3.2 Downstream of mTORC2 
 
mTORC2 is involved in cell survival and cell cycle progression through the 
phosphorylation of Ser473 on AKT, and through activation of serum- and 
glucocorticoid-regulated kinase (SGK) and protein kinase C (PKC) (Cope et al., 
2014, Hou et al., 2012, Laplante & Sabatini, 2012, Liu et al., 2013, Wang et al., 
2013). The full activation of AKT requires phosphorylation on Ser473 by 
mTORC2, alongside phosphorylation on Thr308 by PDK1. AKT phosphorylates 
FoxO1 and FoxO3, transcription factors involved in pro-apoptotic signalling in 
the absence of growth factors. AKT activation results in their exclusion from the 
nucleus and subsequent degradation, promoting cell survival (Guertin et al., 
2006, Tothova et al., 2007).  
 
1.3.4 mTOR and its role in Cancer 
 
mTORC1 lies downstream of commonly mutated PI3K/AKT and 
RAS/RAF/MEK/ ERK pathways and oncogenic signalling results in mTORC1 
hyperactivation in many cancers (Figure 1-9) (Saxton & Sabatini, 2017). 
Inactivating mutations in the tumour suppressor gene, PTEN, a phosphatase 
that antagonises PI3K function are a common feature in cancer cells (Jhanwar-
Uniyal et al., 2017). This causes an up-regulation of PI3K activity in the cell and 
constitutive stimulation of the PI3K/AKT/mTOR pathway (Bianchini et al., 2008, 
Hay, 2010). Activated mTORC1 has a multitude of consequences in cancer 
development, one of the most important being the mTORC1-dependent 
phosphorylation of 4E-BP1. This causes its release from eIF4E, driving eIF4F 
complex formation (Truitt et al., 2015, Truitt & Ruggero, 2017). Ribosome 
profiling studies using nano-cap analysis of gene expression (nanoCAGE) 
technology reveal that some mTOR translationally regulated mRNAs possess a 
5’ terminal oligopyrimidine tract, also termed 5’TOP (Gandin et al., 2016a, 
Gandin et al., 2016b). These mRNAs include those encoding YB1 (Y-box 
binding protein), vimentin, metastasis associated 1 (MTA1) and CD44, all of 
which have a significant role in the process of metastasis. Hyperactive mTOR 
signalling has a profound effect on the translational landscape of cancer cells by 
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positively regulating this four-gene invasion signature alongside metabolic 
effects (Alain et al., 2012, Hsieh et al., 2012). A hallmark of cancer cell 
reprogramming is the switch to aerobic glycolysis metabolism. Activated 
mTORC1 also increases the transcription and translation of HIF1α, which in turn 
regulates glycolytic genes, enabling the tumour cell to meet the high demands 
required for survival and progression (Slotkin et al., 2015, Zhang et al., 2015).  
 
mTORC2 activity has also been implicated in cancer, mainly due its role in the 
AKT-driven uptake of glucose and the inhibition of apoptosis (Hietakangas & 
Cohen, 2008). In mouse models of prostate cancer driven by PTEN loss, 
tumours were reliant on mTORC2 activity and the mTORC2 specific regulator 
protein, RICTOR, was found to be essential (Guertin et al., 2009). There is also 
evidence that both mTORC1 and mTORC2 are implicated in the epithelial-
mesenchymal transition (EMT) (Gulhati et al., 2011). EMT in relation to cancer 
can be defined as the conversion of differentiated epithelial cells into migratory 
mesenchymal cells through the loss of epithelial markers and the gain of 
mesenchymal markers (Tiwari et al., 2012). This is thought to occur in part, 
through the modulation of genes that code for proteins associated with 
cytoskeleton rearrangement, such as RhoA, RAC1 and CDC42 GTPases. 
mTORC1 mediated signalling also plays a role in the phosphorylation of focal 
adhesion proteins and the promotion of cell motility (Zaytseva et al., 2012). 
 
1.3.5 mTORC1/2 Inhibitors  
 
Rapamycin (Sirolimus), the first known inhibitor of mTOR was isolated from the 
bacteria, Streptomyces hygroscopicus, inhabiting the soil in Easter Island 
(Sehgal et al., 1975, Vezina et al., 1975). Its antifungal properties were eclipsed 
by its potent immunosuppressant ability, which led to its licensing under the 
brand name Rapamune (Pfizer), for use in renal transplantation (Johnson, 
2002). The discovery of rapamycin has since led to the development of 
synthetic analogues, known as “rapalogs”. These compounds have been 
developed by modifying the C40 hydroxyl group to improve the pharmokinetics 
of rapamycin. These include everolimus (Norvartis) and temsirolimus (Pfizer) 
(Figure 1-20), which have superior aqueous solubility without the loss of 
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immunosuppressant properties. Everolimus is modified at the C40 position by 
the introduction of a 2-hydroxyethyl group and temsirolimus is the ester 
derivative of rapamycin (Gu et al., 2005, Sedrani et al., 1998). 
 
Rapamycin and rapalogs are allosteric inhibitors of mTORC1, and work by 
recruiting FKBP-12, an accessory protein, to the FRB domain of mTOR. The 
formation of this drug–protein complex causes a conformational change in 
mTORC1, distal from the kinase domain, leading to its inhibition (Liu et al., 
2012, Showkat et al., 2014). Recent structural studies have further elucidated 
the mechanism by which rapamycin inhibits mTORC1 (Aylett et al., 2016). In 
contrast, the rapamycin-FKBP complex does not target mTORC2 directly, 
although prolonged treatment (24 hours) leads to inhibition through the 
disruption of mTORC2 signalling (Jacinto et al., 2004). Rapamycin-FKBP binds 
to free mTOR and prevents its incorporation into mTORC2 (Sarbassov et al., 
2006).  
 
Deregulation of the mTOR pathway is correlated with poor clinical outcome and 
drug resistance (Slotkin et al., 2015). There are currently only two FDA 
approved mTOR inhibitors available for cancer treatment (temsirolimus and 
everolimus). However, both have had limited success in the clinic due several 
factors. Rapamycin and rapalogs fail to block the phosphorylation of all 
mTORC1 substrates, in particular 4E-BPs (Thoreen et al., 2009). In fact the 4E-
BP/eIF4E ratio can be used to predict the sensitivity of cancer cell lines to 
mTOR inhibitors (Alain et al., 2012). In one study, rapamycin treated myeloma 
cells led to the phosphorylation and activation of MNK1 along with its target, 
eIF4E (Bianchini et al., 2008, Joshi & Platanias, 2014). Furthermore, the 
inhibition of mTORC1 can lead to the activation of AKT, promoting cell survival 
and preventing apoptosis (Figure 1-19) (Sarbassov et al., 2005). Rapalogs have 
had some success in cancers with mutations in the components of mTOR 
pathway itself (Iyer et al., 2012, Wagle et al., 2014).  
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Figure 1-20. Chemical structures of mTOR inhibitors. 
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However, after an initial response to treatment, the cancer gained acquired 
resistance (Wagle et al., 2014).   
 
“Second generation” mTOR catalytic site inhibitors hold much promise due to 
their potent inhibition of both mTORC1 and mTORC2, thus attenuating the 
feedback mechanism involving AKT phosphorylation (Efeyan & Sabatini, 2010, 
Liu, Wang et al., 2011, Powles et al., 2016). These inhibitors are ATP 
analogues that contain a heterocyclic structure to exploit the adenine-binding 
pocket and can form hydrogen bonds with the hinge region of the kinase 
(Basnet et al., 2015). Type II inhibitors (discussed in more detail below) 
introduce additional specificity by binding not only the ATP pocket but also an 
adjacent allosteric pocket (Wu et al., 2016, Zhao et al., 2014). The recently 
solved crystal structure of the mTOR kinase domain in complex with ATP-
competitive inhibitor, PP242 (Figure 1-20D), will no doubt facilitate the design 
and synthesis of further active-site (catalytic) mTOR inhibitors (Rodrik-
Outmezguine et al., 2016, Yang et al., 2013). However, long-term treatment of 
catalytic inhibitors eventually leads to the release of negative feedback on the 
insulin/PI3K signalling pathway and AKT is reactivated via phosphorylation on 
Thr308. The initial suppression due to mTORC2 inhibition is overcome (Rodrik-
Outmezguine et al., 2011). This has led to the concept of dual PI3K/mTOR 
inhibitors as a possible solution to block negative feedback stimulation of AKT. 
The similarity in the C-terminal kinase domain of both mTOR and PI3K allows 
the development of single compounds with dual inhibitory properties (Zheng & 
Jiang, 2015). Dactolisib (Novartis) (Figure 1-20E) is an imidazoquinoline 
derivative capable of binding to the ATP binding sites of both mTORC1/2 and 
PI3K (p110α, γ, δ, β) (Maira et al., 2008). Studies using Dactolisib found that 
dual inhibition of PI3K/ mTOR had a stronger anti-proliferative activity than 
inhibiting mTOR alone (Serra et al., 2008).  
 
A new class of mTOR inhibitor has recently been developed that chemically 
links a catalytic site inhibitor with an allosteric inhibitor. This novel inhibitor, 
known as “Rapalink” allows simultaneous inhibition of both the ATP- and FRB-
binding sites of mTOR. The bivalent interaction overcomes resistance to 
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existing inhibitors and was found to potently inhibit cancer cell growth in vitro 
(Figure 1-20F) (Renna, 2016). 
 
The effects of mTOR inhibition are multifaceted, owing to the diverse functions 
of both complexes. For example, although acute mTORC1 inhibition 
suppresses global protein translation, it primarily affects mRNAs containing a 5’ 
TOP. These mRNAs are typically involved in protein synthesis (Hsieh et al., 
2012). mTORC1 inhibition is also correlated with an increase in proteasome-
dependent proteolysis and the induction of autophagy, which enables cancer 
cell survival in nutrient poor microenvironments (Palm et al., 2015, Zhao et al., 
2015). It is therefore worth considering the repercussions of mTOR inhibition 
when implementing a therapeutic approach to target cancer.  
 
1.3.5.1.1 Protein kinase inhibitors 
 
Protein kinases are a large family of enzymes that transfer a γ-phosphate from 
ATP to a tyrosine, serine or threonine residue on the protein substrate (Bhullar 
et al., 2018). Protein kinases are classified into two main categories: serine/ 
threonine kinases and tyrosine kinases. A group of dual-specificity kinases that 
phosphorylate both tyrosine and serine/ threonine residues have also been 
identified (Garcia-Aranda & Redondo, 2017). Aberrant protein kinase activity or 
kinase over-expression often promotes cell survival and drives cellular 
pathways that are implicated in oncogenesis (Kittler & Tschandl, 2018, Maurer 
et al., 2011, Paul & Mukhopadhyay, 2004).  
 
The majority of protein kinase inhibitors target the ATP-binding site, which is 
sandwiched between the N-terminal and C-terminal lobes of the enzyme. The 
“hinge region” connects the two lobes of the enzyme and residues in this region 
often make hydrogen bonds with kinase inhibitors (Bhullar et al., 2018). The 
activation loop of the kinase determines the activity of the enzyme and occurs in 
the open (active ATP-bound) or closed (inactive) conformation. Phosphorylation 
of specific residues by upstream kinases on the activation loop alters the 
position of the N-terminal DFG (Asp Phe Gly) motif. This allows the Asp in the 
DFG motif to coordinate the magnesium ion, which positions the phosphates 
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belonging to ATP for phosphotransfer. In addition, the Phe residue is also 
orientated towards the binding pocket (DFG-in) and is important for the correct 
positioning of the activation loop for catalysis (Cowan-Jacob, 2006, Fabbro et 
al., 2015). Once the phosphoryl group is transferred from ATP to the substrate 
protein, the kinase reverts back to its inactive (DFG-out) conformation (Cowan-
Jacob, 2006). In the inactive form, an additional hydrophobic pocket is exposed. 
This provides an opportunity to design kinase inhibitors that bind to and stabilise 
the inactive form (Garuti et al., 2010). 
 
Protein kinase inhibitors are classified according to their binding mechanism. 
Type I inhibitors are ATP-competitors that mimic the adenine moiety of ATP and 
bind to the kinase in the active conformation. Type I inhibitors display low 
selectivity due to the conservation of the ATP-binding site throughout the 
kinome, resulting in a significant number of off-targets effects (Bhullar et al., 
2018). Lapatinib is a type I kinase inhibitor FDA-approved for the treatment of 
metastatic HER2+ breast cancer. Lapatinib is a dual tyrosine kinase inhibitor 
that targets the HER2 and EGF receptors (Higa & Abraham, 2007, Segovia-
Mendoza et al., 2015). It is also used in combination with anastrazole for post-
menopausal breast cancer that co-expresses HER2 and hormone receptors 
(Johnston et al., 2009). Palbociclib is also a type I inhibitor; binding to the ATP-
binding pocket of the kinase in its active (DFG-in) conformation (Roskoski, 
2016). Palbociclib inhibits the cell cycle and is a selective cyclin-dependent 
kinase 4/cyclin-dependent kinase 6 (CDK4/6) inhibitor (Finn et al., 2009, Fry et 
al., 2004). It is currently administered to individuals with ER+ breast cancer in 
combination with fulvestrant or an aromatase inhibitor (Masuda et al., 2018, 
Walker et al., 2016).  
 
Type II kinase inhibitors bind to the inactive (DFG-out) conformation of the 
protein kinase and exploit the additional hydrophobic pocket that is exposed 
adjacent to the ATP-binding site (Kufareva & Abagyan, 2008). These 
compounds occupy part of the adenine binding pocket and form hydrogen 
bonds with the hinge region of the enzyme. The interactions made in these 
regions provide increased selectivity in comparison with type I inhibitors that 
only recognise the highly conserved ATP-binding site (Davis et al., 2011). An 
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example of a type II kinase inhibitor is imatinib (Gleevec), used for the treatment 
of chronic myelogenous leukaemia (CML) and gastrointestinal stromal tumours 
(GIST) (Iqbal & Iqbal, 2014). 
 
The third class of kinase inhibitor (type III) are non-ATP competitive or allosteric 
inhibitors, and exert their action by binding to sites adjacent to the ATP-binding 
pocket, without making any interactions with the hinge region. These inhibitors 
achieve high selectivity by exploiting specific interactions exclusive to the 
particular kinase (Roskoski, 2016). Trametinib (Mekinist) is a type III kinase 
inhibitor, approved by the FDA in 2013 for the treatment of BRAF V600E 
mutated metastatic melanoma. Trametinib is a highly selective allosteric 
inhibitor of MEK1 and MEK2 (Lugowska  et al., 2015).  
 
Substrate-directed inhibitors, also known as type IV inhibitors, bind reversibly to 
the substrate-binding site outside of the ATP pocket. These inhibitors are non-
ATP competitive and currently no type IV inhibitors have been approved (Gavrin 
& Saiah, 2013, Wu et al., 2016). Recent work describes the development of 
substrate-directed inhibitors of BCR-ABL that overcome the resistance of 
imatinib (Gumireddy et al., 2005, Maekawa et al., 2007). 
 
Type V or covalent inhibitors represent the final class of kinase inhibitors. These 
inhibitors incorporate an electrophilic moiety that targets an exposed 
nucleophilic cysteine residue in the ATP-binding pocket of the active site, 
forming an irreversible covalent bond (Wu et al., 2016). The nucleophilic 
addition to an α,β-unsaturated carbonyl compound, known as a Michael 
addition, results in the formation of an irreversible enzyme-inhibitor complex that 
inactivates the kinase. Covalent inhibitors are highly selective as they target a 
specific cysteine residue in the active site (Bhullar et al., 2018). There are 
several FDA approved covalent inhibitors, for example, afatinib (Gilotrif) is a 
dual HER2/EGFR inhibitor indicated for the treatment of patients with metastatic 
non-small cell lung cancer (Keating, 2016).  
 
One of the major flaws of conventional treatment is the development of drug 
resistance due to the heterogeneous expression of drug targets within a tumour 
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(McGranahan & Swanton, 2015, Ramon, Castellvi et al., 2018). For example, a 
HER2+ breast cancer classification requires only 30% of the cells to stain 
positive for HER2 by immunocytochemistry (Dai et al., 2014). Targeted 
treatment eliminates sensitive subclones but allows the growth of resistant 
subclones and the progression of emergent subclones (Figure 1-21) (Ramon et 
al., 2018). Conventional monotherapies increase the likelihood of drug 
resistance and are often less effective at killing cancer cells than the 
combination therapy approach (Blagosklonny, 2004). Combination therapy 
utilises two or more treatments to target different cellular pathways, working in a 
synergistic manner to destroy cancer cells (Yap et al., 2013). Therefore 
combinations of drugs are currently being investigated in numerous clinical trials 
to increase the response to treatments in tumour cells (Bayat Mokhtari et al., 
2017, Lee & Nan, 2012). 
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Figure 1-21. Schematic of drug resistance in a solid tumour. In this model, chemotherapy 
kills sensitive subclones but resistant subclones survive. As the cancer progresses, growth of 
resistant subclones occurs as well as the development of emergent subclones. 
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1.4 Project Aims 
 
Current understanding discussed above demonstrates the challenges currently 
faced with cancer treatment. The heterogeneous nature of cancer and the 
complexity of cellular signalling means that a single treatment approach is often 
ineffective and eventually leads to drug resistance. MNK1/2 present an 
attractive therapeutic target as they are dispensable for normal development 
and act at the convergence point of p38MAPK and ERK pathways, commonly 
upregulated in cancer cells. However, evidence for a compensatory feedback 
mechanism linking the PI3K/AKT/mTOR pathway and the MNK/eIF4E pathway 
has been reported both experimentally and clinically, where downregulation of 
one pathway correlated with the activation of the other, supporting cancer 
survival. The work described in the following chapters aims to investigate the 
pharmacological inhibition of MNK1/2 and other translational targets, with the 
objective of preventing feedback initiation and therefore reducing the likelihood 
of drug resistance in cancer therapy. 
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2 Materials and Methods 
 
2.1 Cell Culture 
 
MRC5 human male foetal lung fibroblasts, SV40 transformed were sourced 
from the European Collection of Cell Cultures (ECACC). Breast cancer cell lines 
BT-549, MDA-MB-231, and SK-BR-3 were sourced from the American Type 
Culture Collection (ATCC, Manassas, VA, USA), US. The human AML cell lines 
MOLM-13 and MV4-11 were purchased from the German Collection of 
Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany). The 
human prostate cancer cell lines PC-3 and LNCaP were kindly donated by the 
Genome Damage and Stability Centre (GDSC) at the University of Sussex. Cell 
lines were maintained in Minimal Essential Medium with Glutamax and Earl’s 
salts (MEM, Gibco), supplemented with 10% (v/v) foetal bovine serum (FBS, 
Pan Biotech) at 37°C in a humidified atmosphere with 5% CO2. 
 
2.1.1 Cell Passage 
 
Cell passage was performed when cells were 70-80% confluent. Adherent cells 
were first washed with Dubecco’s Phosphate Buffered Saline without calcium 
chloride or magnesium chloride (DPBS, Sigma Aldrich) prior to the addition of 
cell dissociation agent, TripLE Select using 1 mLcm-2 (ThermoFisherScientific). 
 
2.1.2 Storage of Cells 
 
Cells were frozen in a freezing medium containing 90% FBS and 10% DMSO. 
1ml cryo-vials of cells were stored in a Mr. Frosty™ overnight at -80oC before 
being transferred to a liquid nitrogen cryostore. 
 
2.2 Cell Viability 
 
To assess cell viability in vitro, all cell lines were seeded into 96-well plates at 
various cell densities per 100 μL media, then treated with 0.2% (v/v) DMSO or 
varying concentrations of compounds for 72 hr. Cell viability was measured 
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using the CellTiter-Blue reagent (Promega, Madison, WI, USA) with 
fluorescence recorded at 560Ex/590Em using a Synergy HT Multi-Detection 
Reader (BioTek, Winooski, VT, USA). Relative cell viability at a given inhibitor 
concentration was determined by comparing the fluorescence to that of DMSO 
treated cells. 
 
2.3 Migration Assays 
2.3.1 Scratch Assay 
 
A 5 cm diameter culture dish containing a confluent monolayer of cells were 
starved in serum free growth medium for 16 hours. A “wound” was scratched 
into the monolayer of cells using a P-20 pipette tip. The serum-free medium was 
aspirated and replaced with 2 mL of serum-containing medium. Inhibitors were 
added at this point and images were taken at various indicated time points 
using a Nikon Eclipse TS100 light microscope, (10x objective lens). 
 
2.3.2 Wound Healing Assay 
 
The Oris Universal Cell Migration Assembly kit was purchased from AMS 
Biotechnology (Europe) Ltd and the assay was performed according to the 
manufacturer’s instructions. Briefly, a single cell suspension (5 × 104 
cells/well/100 μL for MDA-MB-231 cells) was loaded into stopper-loaded wells 
in a 96-well plate. Cells were incubated in a humidified chamber (37°C, 5% 
CO2) for 4 hours to permit cell attachment. To start cell migration, the stoppers 
were removed, cells were washed with sterile PBS and fresh complete medium 
was added. Images were taken at various indicated time points using an Optika 
XDS-2 light microscope, (4x objective lens). Data were analysed with ImageJ 
software (National Institute of Health, Bethesda, MA, USA). 
 
2.3.3 Trans-well Cell Migration Assay 
 
Using the xCELLigence DP device from Roche Diagnostics real-time 
measurements of cell migration on MRC5 cells were performed. Cells were 
seeded at 30,000 per well in CIM-Plates 16 (Roche Diagnostics) in serum-free 
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medium in the presence or absence of inhibitors. Full growth medium was used 
as a chemo-attractant in the lower chamber. As cells pass through the 8 μm 
pores towards the chemo-attractant they adhere to the underside of the filter, 
embedded with a gold micro-electrode. This produces an electrical impedance 
signal, which correlates with the number of migrating cells. Cell index is an 
arbitrary unit based upon the measured cell-electrode impedance derived by the 
software using the calculation as described in Sun et al (2012). 
 
2.4 Immunoblotting 
 
Cellular lysates were prepared using lysis buffer (20 mM MOPS pH 7.4, 100 
mM KCl, 1 mM DTT, 1 mM EDTA, 2 mM benzamidine, 25 mM NaF, 5 μg/mL 
leupeptin, 10 mM chymostatin, 1 μM microcystin LR, 1 X EDTA-free protease 
inhibitor cocktail (Roche)). The concentration of lysate protein was determined 
by Bradford assay (Bio-Rad). Immunoblotting was performed using the Mini-
PROTEAN Tetra Cell System (Bio-Rad) with 20 μg of lysate protein. The 
primary antibodies used were β-actin (Abcam), cleaved PARP (Cell Signalling 
Technologies), AMPK (phospho-Thr172; Cell Signalling Technologies), eIF4E-
(phospho-Ser209; Abcam), p70S6K(phospho-Thr389; Cell Signalling 
Technologies), p44/42 MAPK (ERK1/2) (phospho-Thr202/Tyr204; Cell 
Signalling Technologies), 4E-BP1 (Cell Signalling Technologies), p38MAPK 
(phospho-Thr180/Tyr182; Cell Signalling Technologies), MNK1 (phospho-
Thr197/202; Cell Signalling Technologies), ribosomal protein S6 (phospho-
Ser240/244; Cell Signalling Technologies), eIF4E (Cell Signalling 
Technologies), AKT (phospho-Thr308; Abcam), ULK1 (phospho-Ser555; Cell 
Signalling Technologies) and Anti-LC3B (Sigma). 
 
2.5 In Vitro Kinase Assays 
 
Compounds were tested as single-dose duplicates at 1 μM by Reaction Biology 
Kinase HotSpot screening. The enzyme activity (%) of the compound relative to 
the DMSO control was evaluated in a panel of five kinases. 
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2.6 Flow Cytometry 
 
Cells were seeded at 1 × 105 in 12-well plates and allowed to adhere overnight. 
The cells were treated with the indicated concentrations of inhibitors for 24 
hours. Samples were collected and fixed in 70%(v/v) ethanol for 1 hour. For cell 
cycle analysis, fixed cells were treated with 10 μg/mL RNAse A for 45 min 
before the addition of 50 μg/mL propidium iodide for 15 min and then analysed 
by FACs using the Accuri C6 Flow Cytometer. 
 
2.7 3D Cell Culture 
 
A centrifugal forced-aggregation method was used to generate MDA-MB-231 
spheroids. Briefly, cells were detached from the flasks by trypsin, washed twice 
with PBS, resuspended, and counted. MDA-MB-231 cells were seeded in 
Costar Low Attachment U-bottom 96-well plates at 2000 cells/well/100 μL of 
normal growth media. A 6% (w/v) Matrigel Matrix (Corning, Corning, NY, USA) 
media mix was prepared on ice and 100 μL added to each well, to give a final 
3% Matrigel Matrix solution. Plates were then centrifuged for 2 min at 1200 g at 
4°C, and incubated for three days at 37°C, 5% CO2. Established spheroids 
were treated with test compounds at various concentrations and analysed using 
the Celigo High Throughput Micro-Well Image Cytometer after 4, 6, and 8 days 
of incubation. 
 
2.8 Chemical Synthesis 
2.8.1 General Procedures 
 
Chemical synthesis was performed by myself unless otherwise stated. All 
reactions were carried out in air using commercial-grade starting materials, 
solvents, and reagents. The progress of all reactions was monitored by thin 
layer chromatography (TLC, Silver Spring, MD, USA) using commercially 
available glass silica gel plates (60 Å, F254). The mobile phase was generally a 
solvent mixture, and the visualization was undertaken using UV light. All NMR 
spectra were measured on a Varian NMR 500 spectrometer (Palo Alto, CA, 
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USA) at 500 MHz 1H). Chemical shifts are quoted in parts per million (ppm; % 
relative to a residual solvent peak for 1H). Chromatographic purifications were 
undertaken using an ISCO purification unit, Combi Flash RF 75 PSI, using 
Biotage silica gel columns. LC-MS (Shimadzu Mass Directed Liquid 
Chromatography mass spectrometry, Kyoto, Japan) purity analyses were 
undertaken using a 5 μm C18 110 Å column. 
 
2.8.2 Experimental 
2.8.2.1 Synthesis of Compound 1: 4-((4-fluoro-2-
isopropoxyphenyl)amino)-5-methylthieno[2,3-d]pyrimidine-6-
carboxylic acid 
 
Methyl 4-((4-fluoro-2-isopropoxyphenyl)amino)-5-methylthieno[2,3-d] 
pyrimidine-6-carboxylate. 
To a solution of 4-fluoro-2-isopropoxyaniline (185 mg, 0.904 mmol) in 1,4-
dioxane (5 mL) were added methyl 4-chloro-5-methylthieno[2,3-d]-pyrimidine-6-
carboxylate (219 mg, 0.902 mmol) and p-toluene sulfonic acid monohydrate (45 
mg, 0.24 mmol). The reaction mixture was heated at 150°C under microwave 
irradiation for 15 minutes (30 minutes in Teo et al., 2015) and concentrated 
using the rotary evaporator. The residue was dissolved in DCM 
(dichloromethane) 25 mL and washed with brine twice. The organic layer was 
dried over magnesium sulphate and concentrated under reduced pressure. The 
residue was purified by chromatography (silica gel, DCM ramping to DCM: 
EtOAc 5% after 10 minutes) to give a white solid (170 mg).  
 
4-((4-Fluoro-2-isopropoxyphenyl)amino)-5-methyl thieno[2,3-d] pyrimidine-6-
carboylic acid.  
To a solution of Methyl 4-((4-fluoro-2-isopropoxyphenyl)amino-5-methyl 
thieno[2,3-d] pyrimidine-6-carboxylate (170 mg, 0.45 mmol) in a mixture of 
THF/MeOH/H2O (1:1:1, 60 mL) was added LiOH (366 mg, 15.3 mmol). The 
reaction mixture was dissolved by sonication and heating prior to adding LiOH. 
The reaction mixture was stirred at room temperature overnight and washed 
with DCM (20 mL). The aqueous layer was heated at 50°C for 10 minutes and 
acidified to pH 3 with 2 M HCl. The precipitate was filtered, washed with H2O (3 
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x 25 mL) and dried under reduced pressure to give 4-((4-Fluoro-2-
isopropoxyphenyl)amino)-5-methyl thieno[2,3-d] pyrimidine-6-carboylic acid as 
a white solid. 1H NMR (DMSO-d6) δ 1.32 (d, 6H, OCH(CH3)2), 3.07 (s, 3H, 
thienomethyl), 4.80 (m, 1H, OCH(CH3)2), 6.82 (dd, 1H, aromatic-H), 7.10 (dd, 
1H, aromatic-H), 8.57 (s, 1H, pyrimidal-H), 13.66 (s, 1H, RCO2H). Elemental 
analysis of C17H16FN3O3S: Carbon 56.39%, Hydrogen 4.38%, Nitrogen 11.56% 
(expected 56.50%, 4.46% and 11.63% respectively). These data were in 
agreement with those in the literature. 
 
2.8.2.2 Synthesis of Hybrid Compound 6: 3-[4-(morpholin-4-yl)thieno[3,2-
d]pyrimidin-2-yl]phenyl-4-{[4-fluoro-2-(propan-2-
yloxy)phenyl]amino}-5-methylthieno[2,3-d]pyrimidine-6-
carboxylate 
 
 
To 4-((4-fluoro-2-isopropoxyphenyl)amino)-5-methylthieno[2,3-d]pyrimidine-6-
carboxylic acid, 1, (40 mg, 0.11 mmol) in DMF (2 mL) was added 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC.HCl) (20 mg, 0.1 mmol), 
1-hydroxybenzotriazole hydrate  (HOBT) (16 mg, 0.1 mmol), 3-[4-(4-
morpholinyl)thieno[pyrimidin-2-yl]phenol (33 mg, 0.1 mmol), triethylamine (100 
µL, 0.67 mmol) and 4-dimethylaminopyridine (catalytic). The reaction mixture 
was stirred at RT overnight. The reaction mixture was diluted with ethyl acetate 
(10 mL) and washed twice with brine and once with sodium carbonate (sat). 
The organic layer was separated, dried (MgSO4), filtered and concentrated in 
vacuo. The residue was purified by ISCO Combiflash as above to afford an off-
white solid (16 mg, 24%). Due to the low yielding reaction, no 13C NMR 
spectrum was recorded. 1H NMR (CDCl3) 1.45 (6H, d, J = 6 Hz), 3.23 (3H, s), 
3.90 – 3.93 (4H, m), 4.07- 4.11 (4H, m), 4.66 (1H, sept, J = 6 Hz), 6.71 (2H, dd, 
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J= 10, 3 Hz), 7.34- 7.36 (1H, m), 7.53 – 7.57 (2H, m), 7.77 (1H, d, J = 5.5 Hz), 
8.33 (1H, dd, J= 2.5, 1.5 Hz), 8.44-8.47 (2H, m), 8.68 (1H, s), 8.83 (1H, dd, J 
=9, 6 Hz). HRMS: C33H29FN6O4S2. H+; Calcd 667.1748; Found 667.1728.  
Elemental anal. Calcd, for C33H29FN6O4S2. 0.75 CH2Cl2; C, 56.27; H, 4.27; N, 
11.67; Fnd, C, 56.79; H, 4.42; N, 11.63. 
 
2.8.2.3 Synthesis of Hybrid Compound 7: 2-[4-amino-1-(propan-2-yl)-1H-
pyrazolo[3,4-d]pyrimidin-3-yl]-1H-indol-6-yl 4-{[4-fluoro-2-(propan-
2-yloxy)phenyl]amino}-5-methylthieno[2,3-d]pyrimidine-6-
carboxylate 
 
 
To compound 1, 4-((4-fluoro-2-isopropoxyphenyl)amino)-5-methylthieno[2,3-
d]pyrimidine-6-carboxylic acid, (39 mg, 0.11 mmol) in toluene (8 mL) was added 
thionyl chloride (15 µL, 0.2 mmol), one drop of dimethylformamide (DMF), and 
the reaction mixture was refluxed for two hours. After cooling, volatiles were 
removed in vacuo. The residue was re-dissolved in dichloromethane (2 mL) and 
reconcentrated then redissolved in dichloromethane (2 mL). To the reaction 
mixture was added PP242, 2-[4-amino-1-(propan-2-yl)-1H-pyrazolo[3,4-
d]pyrimidin-3-yl]-1H-indol-5-ol, (35 mg, 0.11 mmol) and excess triethylamine (95 
µl) in dichloromethane (2 mL) and the reaction mixture was stirred at RT 
overnight. The reaction mixture was extracted with dichloromethane (10 mL) 
and washed (sat. NaHCO3 solution, 10 mL). The organic extracts were 
separated, dried (MgSO4) then filtered and concentrated in vacuo. Pure product 
was obtained by chromatography on an ISCO Combiflash from 
dichloromethane (neat) to EtOAc/dichloromethane (9:1) gradient. A red 
crystalline solid (10 mg, 14% yield) was obtained from a CDCl3 solution, one 
crystal of which was studied in the solid state. Due to the low yielding reaction, 
no 13C NMR spectrum was recorded.1H NMR (CDCl3) 1.27 (6H, d, J =  6 Hz), 
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1.44 (6H,d, J = 5 Hz), 3.22 (3H, s), 4.68 (1H, sept, J = 6 Hz), 5.21 (1H, sept, J = 
6 Hz),  6.04 (2H, br s), 6.73 (2H, dd, J= 10, 3 Hz), 6.90 (1H, s), 7.13 (1H, m), 
7.48 (2H, d, J = 2 Hz), 8.42 (2H, d, J = 2 Hz), 8.67 (1H, s), 8.81 (1H, dd, J =9, 6 
Hz), 9.30 (1H, s). HPLC purity (>96 %). HRMS: C33H29FN6O4S2. H+ calcd; 
652.2249; found 652.2256. 
 
 
2.9 Commercial inhibitors 
 
Inhibitor Target Supplier 
Cercosporamide MNK1/2, JAK3 Tocris Bioscience 
CGP57380 MNK1/2 Tocris Bioscience  
PP242 mTORC1/2 Med Chem Express 
Staurosporine Multiple Sigma Aldrich 
RK-33 DDX3 Sellekchem 
RO-3306 CDK1 Sigma Aldrich 
PI-103 PI3K Sellekchem 
 
2.10 Statistics 
 
All statistical analyses were performed using GraphPad Prism 7 software (La 
Jolla, CA, USA). In vitro log dose-response curves were calculated using 
nonlinear regression with variable slope after normalising absorbance to DMSO 
treated controls, with the concentration required to inhibit the Resorufin 
response by 50% reported as the IC50. 
 
2.11 Molecular modelling 
 
Molecular modelling was performed using UCSF Chimera (Pettersen, Goddard 
et al., 2004) following attendance at a ligand-protein docking and computer-
aided drug design course at the Swiss Institute of Bioinformatics (SIB). 
 
2.12 RNA extraction and qRT-PCR 
 
92 
 
RNA extractions were performed using the Qiagen miRNeasy RNA extraction 
kit, with an on-column DNase digestion. RNA concentrations were measured on 
a NanoDrop 1000 spectrophotometer. For qRT-PCR, RNA samples were 
diluted to a consistent concentration then cDNA was prepared in duplicate using 
a High Capacity cDNA Reverse Transcription Kit from Life Technologies with 
random primers. A control “no RT” reaction was performed in parallel to confirm 
that all genomic DNA had been degraded. qRT-PCR was performed on each 
cDNA in duplicate (i.e. two technical replicates), using TaqMan Universal PCR 
Master Mix, No AmpErase UNG (Life Technologies)) and TaqMan DDX3X 
assay (Life Technologies). GAPDH and HPRT1 were used for normalisation.  
 
2.13 CRISPR 
 
A protocol based on the CRISPR-Cas9 endonuclease (Ran et al., 2013) was 
used to create genetic modification to MRC5 cells. 
 
2.13.1 Design of sgRNA 
 
The genomic DNA sequence from the gene of interest was imported from 
Ensembl into Benchling, after cross-referencing with Uniprot. The CRISPR 
sgRNA design tool was used to analyse a 1 kb fragment of the region of interest 
and locate suitable target sites by identifying 20-bp sequences directly 
upstream of any 5’NGG (PAM sequence). Both on- and off-target sites were 
computationally predicted, allowing selection of the three highest ranked sgRNA 
sequences. Primers were also designed at this stage for future use in the 
surveyor assay. Using Primer-Blast, oligonucleotides were designed to anneal 
approximately 500 bp upstream and downstream from the intended target site. 
 
sgRNA 5’-3’ 3’-5’ 
1 CACCGAACAAACACTCGCTTAGCAG AAACCTGCTAAGCGAGTGTTTGTTC 
2 CACCGGTGGCAGTGGAAAATGCGCT AAACAGCGCATTTTCCACTGCCACC 
3 CACCGCGAGTTCTCGGTACTCTTCA AAACTGAAGAGTACCGAGAACTCGC 
 
Oligonucleotide 5’-3’ 
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pF AAAGGGGAGCGAATGCGTAA 
pR2 TTTCCACTCCGGAAACGCAG 
 
2.13.2 Cloning of sgRNA into the pSpCas9(BB) Vector for Co-expression 
with Cas9 
 
The top and bottom strands of the oligonucleotides for each sgRNA were 
resuspended in nuclease-free water to a final concentration of 100 µM. The 
following mixture was prepared for phosphorylation and annealing the top and 
bottom strands of the sgRNA oligos: 
 
Component Volume (µL) 
sgRNA top (100 µM) 1 
sgRNA bottom (100 µM) 1 
T4 ligation buffer 10x 1 
T4 PNK 1 
ddH20 6 
Total 10 
2.13.3 Functional Validation of sgRNA 
 
MRC5 cells were maintained in MEM with 10% FBS at 37°C and 5% CO2. Cell 
maintenance and passage was performed as detailed previously in the tissue 
culture protocol above.  
 
2.13.4 Transfection of MRC5 
 
Cells were seeded in a 6-well plate at a density of 1 x 105 cells/ 500 µL MEM 
without selection 16 hours prior to transfection. Individual wells were seeded for 
each sgRNA plasmid and for the YFP-control plasmid. Cells were transfected at 
70-90% confluency with Lipofectamine 2000 according to the manufacturer’s 
instructions. For pSpCas9(sgRNA) plasmids, 500 ng  of sequence verified 
plasmid was transfected. In addition, a YFP plasmid was transfected to monitor 
transfection efficiency. After 24 hours, the cells were checked for transfection 
efficiency using a standard epi-fluorescent microscope. After 48 hours, G418 
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was added at 400 µg/ml and cells were incubated at 37°C for five days. Cells 
that had undergone successful transfection with a pSpCas9(sgRNA) plasmid 
were resistant to G418, whilst those that had not (including YFP-control) died. 
The pSpCas9(sgRNA) transfected cells were dissociated from the plate, 
pelleted and re-suspended in complete media. 100 µL of each sample of 
pSpCas9(sgRNA) transfected cells (sgRNA1, sgRNA2 and sgRNA3) were 
utilised for the surveyor assay and the remainder were taken forward for the 
limiting dilution.  
 
2.13.5 Surveyor Assay for Assessment of CRISPR Cleavage Efficiency 
 
Genomic DNA extraction was performed on each polyclonal pSpCas9(sgRNA) 
transfected cell line (sgRNA1, sgRNA2 and sgRNA3) and wildtype MRC5. The 
Sigma Aldrich Genelute mammalian genomic DNA miniprep kit was used for 
DNA extraction. The extracted DNA was normalised to a final concentration of 
100-200 ng/µL with ddH2O. PCR was performed using oligonucleotides pF and 
pR2 (see above) on wildtype MRC5 (negative control) and each 
pSpCas9(sgRNA) transfected cell line (sgRNA1, sgRNA2 and sgRNA3). The 
PCR product (5 µL) was resolved on a 1% (w/v) agarose gel to check for single 
band products using a high UV transilluminator. 
 
Component Volume (µL) 
5x Phusion HF  buffer 4 
10 mM dNTPs 0.4  
Oligonucleotide pF 0.5 
Oligonucleotide pR2 0.5 
Template DNA (100 ng) Variable 
Phusion DNA polymerase 0.5  
Nuclease-free water Up to 20  
Total 20  
 
The following cycling conditions were used: 
 
Cycle number Denature Anneal Extend 
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1 95°C, 2 min   
2-31 95°C, 20 sec 60°C, 20 sec 72°C, 30 sec 
32   72°C, 3 min 
 
The following components were added directly to the remaining 15 µL of PCR 
product for each sample: 
 
Component Volume (µL) 
NEB buffer #2 2 
ddH2O 2.5 
T7E1 0.5 
Total 5 
 
The mixture was incubated at 37°C for 30 mins before adding 1 µL 0.5M EDTA 
to stop the reaction. The final products were resolved on a 1% (w/v) agarose gel 
and imaged using a high UV transilluminator. The negative control showed one 
band corresponding to the size of the PCR product, whereas the 
pSpCas9(sgRNA) transfected cell lines (sgRNA1, sgRNA2 and sgRNA3) had 
smaller fragments indicating efficient cleavage (data not shown). 
 
2.13.6 Isolation of clonal cell lines by dilution 
 
Cells were counted and diluted in MEM with 10% FBS to a final concentration of 
0.33 cells per 100 µL to reduce the likelihood of having multiple cells per well. 
Using a multi-channel pipette, 100 µL of diluted cells were added to each well of 
a 96-well plate, two plates were prepared for each sample of pSpCas9(sgRNA) 
transfected cells (sgRNA1, sgRNA2 and sgRNA3). The putative monoclonal cell 
lines were grown in MEM with 10% FBS for a further for 21 days, before each 
line was transferred to culture flasks for further growth. 
 
2.13.7 Initial Knockout Validation by Western Blotting 
 
Putative monoclonal cell lines were harvested and lysed according to the 
standard protocol, with their eluate resolved by SDS-PAGE and Western 
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blotting (Section 2.4). Primary antibodies for monitoring the loading and for the 
protein of interest were utilised as indicated. 
 
2.13.8 Genotyping by Sanger Sequencing 
 
A genomic DNA extraction was performed on knockout cell lines confirmed by 
Western blotting. The 1000 bp region surrounding the target sequence for the 
sgRNA-directed Cas9 was amplified by PCR and subsequently sequenced by 
GATC Biotech. 
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3 Dual-inhibition of MNK-eIF4E and PI3K/AKT/mTOR 
Pathways and the Effect on Cell Migration 
 
3.1 Introduction 
 
During translation initiation, the cap structure on eukaryotic mRNA facilitates the 
recruitment of initiation factors to allow ribosome binding and initiation at the 
correct start site (Sonenberg & Hinnebusch, 2009). eIF4E interacts directly with 
the cap and forms complexes on its convex surface with either inhibitory 
regulatory proteins (4E binding proteins, 4E-BPs; see Section 1.1.4.1) or with 
the scaffold proteins, eIF4GI and eIF4GII. In vivo eIF4G exists partly in the form 
of a complex with eIF4E and eIF4A, constituting the initiation factor eIF4F (see 
Section 1.1.1). Within the sequences of eIF4GI and eIF4GII there are domains 
that interact with eIF4E, eIF4A, eIF3, PABP and the kinases, MNK1/2, which 
modulate the phosphorylation of eIF4E on Ser209 (Beggs et al., 2015, Klann & 
Dever, 2004). MNK1 and MNK2, which act at the convergence point of ERK 
and p38MAPK, phosphorylate eIF4E at the physiological site in vitro and in vivo 
(Bhat et al., 2015). In contrast, the association of 4E-BPs with eIF4E is 
modulated by phosphorylation events controlled via the mTORC1 signalling 
pathway. (Figure 3-1). Current models suggest that hypophosphorylated 4E-
BP1 binds to eIF4E to inhibit cap-dependent translation, a process readily 
reversed following its phosphorylation. In several model systems, the 
dissociation of hyperphosphorylated 4E-BP1 from eIF4E leads to the binding of 
eIF4G to eIF4E, promoting the phosphorylation of eIF4E and the initiation of 
protein synthesis. This increased level of phosphorylation of eIF4E also 
correlates with an increase in levels of mesenchymal markers such as N-
cadherin, fibronectin and vimentin, along with the acquisition of invasive 
properties and increased cell migration (Robichaud et al., 2015). 
 
MKNK1 and MKNK2 genes were altered by mutation, deletion and 
amplification. Bioinformatic analysis using cBioPortal, found that MKNK1 and 
MKNK2 were amplified by copy number in 18.7% of queried samples in 
neuroendocrine prostate cancer. Both genes were also amplified in pancreatic 
(17%), ovarian (13%) and breast (10%) cancers (Figure 3-2A). High levels of  
98 
 
 
 
 
Figure 3-1. A simplified schematic representation of MNK1/ 2 and mTOR pathways. Red 
boxes depict several inhibitors of specific pathway components used in this study. MNK1/2 lie at 
the convergence point of both the p38MAPK pathway and ERK pathways and upon activation, 
phosphorylate eIF4E. Class I PI3 kinases are activated by RTKs resulting in the conversion of 
PIP2 to PIP3, a secondary messenger that is essential for AKT translocation to the plasma 
membrane. The level of PIP3 is negatively regulated by the tumour suppressor, PTEN. AKT is 
partially activated by PDK1 and becomes fully activated upon phosphorylation at Ser473, a 
process that can be catalysed by multiple proteins. mTOR forms two distinct multiprotein 
complexes, mTORC1 and mTORC2. mTORC1 is activated indirectly through AKT, which also 
phosphorylates the negative regulator, PRAS40. Activated mTORC1 stimulates protein 
translation by phosphorylating 4E-BP1 on several residues, releasing eIF4E allowing it to 
participate in translation initiation. In addition to phosphorylating other translational targets, 
mTORC1 also phosphorylates p70S6 kinase (p70S6K), which becomes fully activated following 
PDK1-mediated phosphorylation. 
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Figure 3-2. Bioinformatic analysis of MKNK1 and MKNK2. A. Cross-cancer alteration summary for MKNK1, MKNK2 using cBioPortal (showing the top ten 
studies in which most alterations occurred). The histogram is colour-coded to indicate the alteration type. B. Kaplan Meier analysis of MKNK1 in pancreatic 
ductal adenocarcinoma (132 samples) showing that high MKNK1 expression correlates with a lower overall survival probability (Stratford et al., 2010).
A. B. 
100 
 
MKNK1 reduced survival time in several studies, including in a recent 
pancreatic ductal adenocarcinoma study, shown in Figure 3-2B (Stratford et al., 
2010). 
 
MNK1/2 are key regulators of the translational machinery, and their primary 
target is eIF4E (Truitt et al., 2015). eIF4E is a general translation factor, which 
has the potential to selectively enhance a subset of mRNAs involved in 
oncogenesis upon eIF4E phosphorylation on Ser209 by MNK1/2. The 
phosphorylated form of eIF4E has strong links to carcinogenesis (Hou et al., 
2012). Recent studies have found that high levels of eIF4E-P coincided with 
poor clinical outcome and chemoresistance in human cancers ((Bhat et al., 
2015, Li et al., 2017, Mamane et al., 2007). In addition, MNK1/2 provide an 
attractive cancer target as MNK1/2 KO mice were found to be completely viable 
(Ueda et al., 2004).    
 
Cancer cells require elevated protein synthesis and exhibit augmented activity 
of the translation machinery. Exploiting this “addiction” to protein synthesis has 
emerged as a promising therapeutic option for cancer treatment (Teo et al., 
2015b). As outlined above, eIF4E is necessary for mRNA translation and its 
availability and phosphorylation are regulated by the PI3K/AKT/mTOR and 
MNK1/2 pathways, respectively. There is now evidence for a direct functional 
interaction between the AKT/mTOR pathway and the MNK/eIF4E pathway. 
Recent work has shown evidence for a MNK-associated mTORC1 complex 
(Figure 3-3). In T cell activation, active MNK facilitates mTORC1 association 
with its downstream substrates and stabilises the interaction of mTORC1 with 
TEL2 (Phosphatidyl Inositol 3ʹ Kinase-related Kinase (PIKK) stabiliser) (Brown & 
Gromeier, 2017) and prevents DEPTOR binding to the complex. This interaction 
between MNK and mTORC1/TEL2 is believed to support mTORC1/substrate 
proximity in a MNK-responsive manner and is required for efficient T cell 
activation and for mitogenic signalling (Brown & Gromeier, 2017). However, the 
AKT/mTOR pathway and the MNK/eIF4E pathway are not always linked in this 
way. This was reported recently, where the downregulation of one pathway 
correlated with the activation of the other, which subsequently supported cell 
proliferation and cell survival in prostate and lung cancer   
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Figure 3-3. MNK1/2 controls mTORC1: substrate association. MNK1/2 regulates mTORC1 
signalling and associates with mTORC1 directly. This interaction results in the displacement of 
DEPTOR, while enhancing TEL2:mTORC1 binding. The latter stabilises mTORC1/substrate 
interactions whilst DEPTOR prevents TEL2 binding and reduces mTORC1/substrate binding 
(Adapted from (Brown & Gromeier, 2017)). 
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Figure 3-4. The role of mTORC1 in regulating growth factor signalling. mTORC1 
orchestrates feedback inhibition of PI3K-AKT signalling by activating GRB10 while inhibiting IRS 
proteins. Acute mTORC1 inhibition leads to dephosphorylation of GRB10 and IRS1, whilst 
chronic mTORC1 inhibition leads to changes in the levels of IRS and GRB10 proteins. (Adapted 
from (Hsu et al., 2011)). 
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(Folkes et al., 2008, Hemmings & Restuccia, 2015). The apparent interplay 
between the MNK and mTOR signalling pathways provides a novel therapeutic 
opportunity to target aggressive migratory cancers (O'Connor et al., 1997, Teo 
et al., 2015a). 
 
Increases in the eIF4E/4E-BP1 ratio, limits the effect of mTOR inhibitors in 
regulating levels of eIF4E available to participate in translation initiation (Apsel 
et al., 2008, Grzmil et al., 2011). Inhibiting MNK kinases may prevent such 
feedback initiation by targeting eIF4E signalling downstream of mTOR (Zheng & 
Jiang, 2015). This was observed in both prostate cancer and glioblastoma cell 
lines, when simultaneous inhibition of MNK1/2 kinases and mTORC1 
suppressed cell cycle progression and blocked proliferation. This effect was 
increasingly pronounced when dual inhibition was employed as opposed to the 
treatment of single-agents (Folkes et al., 2008, Hemmings & Restuccia, 2015). 
 
Many small molecule inhibitors have been developed to target constitutively 
active protein kinases and have made a considerable impact in cancer therapy 
(Bianchini et al., 2008). However, inhibitor-resistant kinases can evolve rapidly 
in the presence of the drug and the development of drug resistance points 
towards the need for a multi-targeted approach (Coles, 2012, Vassilev, 2006). 
Therefore, combinations of drugs are often used to increase the response to 
treatment in tumour cells. The complex nature of cancer and intra-tumour 
heterogeneity has led to the concept of hybrid drugs, which act on multiple 
targets with the need to deliver more than one drug concurrently. This approach 
involves the linking of two selected pharmacophores that act against different 
therapeutic intracellular targets simultaneously (Coles, 2012). 
 
It is pertinent at this stage to present an overview of physiochemical parameters 
relevant to drug discovery including Lipinski's rules. Lipinski’s rule of five 
predicts that poor absorption or permeation is more likely when a drug 
candidate has more than five hydrogen bond donors, more than ten hydrogen 
bond acceptors, a molecular weight greater than 500 and a log P value greater 
than 5 (Lipinski et al., 2001). The Veber rules propose that in addition to the 
Lipinski rules, other parameters exist for the description of drug likeness. One of 
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these parameters being the number of rotatable bonds, an indication of 
molecular flexibility. Furthermore Veber et al (2002) found that the polar surface 
area can be used as a reliable indicator of permeation. A total polar surface 
area (TPSA) of 140 Å2 or above leads to reduced uptake over the lipid bilayer 
(Veber et al., 2002).  
 
The work described here provides the proof of principle for the development of 
dual MNK1/2 and PI3K/mTOR inhibiting hybrid molecules and describes their 
subsequent synthesis. These agents may be an effective option in the treatment 
of highly migratory cancers through the inhibition of eIF4E. 
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3.2 Results 
3.2.1 Homology Modelling of MNK1 and Predicted Binding Mode of 
Compound 1 
 
The catalytic domains of MNK1 and MNK2 share 78% sequence identity and 
are highly conserved ((Oyarzabal et al., 2010). MNK1/2 also possess an 
unusual (Asp-Phe-Asp) DFD motif in place of the Asp-Phe-Gly (DFG) motif 
found in all other protein kinases. The DFD motif has less affinity for ATP than 
the equivalent DFG motif present in other kinases. This is due to a 180° rotation 
relative to the DFG motif, which locks the kinase in the DFD-out conformation. 
The Phe in the activation segment flips into the ATP binding site, which 
obstructs the ATP binding pocket and prevents binding (Jauch et al., 2005). 
 
The design of novel MNK inhibitors has been slow due to the lack of structural 
information available. MNK1 and MNK2 crystal structures only exist in their 
DFD/out, inactive conformation (PDB: 2HW6 and 2AC3, respectively). There is 
one crystal structure available for the active conformation of MNK2 bound to 
staurosporine (PDB: 2HW7). This has been accomplished by mutating the DFD 
motif to the generic DFG motif found in other kinases (Jauch et al., 2006, Jauch 
et al., 2005).  
 
There are three main classes of kinase inhibitors (discussed in detail in Section 
1.3.5.1.1). Type I inhibitors, for example, CGP57380 and cercosporamide work 
by targeting the ATP-binding site in MNK1/2. The ATP-binding site is well-
conserved between kinases and so type I inhibitors often have many off-target 
effects. Cercosporamide was also found to inhibit kinases such as Jak3, GSK3, 
ALK4 and PIM1 in addition to the MNKs (Basnet et al., 2015). Type II kinase 
inhibitors exploit both the ATP-binding site and the less conserved adjacent 
hydrophobic pocket (allosteric site) created by the kinase activation loop (Teo et 
al., 2015a, Zhao et al., 2014). Following an extensive literature search, type II 
inhibitor, MNKI-19, was found to be a potent MNK1/2 inhibitor in the nanomolar 
range in cell-free kinase assays ((Teo et al., 2015a). Subsequent work refers to 
MNKI-19 as compound 1.  
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Based upon the available crystal structures, a homology model of active MNK1 
bound to compound 1 was created. Chimera and Modeller were used to build a 
homology model of MNK1 in the active form (DFD-in) using PDB: 2HW7 as a 
template. The consensus amino acid sequence of MNK1 was imported into 
Chimera from Uniprot (Q9BUB5). A BLAST was run on the query sequence and 
the highest scoring hits displayed (Figure 3-5). A multiple sequence alignment 
(MSA) was performed on the query sequence and the template PDB: 2HW7 
from the BLAST search. The consensus sequence produced from the MSA was 
used to generate a series of models using Modeller.  
 
A number of models were produced and ranked according to the 
percentage probability of having the correct fold: 
 GA341 - model score derived from statistical potentials; a value > 
0.7 generally indicates a reliable model, >95% probability of having 
the correct fold; 
 zDOPE - normalized Discrete Optimized Protein Energy (DOPE), an 
atomic distance-dependent statistical score; negative values indicate 
better models. 

The initial models showed poor zDOPE scores due to the termini of the query 
extending beyond the template (PDB: 2HW7) structure, leading to unreliable 
modelling. The termini were removed and the models rescored. The top-
scoring model was selected and used to predict the binding mode of 
compound 1 (Figure 3-6).The MNK1 homology model was prepared for 
docking using AutoDock Vina. A number of predictions for the binding mode 
of compound 1 were proposed. The top scoring (most likely) binding mode 
was chosen (Figure 3-7). The pyrimidine moiety occupies the ATP-binding 
pocket, while the fluoroaniline projects into the large hydrophobic pocket.
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Figure 3-5. BLAST search and multiple sequence alignment (MSA) of MNK1 protein. A. Consensus amino acid sequence of MNK1 imported from 
Uniprot (Q9BUB5). B. BLAST of consensus amino acid sequence of MNK1 showing the highest scoring matches in blue. C. Multiple sequence alignment 
(MSA) of the query sequence, MNK1, and the template (PDB: 2HW7). Completely conserved residues are capitalized and shown in colour from N-terminal 
blue to C-terminal red. Black capital letters represent highly conserved residues (80% or greater) and black dots represent gaps in the sequence. Molecular 
graphics and analyses were performed with the UCSF Chimera package (Pettersen et al., 2004).  
A. 
B. 
C. 
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Figure 3-6. Homology modelling of MNK1. A. Modeller was used to generate a series of 
models of MNK1 in the active form. Models were produced and ranked according to the 
percentage probability of having the correct fold. B. Illustration of Model 1.4, the best overall 
fitting model. Coloured from N-terminal (blue) to C-terminal (red). C. Docking of compound 1 
in model #1.4. Each line of the table represents each docking solution. The RMSD lb (lower 
bound) and RMSD ub (upper bound) of a docked ligand are calculated by AutoDock Vina. 
This indicates how similar each position is to the best-scoring position found. Molecular 
graphics and analyses were performed with the UCSF Chimera package (Pettersen et al., 
2004).
A. C. 
B. 
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Figure 3-7. Predicted binding mode of compound 1. A. Structure of compound 1. B. MNK1 homology model shown in purple with the highest scoring 
predicted binding mode of compound 1 (grey). C. MNK1 homology model coloured by hydrophobicity surface: from blue for the most hydrophilic, to white, to 
red for the most hydrophobic. Molecular graphics and analyses were performed with the UCSF Chimera package (Pettersen et al., 2004). 
B. C. 
A. 
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3.2.2 Synthesis of MNK1/2 Inhibitor, Compound 1 
 
 
Compound 1 was not available commercially and was synthesised in two steps 
(Figures 3-8 to 3-11). The first step was a nucleophilic aromatic substitution 
reaction and can be explained by the addition-elimination mechanism. This 
involves the addition of a nucleophile, an electron-rich group or atom, followed 
by the elimination of the leaving group. In a carbon-chlorine bond, the chlorine 
is more electronegative than the carbon. The carbon in the carbon-chlorine 
bond is electrophilic i.e. has a partial positive charge. The amino group on the 
fluoroaniline acts as a nucleophile. The second step involves the base-
catalysed hydrolysis of the ester formed in the first step. A strong base, LiOH, 
hydrolyses the ester to a carboxylate salt and produces methanol as a 
byproduct. The carboxylate salt is then protonated to form the carboxylic acid, 
the final product (Figures 3-10 and 3-11). This thienopyrimidinyl compound 
provides a scaffold for the development of future novel compounds and hybrid 
drugs. 
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Figure 3-8. Synthesis of thienopyrimidinyl derivative, 1. a) Aromatic substitution under microwave conditions. b) Hydrolysis of the ester to produce 
the final compound. 
  
1 
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Figure 3-9. Proposed mechanism of aromatic substitution. 
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Figure 3-10. Proposed mechanism of ester hydrolysis.
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                                                          Figure 3-11. 1H NMR (DMSO-d6) spectrum of compound 1.
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3.2.3 Compound 1 Inhibits eIF4E Phosphorylation 
 
MNK1 and MNK2 lie downstream of both p38MAPK and ERK pathways and 
phosphorylate Ser209 of eIF4E, enhancing translation of specific mRNAs 
involved in cell survival (Hou et al., 2012). Western blot analysis was carried 
out to determine if compound 1 was an effective MNK1/2 inhibitor in cells. 
MRC5 cells were chosen on the basis that they exhibited a relatively high 
basal level of eIF4E-P and could be used in future work to study cell migration. 
As shown in Figure 3-12A and quantified in Figure 3-12B, compound 1 
reduced the level of eIF4E phosphorylation in concentration-dependent 
manner, being effective at concentrations above 2.5 µM. As expected, the 
known MNK1/2 inhibitors CGP57380 and cercosporamide, also caused a 
reduction in eIF4E phosphorylation. The inactive form of CGP57380 (neg 
CGP) had no effect on eIF4E phosphorylation compared to the DMSO control. 
 
Compound 1 was profiled against a panel of kinases to assess its activity 
against several targets including upstream MNK1/2 proteins, AKT and 
p38MAPK, to be confident that the reduction in phosphorylation of eIF4E was 
due to the effect of compound 1 on its intended target, MNK1/2. Compound 1 
was found to be a very potent inhibitor of MNK1/2 (Figure 3-12C) and showed 
greater inhibitory activity towards eIF4E phosphorylation compared to 
cercosporamide, reported previously in the literature (Beggs et al., 2015). 
Compound 1 had no effect on AKT or p38MAPK activity in vitro, however, 
compound 1 did have a significant off-target effect on the kinase, PIM1. PIM1 is 
a serine/ threonine kinase, which has been shown to have roles in cell survival, 
proliferation and differentiation (Shah et al., 2008). It is also implicated in 
translational control, as studies have identified 4E-BP1 as a target. PIM1 
phosphorylates 4E-BP1 on Thr37/Thr46, priming the protein for subsequent 
phosphorylation. Partial PIM1 inhibition by compound 1 may promote the 
hypophosphorylated form of 4E-BP1, increasing the ratio of 4E- BP1 -bound 
eIF4E thereby inhibiting translation rates (Chen et al., 2011). 
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Figure 3-12. Validation of target inhibition by compound 1. A. Western blot analysis showing the effect of 1 at different concentrations on eIF4E 
phosphorylation at Ser209. MRC5 cells were incubated with DMSO alone or the indicated concentrations of inhibitors for 24 hours. Cellular lysates were 
prepared and immunoblotting was performed using 20µg of total lysate protein, as described in the Materials and Methods. B. Quantification of eIF4E 
phosphorylation levels relative to DMSO. Data are presented as the means ± SD, n=3 (ns = non-significant; **p ≤ 0.01 and ***p ≤ 0.001). C. Selectivity of 1 
against a panel of kinases. Compounds were tested under commercial conditions in single dose duplicates at 1 µM and reactions were carried out at 10 
µM ATP (Reaction Biology HotSpot Screening). 
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3.2.4 Compound 1 has no Significant Effect on Cell viability 
 
The equivalent concentrations of compound 1 used in the Western blots (Figure 
3-12) were taken forward to assess for effects on cell viability over 72 hours in 
MRC5 cells (Figure 3-13A). In comparison to the DMSO control, there appeared 
to be no significant effect of compound 1 on cell viability. Similarly, CGP57380, 
neg CGP57380 and cercoporamide had no effect on cell viability under these 
assay conditions. The cell titer blue assay was also used to detect cell viability 
in various cancer cell lines (Figure 3-13B). Cells were incubated with compound 
1 at a set concentration of 5 µM for 72 hours. The data were slightly more 
variable in the two leukemia cell lines used here (MOLM-13 and MV-4-11); 
however, no significant effect on cell viability was observed in any of the cell 
lines tested (MRC5, BT-549, MDA-MB-231 and SK-BR- 3). 
 
In order to test whether compound 1 had an effect on cell proliferation, cells 
were incubated with DMSO alone or compound 1 at either 1 µM or 10 µM and 
cell numbers counted over a period of 48 hours. Cell number did not change 
significantly relative to the DMSO control. 
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A.                                                                                        B.                                                                                     
                                         
 
Figure 3-13. Cell viability of compound 1. A. MRC5 cells were treated for 72 hours with compound 1 at the indicated concentrations. B. Various cell 
lines were treated for 72 hours with compound 1 at 5 µM. Viability was assessed by Cell Titer Blue assay (see Materials and Methods for details). Data are 
presented as the means ± SD, n=3. C. Cell proliferation assay of compound 1 on MRC5 cell lines. MRC5 cells were treated for 48 hours with compound 1 
as a single-agent. Data are presented as the means ± SD, n=3. 
 C. 
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3.2.5 Dual-inhibition of MNK-eIF4E and PI3K-AKT-mTOR in MRC5 Cells 
 
MNK1/2 phosphorylate eIF4E on Ser209, enhancing the translation of specific 
mRNAs involved in cell survival and metastasis. MNK1/2 kinases are an 
attractive therapeutic target as they are dispensable during normal development 
and hence could be used to selectively kill cancer cells (Teo et al., 2015b). In 
this study, highly migratory MRC5 lung fibroblasts and MDA-MB-231 breast 
cancer cells were both used to probe the response of dual-inhibition of the 
eIF4E-MNK pathway and PI3K-AKT-mTOR pathways (Figure 3-1). In MRC5 
cells, compound 1 was found to reduce the level of eIF4E phosphorylation in a 
concentration-and time-dependent manner, being effective at concentrations 
above 1 μM for 4 hours or longer (Figure 3-15A and 3-15B). In contrast, 
CGP57380, a known MNK inhibitor (Figure 3-15A, lane 8) and staurosporine, a 
pan-general kinase inhibitor, (Figure 3-15A, lane 9) had no effect on eIF4E-P 
under these assay conditions. The inhibition of MNK1/2 did not affect the 
upstream activation of MNK1/2, or lead to an increase in cell stress, as 
observed by the constant level of AMPK T172 phosphorylation in relation to the 
DMSO control. Increased incubation time with compound 1 for 16 hours and 
above, resulted in partial inhibition of 4E-BP1 phosphorylation, as depicted by 
an increase in the level of the less-phosphorylated form of 4E-BP1 upon 
Western blotting (Figure 3-15A and 3-15B). This could reflect the inhibition of 
MNK resulting in decreased binding of TEL2 to mTORC1, promoting DEPTOR 
binding, inhibition of substrate binding to RAPTOR and decreased 
phosphorylation of 4E-BP1 (Figure 3-3). 
 
To assess the significance of simultaneous MNK1/2 and PI3K inhibition, an 
effective PI3K p110α inhibitor, 3-[4-(4-morpholinyl)thieno[pyrimidin-2-yl]phenol, 
compound 2, (Folkes et al., 2008), was used to observe the effect on various 
signalling molecules (Figures 3-14 and 3-15C). The efficacy of compound 2 as 
a PI3K inhibitor was measured by monitoring the inhibition of phosphorylation of 
AKT-T308. This phosphorylation is PI3K-dependent, resulting from the 
conversion of PIP2 to PIP3 and the activation of membrane-bound PDK1 
(Hemmings & Restuccia, 2015). Compound 2 was found to inhibit AKT-T308 
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phosphorylation at concentrations greater than 100 nM in MRC5 cells. The 
observed effect of compound 2 on mTOR signalling was also as predicted, with 
mTORC1 substrates, 4E-BP1 and p70S6K inhibited in a dose-dependent 
manner. In addition, ribosomal protein S6 (rpS6) phosphorylation was also 
inhibited (Figure 3-15C).  
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Figure 3-14. Inhibitors used for combination studies. A. Structure of 1, a MNK1/2 inhibitor. B. Structure of 2, a PI3K p110α inhibitor. C. Structure of 
PP242, an mTORC1/2 inhibitor. D. Structure of cercosporamide, a MNK1/2 inhibitor. E. Structure of CGP57380, a MNK1/2 inhibitor. 
  
A. B. C. 
D. E. 
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Figure 3-15. Representative Western blot analysis of both the eIF4E-MNK and PI3K-AKT-
mTOR pathways in the presence of inhibitors.  A. Western blot analysis showing the effect 
of different concentrations of 1 on eIF4E-P and various signalling molecules. MRC5 fibroblast 
cells were incubated with DMSO alone (lane 1) or with the indicated concentrations of inhibitors 
for 24 hours. Cellular lysates were prepared and immunoblotting was performed using 20 µg of 
total lysate protein, as described in the Materials and Methods. B. Western blot analysis 
showing the effect of 1 incubation time on eIF4E-P and various signalling molecules. MRC5 
fibroblast cells were incubated with DMSO alone (lane 1) or with 1 (5 μM) for the indicated 
times. C. Western blot analysis showing the effect of different concentrations of 2 on AKT308 
and various signalling molecules and the effect of 2 in combination with 1. MRC5 fibroblast cells 
were incubated with DMSO alone (lane 1) or with the indicated concentrations of inhibitors for 
24 hours. 
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This is explained by the shared sequence similarity in the C-terminal kinase 
domain of both mTOR and PI3K (Zheng & Jiang, 2015). Interestingly, 
compound 2 also appeared to reduce the level of eIF4E-P at high 
concentrations, suggesting an overlapping function in the eIF4E-MNK pathway. 
The phosphorylation of eIF4E was abolished when compound 2 was used in 
combination with compound 1.  When monitored by Western blotting, the level 
of eIF4E protein remained constant throughout the drug treated cells. A low 
level of cleaved PARP was observed when compound 2 was used at high 
concentrations alone or in combination with 1 (Figure 3-15C), indicating 
apoptosis was occurring at elevated final drug concentrations.   
 
In addition to targeting the mTORC1 signalling pathway at the level of PI3K, this 
study used the well-studied pyrimidine derivative, PP242 (torkinib). PP242 
(Figure 3-14) has an IC50 of 8 nM in cell-free assays and selectively targets both 
mTORC1 and mTORC2 complexes over PI3K isoforms (Apsel et al., 2008) 
(Figure 3-1). Consistent with published data (Apsel et al., 2008), PP242 at a 1 
μM final concentration inhibited the hyperphosphorylation of 4E-BP1 (Figures 3-
16A and B, lanes 1 vs lanes 2). In addition, PP242 treatment of cells also 
inhibited other targets downstream of mTORC1, including p70S6K (Thr389 
phosphorylation) and rpS6 phosphorylation (Figure 3-16B). There was a low 
level of cell death in cells exposed to the compound 1/PP242 combination, with 
more cleaved PARP observed at the highest concentration of compound 1 (10 
μM; lane 2). Incubation of cells with PP242 at 1 μM final concentration in 
combination with various concentrations of compound 1 did not affect the 
efficacy of the latter on eIF4E-P. In a similar manner, the level of ERK-P 
appeared to be unaffected under all of the conditions tested. 
 
mTORC1 is an important regulator of autophagy. Autophagy involves the 
proteolytic degradation of cytosolic components in the lysosome. Its role is 
essential for balancing the cell’s energy resources, removing misfolded or 
aggregated proteins and eliminating intracellular pathogens (Glick et al., 2010). 
mTORC1 induces autophagy in response to stress and starvation conditions. 
However, under normal physiological conditions, mTORC1 directly 
phosphorylates the ULK1 kinase complex (ULK1-ATG13-FIP200-ATG101),  
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Figure 3-16. Representative Western blot analysis of both the eIF4E-MNK and PI3K-AKT-
mTOR pathways in the presence of inhibitors. A. Western blot analysis showing the effect of 
different concentrations of PP242 on 4E-BP1 phosphorylation. MRC5 cells were incubated with 
DMSO alone (lane 1) or the following final concentrations of PP242: lane 2: 5 µM, lane 3: 2.5 
µM, lane 4: 1 µM, lane 5: 500 nM, lane 6: 100 nM. B. Western blot showing the effect of 
different concentrations of 1 in combination with PP242 1 µM.  Cells were incubated with DMSO 
alone (lane 1) or the following final concentrations of inhibitors: lane 2: 1 10 µM, PP242 1 µM, 
lane 3: 1 5 µM, PP242 1µM, lane 4: 1 2.5 µM, PP242 1 µM lane 5: 1 1 µM, PP242 1 µM, lane 6: 
1 500 nM, PP242 1 µM lane 7: 1 100 nM, PP242 1 µM Cellular lysates were prepared and 
immunoblotting was performed using 20µg of total lysate protein, as described in the Materials 
and Methods.  
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inhibiting autophagosome formation and hence autophagy (Chiarini et al., 2015, 
Cope et al., 2014, Laplante & Sabatini, 2012) (Fig 3-17). Figure 3-18C shows 
that low concentrations of compound 2 (<2.5 μM) stimulated the 
phosphorylation of ULK1, an event which prevents autophagosome formation 
(Cope et al., 2014). This is indicative of active mTORC1 signalling in the treated 
cells and further supports the evidence of dose-dependent inhibition of 
mTORC1 activity by compound 2. Microtubule-associated protein 1 light chain 3 
beta (LC3B-I) can also be used to monitor autophagy in treated cells. To enable 
its recruitment to autophagosomal membranes, LC3B-I is conjugated to 
phosphatidylethanolamine to form LC3-phosphatidylethanolamine conjugate 
(LC3-II). The addition of phosphatidylethanolamine can be detected by Western 
blotting, resulting in increased migration upon SDS-PAGE (Tanida et al., 2008). 
In Figure 3-18A, the shift in intensity from LC3B-I to LC3B-II is clearly visible 
when MRC5 cells are treated with 5 μM compound 2 for 24 hours. These data 
suggest that when used independently, high doses of compound 2 (>2.5 μM) 
stimulate autophagy. Relative to the DMSO control, compound 1 used either 
alone or in combination with compound 2 had no effect on autophagy, as 
monitored by conversion of LC3B-I to LC3B-II. In contrast, a shift in intensity 
from LC3B-I to LC3B-II was observed when MRC5 cells were treated with 5 μM 
PP242 for 24 hours. Relative to the DMSO control, PP242 used either alone or 
in combination with compound 1 stimulated autophagy, and promoted the 
cleavage of PARP, indicative of apoptosis (Figure 3-18B). 
 
3.2.6 Inhibition of the MNK1/2 and PI3K-AKTmTOR Pathways Slows the 
Rate of Migration in MDA-MB-231 Cells 
 
The phosphorylation of eIF4E has been shown to correlate with an increase in 
levels of migration and enhanced expression of mesenchymal markers such as 
N-cadherin, fibronectin and vimentin (Robichaud et al., 2015). Disrupting 
cellular migration is a promising therapeutic option for the treatment of cancer 
(Levin, 2005). Here, the rate of migration of a breast cancer cell line has been 
assessed using real-time monitoring of cell migration. 
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Figure 3-17. Regulation of autophagy by mTORC1. In nutrient rich conditions mTORC1 
represses autophagy by phosphorylating ULK1 and ATG13, preventing autophagosome 
formation. Glucose or amino acid starvation results in the repression of mTOR activity. 
Subsequently, ULK1 phosphorylates both FIP200 and ATG13, activating downstream effector 
proteins leading to autophagy (Adapted from (Randall-Demllo, Chieppa et al., 2013). 
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Figure 3-18. The effects of MNK1/ 2, mTOR and PI3K inhibition on cell death and 
autophagy. a) Representative Western blot analysis for the expression of LC3B and cleaved 
PARP in MRC5 cells treated with DMSO, compound 1, compound 2 and a combination 
compounds 1 and 2 for 24 hr, n=3. b) Representative Western blot analysis for the expression 
of LC3B and cleaved PARP in MRC5 cells treated with DMSO, compound 1, PP242 and a 
combination of compound 1/ PP242 for 24 hr. Cellular lysates were prepared and 
immunoblotting was performed using 20 µg of total lysate protein, as described in the Materials 
and Methods   
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MDA-MB-231 cells were incubated in the absence or presence of various 
inhibitors alone or in combination as they moved towards a chemo-attractant. 
Cell migration kinetics were recorded on a RTCA DP instrument for 12 hours. 
As shown in Figure 3-19A (and quantified in Figure 3-19B), when cells were 
treated with a combination of compounds 1 and 2 (both at 1 μM final 
concentration), a substantial reduction in cell migration was observed relative to 
the DMSO control or when compounds 1 or 2 were used as single agents. 
 
Cell viability data demonstrated that the MNK1/2 inhibitor, compound 1, 
exhibited minimal cytotoxicity at 1 μM in MDA-MB-231 cells (Figures 3-19E and 
F). In contrast, the PI3K inhibitor, compound 2, reduced cell viability to 75%, 
when used either as a single agent or in combination with compound 1. The 
synergistic effect of MNK1/2 and PI3K inhibition on cell migration led to the 
investigation of inhibition of both MNK1/2 and mTORC1/2, but using PP242. 
The latter, impaired cell migration to the greatest extent (Figure 3-19C), 
although this could in part be explained by a reduction in cell viability to 60% 
seen with this compound (Figure 3-19F). A combination of compound 1 with 
PP242 appeared to rescue the effect of PP242 used alone, with the cell index 
returning to the level of the DMSO control (Figure 3-19C). One possible 
explanation for this reflects a recent publication demonstrating that MNK forms 
a complex with mTORC1, promoting mTORC1 association with TEL2, which 
facilitates efficient mTORC1/substrate binding (Brown & Gromeier, 2017). The 
dual inhibition of MNK1/2 and mTORC1/2 significantly reduced cell viability to 
35% on control levels (Figure 3-19F), an observation that has been reproduced 
in several cancer cell lines (Bianchini et al., 2008, Grzmil et al., 2011). The 
rescue effect seen when a combination of MNK1/2 and mTORC1/2 inhibition 
was used in the cell migration assay suggests only a selected pool of surviving 
cells were scored in this assay. 
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Figure 3-19. Cell viability and kinetics of migration in drug-treated MDA-MB-231 cells. Cell 
migration in real time was analysed by the xCELLigence RTCA. A. and C. show the cell 
indexes over 12 hours for each drug treatment at 1 µM. B. and D., cell migration analysis at 6 
hr. E. and F. Viability was assessed by Cell Titer Blue assay. MDA-MB-231 cells were treated 
for 72 hours with indicated drugs at 1 µM. Data are mean ± S.D, n = 3 (ns = non-significant; 
*p ≤ 0.05; **p ≤ 0.01 and ****p ≤ 0.0001). 
  
A. B. 
C. D. 
E. F. 
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3.2.7 The Combination of MNK1/2 and mTORC1/2 Inhibition Induces G1 
Cell Cycle Arrest in MDA-MB-231 Cells 
 
FACs analysis was employed to determine whether a combination of MNK1/2 
and PI3K or mTORC1/2 inhibition was associated with arresting the cell cycle at 
a specific stage in proliferating MDA-MB-231 cells over a period of 24 hours. 
The CDK1 inhibitor, R0-3306, was used as a control for the arrest of cells at the 
G2/M phase border (Vassilev, 2006). Following incubation, cells were isolated, 
fixed and stained as described the Materials and Methods. As demonstrated in 
Figure 3-20A, each phase of the cell cycle was observed in unsynchronised 
cells incubated with DMSO. The MNK1/2 inhibitor, compound 1, had no effect 
on cell cycle distribution, whereas both mTORC1/2 and PI3K inhibition, (PP242 
and compound 2, respectively) increased the number of cells in the G1 phase of 
the cell cycle (quantified in Figure 4-20B). However, following exposure to a 
combination of compound 1 and PP242 at 5 μM, the number of cells 
corresponding to the G1 phase was increased, while the numbers of cells in the 
S and G2/M phases were decreased, suggesting a weak block in the G1 phase 
of the cell cycle.  
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Figure 3-20. Flow cytometry analysis of the effect of compound 1, compound 2 and 
PP241 both as single agents and in combination (5 M) on cell cycle progression. The 
cells were treated with the indicated concentrations of inhibitors for 24 hours. Samples were 
fixed and treated with propidium iodide and then analysed by FACs using the Accuri C6 Flow 
Cytometer (see Materials and Methods). Gating was performed sequentially to eliminate cellular 
debris. A. Representative plots for MDA-MB-231 cells treated for 24 hr with indicated inhibitors 
at 5 µM unless otherwise stated in the data table. B. Data are mean ± S.D, n = 2.  
 
  
A. 
B. 
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3.2.8 Synthesis of Hybrid Agents 
 
Based upon the observations above and literature precedence, it was 
postulated that a compound containing both MNK1/2 and PI3K/mTOR inhibitory 
activities might be very effective against cellular migration. A further aim of this 
work was to synthesise novel hybrid molecules based upon compound 1 and 
either PP242 or compound 2 used in this study. The desired outcome was the 
development of a novel, single molecular framework incorporating both 
moieties. The hybrid concept covers either permanent or prodrug, cleavable 
dual-action molecules, i) or ii) (Figure 3-21). The “type ii)” hybrid compounds (6 
and 7) were prepared as outlined in Figure 3-22. Compound 6 was prepared via 
a simple one-pot synthesis as detailed in the Materials and Methods. 
Compound 7 was prepared by initially converting the carboxylic acid 
functionality of the starting material, compound 1 (Teo et al., 2015a) into an acid 
chloride. This intermediate then underwent an esterification reaction with 
PP242, leading to the formation of compound 7 in the presence of base. The 
final products were fully characterised by HRMS and 1H NMR (Figures 3-23 and 
3-24). Single crystals of both compounds 6 and 7 were isolated from a 
chloroform solution and the resulting X-ray analysis is depicted in Figure 3-25 
which showed the expected connectivity i.e. the ester bonds in the products 
(Coles, 2012). 
 
 
 
 
Figure 3-21. “Permanent” vs. cleavable hybrid approach.
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Figure 3-22. Synthesis of ester-linked, cleavable hybrid molecules. Reagents and conditions: A. i) DMF, Et3N, EDC hydrochloride, HOBt, 
DMAP, RT overnight B. i) SOCl2, toluene, reflux 2 h ii) Et3N, CH2Cl2, RT overnight. 
1 
2 
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i) 
A. 
B. 
1 Intermediate 
PP242 
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134 
 
                         
                          Figure 3-23. 1H NMR (CDCl3) spectrum of compound 6 (acetone signal at 2.19).
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                              Figure 3-24. 1H NMR (CDCl3) spectrum of compound 7. 
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Figure 3-25. Crystal structures of hybrid agents. A. Compound 6 (CCDC 1813013), B. Compound 7 (CCDC 1813012).
A. B. 
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3.2.9 In Vitro Analysis of Hybrid Agents in MRC5 Cells 
 
Compounds 6 and 7 were screened for activity in MRC5 cells by Western 
blotting (Figures 3-26A and B) and compared with known kinase inhibitors, PI-
103 and staurosporine. Cells were incubated in the absence or presence of 
inhibitors for 24 hours and extracts were prepared as described in the Materials 
and Methods. During this work it was found that both compounds 6 and 7 were 
difficult to solubilise in DMSO and delivery onto cells at a known final 
concentration was problematic. Following Western blot analysis of extracts, in 
contrast to compounds 1 and 2 together, compound 6 failed to show any 
noticeable effect on either PI3K or MNK1/2 signalling output relative to the 
DMSO control. This was reflected by the finding that compound 6 had little 
effect on phosphorylation of AKT-T308 or on the levels of eIF4E 
phosphorylation, respectively. mTORC1 read-outs, 4E-BP1, p70S6K Thr389-P 
and phospho-ribosomal S6 protein also indicated a lack of inhibition of 
mTORC1 signalling with effective inhibition seen with compounds 1 and 2 
together. In addition, ULK1-P and AMPKT172-P were unaffected by the 
inhibitors used, indicating that cells had not activated a general stress response. 
When compared to the DMSO control, compound 7 slightly reduced the level of 
eIF4E-P when tested at the highest concentration (10 μM). Similarly, mTORC1 
inhibition was observed at this highest concentration, reflected by the collapse 
of the broad 4E-BP1 signal into a condensed band and a reduction in rpS6 
phosphorylation (Figure 3-26B). There was a low level of cleaved PARP in cells 
treated with the 1:1 mixture of compound 1/PP242 and in cells treated with 
compound 7, suggesting that this combination in both forms contributed to cell 
death. 
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Figure 3-26. Characterisation of hybrid agents. A. and B. Western blot analysis showing the effect of different concentrations of compounds 6 and 7 
respectively on various signalling molecules. MRC5 fibroblast cells were incubated with DMSO alone or with the indicated concentrations of inhibitors for 24 
hours. Cellular lysates were prepared and immunoblotting was performed using 20 µg of total lysate protein, as described in the Materials and Methods. 
139 
 
3.3 Discussion 
 
The results presented in this chapter document the synthesis and initial 
characterisation of compound 1, a potent MNK1/2 inhibitor. This inhibitor was 
previously shown to be more selective than commercially available MNK 
inhibitors, cercosporamide and CGP57380, and also predicted to have fewer 
off-target effects. However, selectivity profiling revealed that compound 1 also 
showed some activity against PIM1, a serine/ threonine protein kinase involved 
in cell survival and proliferation. PIM1 is implicated in numerous signal 
transduction pathways and is highly expressed in lymphoid and haemopoietic 
tissues (Eichmann et al., 2000). PIM1 sits downstream in the JAK/STAT 
pathway and phosphorylates a large subset of cellular substrates (Tursynbay et 
al., 2016). It is involved in regulating myc transcriptional activity, cell cycle 
progression and inhibits pro-apoptotic proteins, such as BAD, MAP3K5 and 
FOXO3 (Gu et al., 2009, Morishita et al., 2008). PIM1 negatively regulates 
cyclin-dependent kinase inhibitor, p27Kip1, at both the transcriptional and post-
translational level (Morishita et al., 2008). As mentioned in Section 3.2.3, PIM1 
has a role in translational control through its interaction with 4E-BP1 and the 
subsequent release of eIF4E. Interestingly, a feedback loop between eIF4E and 
c-myc has been observed; eIF4E promotes the expression of c-myc, which can 
in turn drive eIF4E expression (Clemens & Bommer, 1999, Lin et al., 2008, 
Rosenwald et al., 1993). PIM1 is also associated with MCL-1, a protein with an 
oncogenic, pro-survival role. A previous study has shown that PIM1 inhibitor, 
SGI-1776, reduced MCL-1 transcript and protein levels, inducing apoptosis in 
FLT3-ITD AML cells (Chen et al., 2011). Further studies investigating this off-
target effect may be beneficial in characterising compound 1. Modelling of PIM1 
and MNK1 proteins revealed that although the proteins had relatively low % 
sequence identity between them (~26%), the proteins are structurally very 
similar (Figure 3-27). This may account for the off-target effect of compound 1 
on PIM1 kinase. 
 
MNK1/2 are serine/threonine protein kinases that phosphorylate eIF4E on 
Ser209, leading to the preferential translation of oncogenic proteins (reviewed in 
Section 1.2). To determine whether the compound 1 inhibitor was functional in
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Figure 3-27. Structural alignment of PIM1 kinase and MNK1. The two proteins are 
superimposed and coloured according to conservation. Highly conserved regions are 
coloured in red and less conserved regions are coloured in blue. Molecular graphics and 
analyses were performed with the UCSF Chimera package (Pettersen et al., 2004). 
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MRC-5 cells, its ability to inhibit eIF4E phosphorylation was tested. Compound 
1 reduced the level of eIF4E phosphorylation in a concentration-dependent 
manner, being effective at concentrations above 2.5 µM. The phosphorylated 
form of eIF4E is correlated with an increase in mesenchymal markers and poor 
clinical outcome in human cancers. Therefore, targeting the translational 
machinery through the inhibition of eIF4E is a promising therapeutic option for 
the treatment of aggressive metastatic cancers. The only available crystal 
structure of MNK1 is in the DFD-out (inactive) conformation, which has hindered 
the docking attempts of small-molecule inhibitors. In contrast, a crystal structure 
of MNK2 exists in the DFD-in (active) conformation. The MNK2D228G-
staurosporine complex (PDB: 2HW7), provides a valuable source of structural 
information. The homology model of active MNK1 using PDB: 2HW7 as a 
template may aid the design of selective MNK inhibitors. The predicted binding 
mode of compound 1 in the MNK1 homology model indicated the fluoroaniline 
projected into the hydrophobic pocket adjacent to the DFD-motif. This 
information provides a starting point for further structural modification of 
compound 1. Using MDA-MB-231 cells, this work has determined that a 
synergistic combination of MNK1/2 and PI3K inhibitors slowed the rate of cell 
migration. Additionally, a combination of MNK1/2 and mTORC1/2 inhibitors 
resulted in cell cycle arrest and a decrease in cell viability to a greater extent 
than when the inhibitors were used as single agents. This led to the attempted 
development of novel hybrid entities, encapsulating MNK1/2 and PI3K/mTOR 
inhibitory activities. However, in part due to solubility issues, the novel hybrid 
compounds did not prove to be effective in vivo. The poor solubility of 
compounds 6 and 7 can be explained in part by their physiochemical properties, 
including their high molecular weight (>500), TPSA (>140 Å2), clog P (>5) 
(Table 3-1). Both compounds 6 and 7, violate two of Lipinski’s rules, by 
exceeding a molecular weight of 500 and a log P value of 5. Compounds 6 and 
7 also violate one of Veber’s rules, by surpassing a TPSA of 140 Å2 (Veber et 
al., 2002). The relatively high log P values of compounds 6 and 7 may imply 
reduced membrane permeability. Highly lipophilic compounds with high log P 
values permeate poorly through membranes as they aggregate in the 
hydrophobic interior of the membrane bilayer (Leeson & Springthorpe, 2007).   
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Although molecular hybridisation approaches hold significant promise, they 
currently face considerable challenges as therapeutic modalities (Berube, 2016, 
Cai et al., 2010, de Lera & Ganesan, 2016, Fortin & Berube, 2013, Gediya et 
al., 2008, Nepali et al., 2014, Patel et al., 2014, Rodrik-Outmezguine et al., 
2016, Woo et al., 2011). However, simultaneous MNK1/2 and PI3K/mTOR 
inhibition warrants further investigation as a therapeutic option for treating 
aggressive migratory cancers (Lineham et al., 2017). Subsequent work will look 
at the development of novel analogues of the MNK1/2 inhibitor, compound 1, 
with a view to enhance the potency and specificity against the target protein.
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Table 3-1. Physiochemical properties and lipophilicity prediction of inhibitors used in this study, calculated using SwissADME software (Daina, 
Michielin et al., 2017).
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4 Probing the Anticancer Action of Novel Ferrocene 
Analogues of MNK Inhibitors 
 
4.1 Introduction 
 
The incorporation of ferrocene into drugs has attracted significant attention in 
the field of medicinal chemistry, and several ferrocene derivatives have been 
investigated (Figure 4-1), including ferroquine and ferrocifen (Figure 4-1B), 
which act as antimalarial and anticancer compounds, respectively (Patra & 
Gasser, 2017). Ferrocene is a nontoxic, air- and water-stable complex, 
comprised of an iron atom sandwiched between two cyclopentadienyl rings 
(Jaouen et al., 2015). The reversible redox properties of ferrocene have 
enabled ferrocene derivatives to be used as prodrugs in certain biological 
environments where ferrocene (Fc) is oxidised to form a cytotoxic ferrocenium 
cation (Fc+) (Patra & Gasser, 2017). 
 
Tamoxifen (TAM) is a prodrug that is currently used to treat ER+ breast cancer 
(Figure 4-1A). The hydroxylated metabolite, hydroxytamoxifen (OH–TAM), 
competes with estradiol for binding to ERα and ERβ (Gottardis & Jordan, 1987, 
Jordan et al., 1980). However, many patients that respond initially to TAM 
develop resistance to the drug (Ring & Dowsett, 2004). Ferrocenyl analogues of 
TAM have been investigated as anticancer agents and have been found to have 
superior activity against both ER+ and ER- breast cancer cell lines, in contrast to 
OH–TAM, which is only active against ER+ cells (Nguyen et al., 2007). The 
replacement of the phenyl group in TAM with a ferrocenyl group led to the 
formation of the prodrug ferrocifen (Fc–TAM) and the hydroxylated metabolite, 
hydroxyferrocifen (Fc–OH–TAM), which has an IC50 of 0.5 µM in TNBC MDA-
MB-231 cells (Gormen et al., 2010). The dual action of Fc–OH–TAM is 
responsible for its increased anticancer activity. In addition to the competitive 
binding of ER, Fc–OH–TAM loses two electrons and two protons to form a 
quinone methide intermediate, a Michael acceptor, capable of instigating a 
cytotoxic response (Bolton, 2014). Fc–OH–TAM was also found to induce 
cellular senescence, apoptosis, and the formation of reactive oxygen species 
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(ROS) in a concentration and cell-line dependent manner (de Oliveira et al., 
2011, Vessieres et al., 2010, Wlassoff et al., 2007). 
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Figure 4-1. Chemical structures of inhibitors and ferrocene derivatives. A. and B. 
Structures of prodrugs and hydroxylated drugs; tamoxifen and ferrocifen, C. structure of 
compound 1, a MNK1/2 inhibitor, D. structure of methyl ester ferrocene derivative, 2, E. 
structure of ferrocene derivative, 3, F. structure of methyl ester ferrocene derivative, 4, G. 
structure of ferrocene derivative, 5.    
A. B. 
C. D. E. 
F. G. 
147 
 
    
The Spencer lab (Sussex) have previously reported the incorporation of 
ferrocene, as a phenyl bioisostere, into a variety of different molecules for 
biological evaluation (Amin et al., 2013, Librizzi et al., 2012, Ocasio et al., 2017, 
Spencer et al., 2009). Using a known MNK1/2 inhibitor, compound 1 (Figure 4-
1C) as a starting point, the following work describes the initial characterisation 
of novel ferrocene containing compounds in tissue culture cells (Figures 4-1D 
and E). From our previous research, we envisaged that the introduction of a 
ferrocene group would both enhance the binding potency and potentially confer 
other desirable biological properties to the molecules. 
 
4.2 Results 
4.2.1 Molecular Modelling of Compound 1 Reveals a Large Hydrophobic 
Cavity in MNK2 
 
The crystal structures of MNK1 and MNK2 are available in the DFD-out 
(inactive) conformation, which blocks ATP-binding (Hou et al., 2013, Kannan et 
al., 2015). A crystal structure of MNK2-D228G in complex with staurosporine 
(PDB: 2HW7) was used to model the MNK1/2 inhibitor, 1 (Figures 4-2A and B). 
This mutation from wildtype DFD to the canonical DFG motif creates a structure 
that has both DFG-in and DFG-out conformations that ease crystallisation of the 
protein (Jauch et al., 2005). The predicted binding mode of compound 1 in 
MNK2-D228G indicates that the pyrimidine moiety occupies the ATP-binding 
pocket, the carboxyl group is solvent exposed, and the fluoroaniline projects 
into the large hydrophobic pocket. There are a few important interactions to 
note (Figure 4-2B). Firstly, the aromatic side chain of gatekeeper residue, 
Phe159, provides an electron rich surface that allows the formation of cation-π 
interactions between the active site and compound 1. The cations present on 
the edge of the fluoroaniline ring interact with the face of the benzene ring 
present in Phe159.  
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A. 
        
B. 
        
C. 
          
 
Figure 4-2. Docking of compound 1 in MNK2 crystal structure. A. Predicted binding mode 
of compound 1 in MNK2-D228G (PDB code: 2HW7) coloured by hydrophobicity surface: from 
blue for the most hydrophilic, to white, to red for the most hydrophobic. B. Important regions 
within the MNK2 active site and proposed interactions with compound 1. Molecular graphics 
and analyses were performed with the UCSF Chimera package (Pettersen et al., 2004). C. 
Ferrocene as a bioisostere (adapted from Patra & Gasser, 2017). 
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There is also a strong sulphur-aromatic interaction between the pre-DFG 
Cys225 residue and the pyrimidine in compound 1, with the sigma hole of the S 
atom accepting pi electrons. Modelling of compound 1 revealed a large 
hydrophobic pocket, a region that could be exploited by substituting the aniline 
ring with a bulkier group such as ferrocene (Figure 4-2C). In order to predict the 
binding mode of the ferrocene derivatives, compounds 3 and 5, the structures 
were manually altered. The sandwich-structure of ferrocene prevents the 
modelling software from recognising the structural features of the compound. 
The ferrocene groups were therefore substituted for an adamantyl group, a 
ferrocene bioisostere, to produce similar compounds for modelling (Figures 4-
3A and B). The most likely binding modes of each compound are depicted in 
Figures 4-3C and D. 
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Figure 4-3. Docking of ferrocene-like compounds in MNK2 crystal structure. A. Structure 
of the “ferrocene-like” compound 3 used for molecular modelling, with the ferrocene moiety 
substituted for an adamantyl group. B. Structure of the “ferrocene-like” compound 5 used for 
molecular modelling, with the ferrocene moiety substituted for an adamantyl group. C. Predicted 
binding mode of “ferrocene-like” compound 3 in MNK2-D228G (PDB code: 2HW7) coloured by 
hydrophobicity surface: from blue for the most hydrophilic, to white, to red for the most 
hydrophobic. D. Predicted binding mode of “ferrocene-like” compound 5 in MNK2-D228G. 
Molecular graphics and analyses were performed with the UCSF Chimera package (Pettersen 
et al., 2004).  
  
A. B. 
C.     D. 
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4.2.2 Ferrocene Analogues of Compound 1 
 
The preparation of the ferrocene analogues (compounds 3 and 5; Figure 4-1) 
was conducted in collaboration with Dr. Storm Hassell-Hart using an analogous 
strategy to the synthesis of 1 (Figure 4-1C) (Teo et al., 2015b). In both 
instances, microwave-mediated acid-catalysed SNAr (nucleophilic aromatic 
substitution) followed by basic hydrolysis to remove the ester group enabled us 
to synthesise the desired inhibitors in good to excellent yields (Figure 4-4). A 
solid-state determination confirmed the crystal structure of 3 (Figure 4-5). 
 
4.2.3 In Vitro Analysis of Compounds 1, 3, and 5 in Cancer Cell Lines 
 
To test whether the compounds 1, 3 and 5 had any effect on cell viability, a 
number of mammalian cancer cell lines were incubated with DMSO alone or 
with different final concentrations of compounds for 72 hours. Cell viability was 
determined using the Cell Titer Blue assay (as described in Section 2.2). These 
data are summarised in Table 4-1 and show that compound 1 had no significant 
effect on cell viability in any of the three breast cancer cell lines tested, including 
TNBC cell lines (BT-549 and MDA-MB-231) and the HER2+ breast cancer cell 
line, SK-BR-3. However, 1 did decrease cell viability in MOLM-13 cells and MV-
4-11 acute myeloid leukaemia (AML) cell lines, with IC50 values of 5.39 µM and 
9.72 µM, respectively. The cell viability of compound 3 treated cancer cell lines 
varied according to cell type. Compound 3 appears to have greater potency 
against BT-549 and MDA-MB-231 cells and is less effective against the HER2+ 
breast cancer cell line, SK-BR-3. The effect of 3 on cell viability in AML cell lines 
was cell-line-specific, with no significant effect on MOLM-13 and a moderate 
decrease in cell viability observed in MV-4-11. Compound 5 showed the highest 
potency, with an IC50 < 2 µM in four of the cell lines tested. Compounds 3 and 5 
both showed greater potency towards the TNBC cell line, MDA-MB-231, with 
IC50 values of 2.83 µM and 0.55 µM, respectively (Table 5-1 and Figure 5-6). 
The sensitivity of MDA-MB-231 towards 5 prompted further evaluation and 5 
was taken forward for additional studies. 
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      Figure 4-4. Schematic of ferrocene analogue synthesis. A. Synthesis of ferrocene analogue, 3, B. synthesis of ferrocene analogue, 5.
A. 
B. 
2 3 
4 5 
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Figure 4-5. Crystal structure of compound 3 (CCDC 1862154). 
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Table 4-1. IC50 values of compound 1 vs ferrocene analogues 3 and 5 in vitro (µM). Cells 
were treated for 72 hr and assessed by Cell Titer Blue assay. IC50 values are given as mean of 
three independent experiments (n=3), n.s, non-significant.   
 
 
      
 
Figure 4-6. Dose-response curves for ferrocene analogues, 3 and 5 in MDA-MB-231 cells. 
Cells were treated for 72 hr and assessed by Cell Titer Blue assay. Data shown as mean ± SD 
of triplicate wells and are representative of three independent experiments (n=3).
Cell Line 
Compound IC50 (µM) 
1 3 5 
BT-549 n.s 6.67 1.73 
MDA-MB-231 n.s 2.83 0.55 
SK-BR-3 n.s 114.30 10.63 
MOLM-13 5.39 n.s 1.82 
MV-4-11 9.72 8.37 1.98 
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To investigate the effect of compounds 3 and 5 on cell signalling processes, 
MDA-MB-231 cells were incubated with 5 µM of 3 and 5 for either 6 hr or 24 hr, 
extracts prepared and equal amount of protein analysed by SDS-PAGE and 
Western blotting (Figure 4-7). Surprisingly, although 1 has been shown to 
prevent phosphorylation of eIF4E on Ser209 (Chapter 3), Figure 4-7 shows that 
incubation of cells with 5 μM of compound 3 or 5 for 6 hr had no effect on the 
level of eIF4E phosphorylation. An increase in incubation time to 24 hr did not 
result in an inhibition of eIF4E phosphorylation (Figure 4-7, lanes 5 and 6 vs 
lane 4); the slight increase in eIF4E phosphorylation observed in all the latter 
cells probably reflects an overall increase in cellular growth over the 24 hr 
incubation. In addition, the treatment of MDA-MB-231 cells with 3 and 5 as 
single agents did not appear to effect PI3-K signalling, indicated by little change 
in the level of phosphorylation of AKT(T308-P) in comparison to the DMSO 
vehicle. Phosphorylation of p70S6K (T389) and ERK1/2 (T202/Y204) were not 
inhibited upon incubation of cells with the ferrocene analogues, 3 and 5, either 
at 6 hr or 24 hr. However, there was a slight increase in the level of rpS6 and 
ERK1/2 phosphorylation when cells were incubated with 5 at 5 μM, eluding to a 
possible role of 5 in modulating ERK1/2 and rpS6 phosphorylation at early 
times. 
  
156 
 
 
 
                       
 
 
Figure 4-7. Representative Western blot analysis of both 3- and 5-treated MDA-MB-231 
cells. Western blot analysis showing the effect of 5 µM of 3 and 5 on the phosphorylation status 
of S6K, eIF4E, AKT, ERK and spS6 after 6 hr and 24 hr incubation. MDA-MB-231 cells were 
incubated with DMSO alone (lanes 1 and 4), 3 (lanes 2 and 5) or with 5 (lanes 3 and 6). Cellular 
lysates were prepared and immunoblotting was performed using the indicated antibodies using 
20 µg of total lysate protein, as described in the Materials and Methods. 
  
157 
 
4.2.4 Treatment of MDA-MB-231 Cells with Compound 5 Increases the 
Rate of Cell Migration 
 
TNBC is an aggressive form of breast cancer typified by highly migratory and 
invasive cells (Podo et al., 2010). To investigate the effect of 1 and 5 on cell 
migration, the rate of migration of the TNBC cell line, MDA-MB-231, was 
assessed in the absence or presence of compounds, using real-time monitoring 
of cell migration (Figure 4-8). MDA-MB-231 cells were analysed in the presence 
of DMSO alone, compound 1, or compound 5 as they moved towards a chemo-
attractant. Cell migration kinetics were recorded on an RTCA DP (Real-Time 
Cell Analyser Dual-Plate) instrument for 12 hr. As shown in Figure 4-8A, when 
cells were treated with 1 at 1 μM final concentration, a slight, reproducible 
increase in cell migration was observed. The effect of 5 at 1 μM concentration 
on cell migration was more substantial, with a significant increase in cell 
migration at 6 hr relative to the DMSO control (Figure 4-8B). This might reflect 
the possible role of 5 in modulating ERK1/2 and rpS6 phosphorylation at early 
times (Figure 4-7), events commonly associated with cell growth. It may also be 
a result of oncogene activation, driven by cellular stress and subsequent eIF2α 
phosphorylation (Garcia-Jimenez & Goding, 2019) (discussed in Section 
1.1.4.3).  
 
4.2.5 Analysis of Compounds 1 and 5 on MDA-MB-231 Spheroid Growth 
 
Three dimensional (3D) cell culture is an artificially created environment in 
which cultured cells are permitted to grow and interact with their surroundings in 
all three dimensions. Unlike classical 2D environments, a 3D culture allows cells 
in vitro to grow in all directions, similar to how they might function in vivo. As 
MDA-MB-231 cells grow in 3D culture, the sensitivity of these cells to compound 
1 and 5 was monitored under these conditions. Having established the optimal 
conditions for spheroid assembly (detailed in Materials and Methods), the effect 
of increasing concentrations of compounds 1 and 5 on spheroid growth was 
examined as described in Figure 4-9. Three-day-old spheroids were treated 
with DMSO alone, compound 1, or 5 and their growth monitored using the 
Celigo Image Cytometer. Whole-well bright-field images were acquired multiple 
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days after adding the test compounds and the tumour spheroid diameter was 
measured to provide a quantitative analysis of spheroid growth (Figures 4-9A 
and B). 
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Figure 4-8. Kinetics of migration in MDA-MB-231 cells incubated with ferrocene compounds. Cell migration in real time was analysed by the 
xCELLigence RTCA. A. shows the average cell indexes over 12 hr for each drug treatment (1 µM), B. cell migration analysis at 6 hr, data shown as mean ± 
S.D, n=3 (**p ≤0.01). 
A. B. 
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Figure 4-9. Assessment of growth in MDA-MB-231 spheroids incubated with ferrocene compounds. MDA-MB-231 cells were treated for 4 days with 1 
and 5 as single-agents. Spheroids were imaged and analysed using the Celigo High Throughput Micro-Well Image Cytometer. A. Representative bright-field 
images of MDA-MB-231 spheroids after 4 days. B. The diameter of MDA-MB-231 spheroids after 4 days incubation in the absence of presence of ferrocene 
compounds was measured using ImageJ software. C. Spheroid diameter dose-response curve for compound-5-treated spheroids. Data shown as mean ± S.D 
of triplicate wells (n=3). 
A. DMSO 0.098 0.195 0.391 0.781 1.563 3.125 6.250 12.500 25.000 
1 
(µM) 
5 
B. C. 
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Results show that compound 1 had no effect on spheroid diameter, even at the 
highest concentration of 25 µM. In contrast, 5 showed a concentration-
dependent growth inhibition of MDA-MB-231 spheroids. A dose-response curve 
was plotted for 5 and was used to calculate an IC50 value of 1.25 µM (Figure 5-
9C), approximately twice the IC50 value reported in the 2D cell viability assay 
(IC50: 0.55 µM). As with cell growth characteristics, these results indicate that 
drug susceptibility can vary between 2D and 3D assays and a combination of 
assays are required to ascertain drug effectiveness. 
 
 
4.2.6 In Vitro Kinase Assays Report that Compound 5 has no Effect on 
MNK1/2 Kinase Activity 
 
Incubation of cells with compound 5 had no effect on the level of eIF4E 
phosphorylation and caused a small increase in p70S6K and ERK1/2 
phosphorylation at early times (Figure 4-7). To gain further insights into what 
kinase(s) 5 might be targeting in the cell, in vitro target validation of 1 and 5 was 
carried out using a commercial kinase screening assay (provided by Reaction 
Biology; Table 4-2); for costs reasons and due to its weaker affinity, 3 was not 
included in this screen. As expected, compound 1 dramatically reduced MNK1 
and MNK2 enzyme activity to ~3% and ~1.5%, respectively, relative to the 
DMSO vehicle. Compound 1 had a significant off-target effect on PIM1, in which 
enzyme activity was reduced to <50%. This may be explained by the structural 
similarity between MNK1/2 and PIM1 (discussed in Section 3.3). The inhibition 
of MNK1/2 by compound 1 did not affect upstream protein kinases, AKT or 
p38MAPK (Lineham et al., 2018). In contrast, 5 had no effect on percentage (%) 
enzyme activity in any of the protein kinases screened. These data are in 
agreement with findings presented in Figure 4-7; an extensive screening panel 
would be required for a more in-depth understanding of the targets on 
compound 5. 
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Kinase: 
% Enzyme Activity (relative to DMSO controls) 
1 5 
Data 1 Data 2 Data 1 Data 2 
AKT1 110.03 105.00 106.92 105.28 
MNK1 3.64 2.53 115.13 111.38 
MNK2 1.87 0.79 97.56 96.04 
P38a/MAPK14 125.49 119.86 126.41 125.76 
PIM1 43.11 42.99 118.37 117.29 
 
 
Table 4-2. Selectivity of compound 1 and 5 against a panel of kinases (% enzyme activity 
relative to DMSO vehicle). Compounds were tested under standard commercial conditions (in 
single dose duplicates at 1 µM) and reactions were carried out at 10 µM ATP by Reaction 
Biology Kinase HotSpot Screening. Enzyme activity >100% may be due to a real stimulatory 
effect or an artefact due to interference of the compound with the measurement. 
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4.3 Discussion 
 
Structural modelling of compound 1 (Figure 4-1) in the active site of MNK 
kinase revealed a large hydrophobic pocket that could be exploited with a 
bulkier group such as a ferrocene (Figures 4-2 and 4-3). Although the ferrocene 
derivatives, 3 and 5 (Figures 4-1D and E; Figure 4-4), showed no activity 
against MNK1/2 (Figure 4-7), their potency in cancer cell lines is promising. It is 
unsurprising that compound 1 has no significant effect on cell viability, as the 
MNK kinases are not required for normal development (Teo et al., 2015b). 
MNK1/2 inhibitors exert their effect by preventing the drive of oncogenic 
signalling through the inhibition of eIF4E phosphorylation. The IC50 values for 
the two ferrocene compounds follow a similar pattern across the range of cell 
lines tested (Table 4-1), with both compounds  more effective against TNBC 
lines and less effective in the HER2+ cell line, SK-BR-3. This could reflect a 
variation in the levels of cellular target proteins, or a difference in the rate of 
metabolism. It is possible that the ferrocene itself is responsible for the 
anticancer activity. The production of reactive oxygen species (ROS) in the 
Fenton reaction has been proposed as a mechanism of cytotoxicity in other 
ferrocene derivatives (Tabbi, Cassino et al., 2002). Indeed, the anticancer 
compound, Fc–OH–TAM, elicits an oestrogen receptor-independent mechanism 
of action in addition to its competitive binding of ER. Additionally, ROS 
production was associated with cell cycle arrest and cellular senescence in Fc–
OH–TAM-treated breast cancer cells (Vessieres et al., 2010). The IC50 values 
for compound 5 and Fc–OH–TAM in MDA-MB-231 were both ~0.5 µM (Table 4-
1), which suggests ROS production may be involved in the mode of action for 5.  
 
The synthesised compounds were submitted to a commercial small kinase-
screening panel aimed at assessing their ability to inhibit the activity of selected 
kinases. These data summarised in Table 4-2, suggest that the ferrocene 
derivative 5 targets alternative cellular pathways than those investigated. These 
findings are in agreement with a lack of effect on MNK1/2 and AKT signalling, 
as determined by Western blotting (Figure 4-7). Interestingly, 5, and to a lesser 
extent 3, increased the rate of migration in MDA-MB-231 cells. The reasons for 
this unexpected result are unclear. Compound 5 may target a negative regulator 
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of cell migration; alternatively, the increase in migration rate may be a result of 
cellular stress. Western blotting also suggested that the level of rpS6 and 
ERK1/2 phosphorylation increased upon incubation with 5, indicating a possible 
role of 5 in the inhibition of protein phosphatases. Further analysis would 
require an extensive kinase screen to validate the targets of these compounds. 
Additional eIF2α assays would also elucidate the role of cellular stress induced 
by the ferrocene compounds used in this study. These data, in agreement with 
the literature, highlight the potential of ferrocene-based compounds such as 
ferrocifen as anticancer agents.  
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5 Genetic knockdown and Pharmacological Inhibition 
of DDX3X and its Effect on Cell Migration 
 
7.1 Introduction 
 
The exact role of DDX3X in translation has yet to be elucidated. The most 
studied function is its role in promoting the translation of specific mRNAs 
containing a high degree of secondary structure in their 5’UTR through its 
interaction with eIF4F. However, contradicting evidence suggests that DDX3X 
represses cap-dependent translation by binding to and inhibiting eIF4E (Shih et 
al., 2008), as well as promoting stress granule formation. Furthermore, DDX3X 
can have both oncogenic and tumour suppressor properties depending on the 
cancer type and the expression level of interacting partners. To help unravel 
this, as described, the CRISPR-Cas9 system was used to induce a site-directed 
non-homologous end joining (NHEJ) event in the first exon of DDX3X. Following 
repair the aim was to create a frameshift mutation and subsequently, a 
premature stop codon to decrease expression of DDX3X protein in MRC5 
fibroblasts (summarised in Figure 5-1). Following on from the characterisation of 
the cell lines developed, subsequent analysis focussed on the pharmacological 
inhibition of the ATP-dependent helicase function of DDX3X  in prostate cancer 
cell lines bearing both high and low DDX3X protein expression levels. 
 
5.1 Results 
5.1.1 The Generation of a DDX3X Knockdown Cell Line 
 
The CRISPR-Cas9 system is comprised of two parts, the Cas9 endonuclease 
and the targeting RNA. The targeting RNA, also known as a small guide RNA 
(sgRNA), is a duplex RNA consisting of a CRISPR RNA, transacting RNA 
(tracrRNA) and a spacer located at the 5’end of the CRISPR RNA. The spacer 
finds an identical sequence on the target DNA named the protospacer. Another 
sequence directly downstream of the protospacer, known as the protospacer 
adjacent motif (PAM) must also be recognised by the CRISPR-Cas9 complex 
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before cleavage occurs. The Cas9 endonuclease then creates a double 
stranded break three nucleotides upstream of the PAM site. 
 
A protocol based on the CRISPR-Cas 9 endonuclease (Ran et al., 2013) was 
used to create a genetic modification to DDX3X in  MRC5 cells. The 
experimental workflow is summarised in Figure 5-2 and begins with the in silico 
design of sgRNAs. The genomic DNA sequence from DDX3X was imported 
from Ensembl® into Benchling®, after cross-referencing with Uniprot®.  
 
Next, the CRISPR sgRNA design tool was used to analyse a 1 kb fragment of 
the region of interest and locate suitable target sites by identifying 20-bp 
sequences directly upstream of any 5’NGG (PAM sequence). Both on- and off-
target sites were computationally predicted, allowing selection of the three 
highest ranked sgRNA sequences, i.e. highest on-target with lowest off-target 
scores (Figure 5-3). Following the construction of sequence-verified pSpCas9 
(sgRNA) plasmids, subsequent transfection into MRC5 cells using 
Lipofectamine® and clonal expansion, extracts were prepared from  the cell 
lines derived here and aliquots containing equal amounts of protein resolved by 
SDS-PAGE. Western blotting was used to screen the putative monoclonal 
DDX3X knockout cells generated by this method. As shown in Figure 5-4A, the 
decreased expression of DDX3X protein in clones 2A, 2C and 1F cell lines 
initially indicated that the DDX3X gene had been successfully deleted. 
However, following several cell passages, further Western blotting analysis of 
the cell lines suggested only a partial knockout of DDX3X had occurred (Figures 
5-4B and C). A commercial company was also used to generate DDX3X 
knockout in HAP1 cells (derived from a chronic myelogenous leukaemia (CML); 
a similar result of a partial knockout was also obtained with the cells (data not 
shown), suggesting that total loss of DDX3X protein was likely lethal to cells. 
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Figure 5-1. Simplified model of double strand break (DSB) repair by the non-homologous 
end joining pathway (NHEJ). RNA-guided Cas9 nuclease (green) induces a DSB that can be 
repaired by the error-prone NHEJ pathway. The ends of the DSB are processed by the 
Ku heterodimer (Ku70 and Ku80), which forms a complex with DNA-PKc. The DNA ends are 
processed by additional enzymes and re-joined by the DNA ligase IV/XRCC4. NHEJ directed 
DSB repair may result in random indel mutations at the site of the Cas9 induced “nick”. Indel 
mutations within a coding region create a frameshift mutation, which may lead to the generation 
of a premature stop codon, and ultimately a gene knockout. 
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Figure 5-2. Experimental workflow of CRISPR-Cas9 gene knockout in mammalian cells 
using a protocol from Ran et al., 2013. A. Guide RNAs (sgRNAs) were designed using a 
CRISPR design tool built into Benchling® (light blue bars). B. sgRNAs were then cloned into a 
pSpCas9(BB) plasmid, containing both sgRNA scaffold backbone (BB) and Cas9. C. The 
resulting sequence-verified pSpCas9(sgRNA) plasmids were transfected into MRC5 cells and 
the surveyor assay was used to assess cleavage ability. D. Limiting dilution was used to isolate 
clones. These cell lines were expanded to derive isogenic cell lines with specific mutations. 
(Figure taken and adapted from Ran et al., 2013). 
A. 
B. 
C. 
D. 
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To verify that the level of DDX3X mRNA was significantly reduced in CRISPR 
generated DDX3X clonal cell lines 2C and 2A, comparative qRT-PCR 
(described in the Materials and Methods) was used to measure the level of 
DDX3X mRNA in knockout cell lines. In comparison to wildtype levels, there 
was a reduction in DDX3X mRNA in both cell lines, with the greatest reduction 
seen in clone 2A (Figure 5-5). These data clearly show that the selected MRC5 
clones 2A and 2C exhibit CRISPR-Cas9-mediated, but partial reduction of 
DDX3X mRNA and protein expression. To determine whether loss of DDX3X 
protein caused any changes in level of other initiation factors, cell extracts were 
further characterised by Western blotting and the level of expression of various 
translation factors and signalling molecules were analysed. Figure 5-6 shows 
that, relative to wildtype cells, there was no change in the total levels of 
translation factors analysed in this study when DDX3X protein levels were 
reduced.
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Figure 5-3. Schematic of the 20-nt guide sequences used to target the Cas9 nuclease to the genomic DNA sequence of DDX3X. sgRNA sequences 
1,2 and 3 are highlighted in pink. The sgRNAs were designed to cleave the DNA slightly upstream or in the protein coding region of Exon 1 of DDX3X. 
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Figure 5-4. CRISPR-Cas9-mediated reduction of DDX3X protein expression and mRNA expression in MRC5 cells. A. Cells were cultured as described 
in the Materials and Methods and the CRISPR-Cas 9 system was used to produce clonal cells lines as indicated. Extracts were prepared from these cells as 
described in Materials and Methods and aliquots containing 20 µg protein were resolved by SDS-PAGE and visualised using Western blotting with the 
antibodies indicated.  WT shows parental cells and the others were derived clones. B. CRISPR-Cas9-mediated reduction of DDX3X mRNA expression in 
MRC5 cells as determined by qRT-PCR. mRNA was extracted and processed as described in the Materials and Methods. qRT-PCR was used to show the 
effect of CRISPR-generated DDX3X knock-outs on the level of DDX3X mRNA in comparison to parental (WT) MRC5. GAPDH and HPRT1 mRNA levels were 
used to normalise the levels of mRNAs across different samples. 
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Figure 5-5. CRISPR-Cas9-mediated reduction of DDX3X protein expression in MRC5 cells. 
A. Representative Western blot of WT MRC5 cells and clonal lines 2A and 2C after several 
passages (performed in conjunction with V. William 2017). B. Quantification of DDX3X 
expression levels in WT, 2A and 2C cell lines. Levels of DDX3X expression were quantified 
relative to total eIF4E (set at 100%). 
 
 
           
  
WT 2C 2A 
DDX3X 
Total eIF4E 
W
T
2
A
2
C
0
2 5
5 0
7 5
1 0 0
C e ll l in e
%
 D
D
X
3
X
 e
x
p
r
e
s
s
io
n
B. 
A. 
40.8% 
61.8% 
173 
 
                                          
 
 
Figure 5-6. Reduction of DDX3X protein levels does not change the level of signalling 
molecules in derived cell clones, 2A and 2C. Cells were cultured described in the Materials 
and Methods and the CRISPR-Cas9 system was used to produce clonal cell lines as described 
in Figure 7.5. Extracts were prepared cells as described and aliquots containing 20 µg protein 
were resolved by SDS-PAGE and proteins visualised using Western blotting with the antibodies 
indicated. 
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5.1.2 A Reduction in DDX3X Protein Level Impedes Cell Migration in 
MRC5 Cells 
 
To investigate the effect of decreased levels of DDX3X expression on cell 
migration, an initial phenotypic characterisation of DDX3X knockdown cell lines 
was carried out using the scratch assay described in the Materials and 
Methods. This measures both the proliferation and migration of cells as they 
attempt to fill a gap in the confluent culture induced by scratching cells off the 
surface of the plate. Figure 5-7 shows that DDX3X knockdown clones, 2C and 
2A were reduced in their ability to migrate and fill in the gap in the culture in 
comparison to wildtype cells. These data suggest that DDX3X protein is 
required for efficient cell migration under these assay conditions. The rate of 
migration was further assessed using a variation of the classical scratch assay, 
known as the Oris cell migration assay®. To examine the effect of partial 
depletion of DDX3X on cell migration, wound closure was monitored in serum-
starved cells (to reduce cell proliferation). Wildtype MRC5 cells and DDX3X 
knockdown clone 2A cells were seeded into stopper-loaded wells in a 96-well 
plate for 4 hours to permit cell attachment. To start cell migration, the stoppers 
were removed, cells were washed with PBS and fresh serum-free medium was 
added. Images were taken every 4 hours and analysed using Image J software 
(Figure 5-8A). As shown in Figure 5-8B, these data show that a partial depletion 
of DDX3X resulted in a decreased rate of wound closure. 
 
5.1.3 Molecular Modelling of DDX3X Inhibitor, RK-33, in DDX3X Crystal 
Structure 
 
Following several unsuccessful attempts to knockout DDX3X expression using 
a CRISPR-Cas9 system in MRC5 fibroblasts, efforts were then focussed on 
investigating the pharmacological inhibition of DDX3X. The X-ray crystal 
structure of the conserved DEAD domain and helicase domain of human 
DDX3X in complex with AMP (PDB: 2I4I) was used to analyse the most likely 
binding mode of RK-33, a known DDX3X helicase inhibitor (Figures 5-9A-D). 
The predicted docking pose revealed that RK-33 binds the ATP-binding cleft, 
with the imadazolone ring stacked above Tyr200 (Figure 5-9D).  
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Figure 5-7. Scratch-wound healing assay showing the effect of DDX3X knockdown on 
wound healing over a period of 48 hours. Scratch assays were carried out as described in 
the Materials and Methods. Briefly, confluent cells were grown in serum-free media for 12 hours 
prior to incubation in complete DMEM; a P-20 pipette tip was used to make a “wound” in the 
confluent monolayer of cells and images were then taken at 24 hr and 48 hr time periods of 
wound healing. Representative images are shown here with white dashed lines drawn around 
the wound (n=3). 
2A WT 2C 
0 hr 
24 hr 
48 hr 
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Figure 5-8. Reduction in DDX3X protein levels impedes cell migration in MRC5 cells. A. An example of the wound healing assay in WT MRC5 cells. 
Bright-field images were taken at indicated time points following bung removal at 0 hr. Wound closure was measured using Image J software (illustrated by 
the red dashed circles) and expressed as % of open wound area relative 0 hr. B. Wound-healing assays were carried out as described using parental (WT) 
and DDX3X-depleted clonal cell line, 2A, over a period of 20 hours. Data are presented as the means ± S.D, n=3 (*p ≤ 0.05; **p ≤ 0.01).   
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Figure 5-9. Docking of RK-33 in DDX3X crystal structure. A. Secondary structure of DDX3X, DEAD domain shown in red and Helicase domain shown in 
purple (PDB: 2I4I). B. Chemical structure of DDX3X inhibitor, RK-33. C. Predicted binding mode of RK-33 in DDX3X (PDB: 2I4I). D. Close up of proposed 
interactions between RK-33 and the ATP-binding site of DDX3X. Molecular graphics and analyses were performed with the UCSF Chimera package 
(Pettersen et al., 2004). 
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RK-33 forms hydrogen bond interactions with Gln207 and Tyr200 residues as 
also depicted by Bol et al., (2015). The predicted binding mode supports the 
hypothesis that RK-33 inhibits the ATP-dependent helicase activity of DDX3X 
by blocking the binding of ATP. 
 
5.1.4 In Vitro Analysis of RK-33 in Prostate Cancer Cell Lines 
 
Recent work by Xie et al., (2017) reported that DDX3X expression correlated 
with an increased aggressive phenotype in prostate cancer cell lines and in 
patient samples (Xie et al., 2016). Their prior studies identified the expression of 
levels of DDX3X across a panel of prostate cancer cell lines (Xie et al., 2016). 
To test whether DDX3X expression levels had an effect on the cell viability of 
cells treated with RK-33, the compound was tested in two prostate cancer cell 
lines, one with high DDX3X expression levels (LNCaP) and one with low 
expression levels (PC-3). Cell viability was assessed in both LNCaP cells and 
PC-3 cells treated with RK-33 over a period of 72 hours and determined by the 
Cell Titer Blue assay (Figures 5-10A and 5-10B). These data show that RK-33 
decreased cell viability in both LNCaP and PC-3 cell lines, with IC50 values of 
7.2 µM and 10 µM, respectively. The LNCaP cells were slightly more sensitive 
to RK-33 inhibition, relative to PC-3 cells with low DDX3X expression levels. 
.  
5.1.5 In Vitro Analysis of RK-33 in Combination with MNK1/2 Inhibitor, 
Compound 1 in Prostate Cancer Cell Lines 
 
Owing to the prominent roles that both DDX3X and MNK1/2 play in translation, 
it was hypothesised that the inhibition of both proteins simultaneously may lead 
to a significant reduction in cell viability. As shown in Figures 5-10, compound 1 
had no significant effect on cell viability when tested as a single agent in either 
LNCaP (Figure 5-10C) or PC-3 cells (Figure 5-10D). Cell viability was then 
analysed in LNCaP and PC-3 cell lines with RK-33 and compound 1 added in 
combination (Figure 5-11). No apparent difference was observed in the LNCaP 
cells when treated with RK-33 as a single agent or in combination with 
compound 1, with both IC50 values of approximately 7 µM in each case. 
However, a reduction of cell viability was observed in PC-3 cells treated with a 
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combination of RK-33 and compound 1, demonstrated by a drop in IC50 value 
from 10 µM to 5.9 µM (Figure 5-11B).  
 
In order to explain the apparent increase in cell death in PC-3 cells treated with 
a combination of RK-33 and compound 1, the level of eIF4E phosphorylation in 
these cells was measured by Western blotting (Figure 5-12A). Quantification of 
these data from three independent experiments showed that basal level of 
eIF4E-P was approximately three-fold greater in LNCaP cells in comparison to 
PC-3 cells (Figure 5-12B). The level of eIF4E phosphorylation was similar in 
PC-3, MRC5 cells and another prostate cancer cell line, DU145 cells (Figure 5-
12B). The relatively low levels of eIF4E phosphorylation in PC-3 cells may 
explain their sensitivity toward the combination of RK-33/compound 1. In 
contrast, the relatively high level of eIF4E-P in LNCaP cells suggests resistance 
to the RK-33/compound 1 treatment, a phenomenon that has been observed in 
other cancers (Li et al., 2017).  
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Figure 5-10. Cell viability of RK-33 and MNK1/2 inhibitor, compound 1, in prostate cancer cell lines. A. Dose-response curve for RK-33 treated LNCaP 
cells. B. Dose-response curve for RK-33 treated PC-3 cells. Cells were treated for 72 hr and assessed by Cell Titer Blue assay. Data shown as mean ± SD of 
triplicate wells. C. Cell viability of compound 1. LNCaP cells were treated for 72 hours with compound 1 at the indicated concentrations. D. Cell viability of 
compound 1. PC-3 cells were treated for 72 hours with compound 1 at the indicated concentrations and assessed by Cell Titer Blue assay. 
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Figure 5-11. Cell viability of RK-33 in combination with MNK1/2 inhibitor, compound 1, in prostate cancer cell lines. A. Dose-response curve for RK-
33 and compound 1 treated LNCaP cells. B. Dose-response curve for RK-33 and compound 1 treated PC-3 cells. Cells were treated for 72 hr in a 1:1 ratio of 
drugs and assessed by Cell Titer Blue assay. Data shown as mean ± S.D of triplicate wells. 
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Figure 5-12. Quantification of eIF4E-phosphorylation level in a panel of prostate cancer cell lines. A. Representative Western blot analysis of cell lines: 
MRC5, MRC5 treated with 5 µM of compound 1, DU145, LNCaP and PC-3. Cells were incubated for 24 hours and aliquots of extract (20 µg of total protein) 
were resolved by SDS–PAGE and visualised using immunoblotting. B. Levels of eIF4E-P expression were quantified relative to total eIF4E (set at 100%) in 
the indicated cell lines. 
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5.1.6 Treatment of PC-3 Cells with RK-33 Increases their Rate of 
Migration  
 
As RK-33 was found to reduce cell viability in the prostate cancer cell lines 
tested, the question asked was whether RK-33 treatment of PC-3 cells effected 
their migration. PC-3 cells were chosen to investigate the rate of cell migration 
due to the spindle-like morphology of LNCaP cells, making it difficult to analyse 
the area of the “wound” accurately (Figures 5-13A and B). For this assay, cell 
migration was measured for 6 hr, both in the presence or absence of serum 
(Figures 5-14A and 5-14B, respectively). These data show that there was no 
significant difference in results obtained between serum starved and serum fed 
cells. This was expected for analysis at the 6 hour time point in the migration 
protocol. Surprisingly, Figure 5-14 shows that incubation of cells with 5 µM RK-
33 increases the rate of migration in comparison to cells incubated with DMSO 
alone. Compound 1 has no significant effect on cell migration when used as a 
single agent. Interestingly, when used in combination, compound 1 appeared to 
decrease the effect of RK-33 on cell migration. This “rescue” effect of 
compound 1 was also observed in previous experiments (see Section 3.2.6). 
 
In an attempt to explain this, Western blotting was carried out on PC-3 cells to 
examine the potential effects of RK-33 alone and in combination on the levels of 
proteins involved in signalling and migration (Figure 5-15). PC-3 cells were 
incubated with DMSO (lane 1), RK-33 at various concentrations (lanes 2-4) and 
compound 1 as a single agent (lane 5), or in combination with RK-33 (lane 6) 
for 6 hours. Analysis of cell extracts shows that there were no gross changes in 
the expression levels of 4E-BP1, eIF4G, eIF4A, or DDX3X. Similarly, levels of 
caprin and actin, proteins involved in cell migration, were also unchanged. In 
contrast, taking into account protein loading, the level of total eIF4E was 
reduced in PC-3 cells treated with a combination of RK-33 and compound 1 
compared to DMSO alone (lane 6 vs lane 1). As expected, compound 1 was 
found to reduce the level of eIF4E phosphorylation in PC-3 cells when used as 
a single agent or in combination with RK-33. 
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Figure 5-13. Morphology of prostate cancer cells. A. Bright-field image of PC-3 cells. B. Bright-field image of LNCaP cells. (Both images taken from the 
American Type Culture Collection- ATCC). 
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Figure 5-14. Wound-healing assay showing the effect of RK-33 inhibition alone or in combination with MNK1/2 inhibition over a period of 6 hours. 
A. Wound healing was measured PC-3 cells cultured in serum-free media exposed to DMSO, compound 1 at 5 μM and RK-33 at 5 μM alone and in 
combination with compound 1 at 5 μM each. B. Wound healing was measured in PC-3 cells cultured in complete media exposed to DMSO, compound 1 at 5 
μM and RK-33 at 5 μM alone and in combination with compound 1 at 5 μM each. Cell migration was measured using Image J software and each well was 
normalised to the migration of cells at time 0. Data are mean ± S.D, n=3 (ns= non-significant, *p ≤ 0.05; **p ≤ 0.01; and ***p ≤ 0.001).  
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Figure 5-15. Representative Western blot analysis of PC-3 cells in the presence of RK-33 
and compound 1, alone or in combination. Western blot analysis showing the effect of 
different concentrations of RK-33 on various signalling molecules. PC-3 cells were incubated 
with DMSO alone or with the indicated concentrations of inhibitors for 6 hours.  
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5.2 Discussion 
 
DDX3X is a DEAD-box helicase that is dysregulated in many cancers. 
Consequently, there are increasing efforts to investigate the effect of DDX3X 
inhibition in different types of cancer. In the work described here, the CRISPR 
Cas9 system was utilised in an attempt to knockout the DDX3X gene in MRC5 
cells, derived from a male patient. Attempts to knockout expression were made 
in-house using MRC5 fibroblasts and by a commercial venture to knockout 
DDX3X expression in HAP-1 cells   Western blotting of a resulting in-house cell 
clone showed that the surviving cells had only a partial knockdown of DDX3X to 
approximately 40% of control levels (Figure 5-4), although mRNA levels were 
severely depleted (Figure 5-5). The failure to generate a full DDX3X knockout 
may be due to the impairment of NHEJ in these cells. In a study by Bol et al 
(2015) knockdown of DDX3X resulted in reduced NHEJ activity in lung cancer 
cells (Bol et al., 2015). The NHEJ pathway is the predominant pathway for the 
repair of DSB in the G1/S phase of the cell cycle and as DDX3X has been 
found to facilitate the G1/S transition (Section 1.1.1.2), a DDX3X knockout may 
arrest cells in G1. Subsequent DNA damage would result in the accumulation of 
DSB and ultimately lead to cell death. A recent study found that murine DDX3X 
was essential for both embryo and extraembryonic development. DDX3X 
ablation led to embryonic lethality (Chen et al., 2016). The resulting DDX3X 
knockdown clone was taken forward for further analysis and was found to have 
reduced migration ability (Figure 5-8), which further suggests a role for DDX3X 
in migration. 
 
RK-33 is a small molecule inhibitor of DDX3X, which binds to and inhibits the 
ATP-binding site of DDX3X (Figure 5-9), resulting in the abrogation of helicase 
activity. In the work described here, the biological effects of RK-33 were tested 
in two prostate cancer cell lines and effects on cell viability was measured by 
Cell Titer Blue Assay. The data presented in Figure 7-13 shows that LNCaP 
cells (with high levels of DDX3X expression) showed are greater sensitivity 
towards RK-33 than PC-3 cells (with lower levels of DDX3X). The combination 
of RK-33 with MNK1/2 inhibitor, compound 1, resulted in a small, but significant 
synergistic effect (Figure 5-11). This combination treatment led to an increase in 
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cell death and a reduction in IC50 value from 10 µM to ~6 µM in PC-3 cell. 
Although significant, the effect was not dramatic enough to point towards an 
effective combination treatment with clinical implications. 
 
The effect of inhibition of DDX3X by RK-33 on cell migration was then assessed 
in PC-3 cells. Wound closure using either serum-starved or serum-fed cells was 
measured after a period of 6 hours. Interestingly, RK-33 appeared to accelerate 
the rate of wound closure when tested at 5 µM in both serum-starved and fed 
conditions (Figure 5-14). These data differ from work carried out by Xie et al 
(2016) who observed a reduced ability to close “scratches” after 36 hours of 
RK-33 treatment (Xie et al., 2016). This difference probably reflects inhibition of 
cell proliferation in cells incubated with RK-33 for longer times (Bol et al., 2015). 
The data presented here highlights the cancer-dependent effects of DDX3X 
knockdown or inhibition. This reflects the pleiotropic functions of DDX3X, its 
potential as an anti-cancer target and further underlines the need for more 
research in this area. 
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6 Thesis Summary 
 
6.1 Final Discussion 
 
The overexpression and de-regulation of translation factors, in particular, eIF4E, 
have been linked to the pathogenesis of many aggressive human cancers. The 
phosphorylation of eIF4E by MNK1/2 kinase correlates with invasive and 
metastatic behaviour, through the preferential translation of mRNAs encoding 
mesenchymal markers such as N-cadherin, fibronectin, MMPs and vimentin 
(Robichaud et al., 2015). The level of eIF4E expression has also been found to 
reflect the level of mitogenic proteins such as c-myc, VEGFR and cyclins, 
alongside anti-apoptotic proteins, such as MCL-1 and BCL-2 (Grzmil et al., 
2014; Lu et al., 2016). Experimental evidence has shown that the availability of 
eIF4E for translation can be repressed through the inhibition of mTORC1 
(Figure 3-1; reviewed in Laplante & Sabatini, 2012). Additionally, work has 
shown that silencing MNK1/2 attenuates eIF4E phosphorylation and reduces 
the translation of mRNAs involved in metastasis (Astanehe et al., 2012; Diab et 
al., 2014). However, the independent suppression of either pathway induces 
complex feedback loops that stimulate activation of alternative signalling 
pathways (Figures 1-19 and 3-4). As eIF4E lies at the convergence point of 
both the mTOR and MNK/eIF4E pathways (Figure 1-9), this provides an 
opportunity for dual targeting of these pathways. Multi-targeted therapy is 
becoming an increasingly popular approach to combat drug resistance. Hybrid 
molecules incorporate several moieties that bind to, and inhibit different 
biological targets, delivering a double-blow to cells. In this regard, the 
complementary mTOR and MNK pathways are a promising target for such 
hybrid agents in the treatment of aggressive migratory cancers. 
 
In the work described here, a thorough literature search was first performed to 
identify a potent MNK1/2 inhibitor with desirable properties that would enable 
further modifications. In Chapter three, compound 1, a known MNK1/2 inhibitor 
(not available commercially) was synthesised and characterised in a range of 
mammalian cell lines. Compound 1 was shown to have no effect on cell viability 
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in the variety of cell lines tested. This was anticipated as seminal work by Ueda 
et al (2004) found that mice with a targeted deletion of both MNK1 and MNK2 
exhibited a total lack of eIF4E phosphorylation but were completely viable. This 
led to the development of novel MNK1/2 inhibitor hybrid agents based upon 
compound 1. It was determined that a synergistic combination of MNK1/2 and 
PI3K p110α inhibitors slowed the rate of cell migration in MDA-MB-231 cells 
(Figure 3-19A and 3-19B). Additionally, this work showed that a combination of 
MNK1/2 and mTORC1/2 inhibitors resulted in cell cycle arrest (Figure 3-20) and 
a decrease in cell viability (Figure 3-19F) to a greater extent in comparison to 
when the inhibitors were used as single agents. These inhibitors are ATP-
competitive and work by binding to and inhibiting the ATP-binding site. These 
findings led to the attempted development of novel hybrid entities, 
encapsulating MNK1/2 and PI3K/mTOR inhibitory activities. Although molecular 
hybridisation approaches hold significant promise, they currently face 
considerable challenges as therapeutic modalities. For example, both hybrid 
agents are undoubtedly poorly soluble due to their high molecular weight and 
lipophilicity. Both compounds 6 and 7, violate two of Lipinski’s rules, by 
exceeding a molecular weight of 500 and a log P value of 5. Both hybrid 
compounds also violate one of Veber’s rules, by surpassing a TPSA of 140 Å2 
(Veber et al., 2002). Highly lipophilic compounds permeate poorly through 
membranes as they aggregate in the hydrophobic interior of the membrane 
bilayer (Leeson & Springthorpe, 2007). Current work in the Spencer Lab aims to 
improve the solubility of these novel hybrid molecules by introducing hydrophilic 
polyethylene glycol (PEG) linkers to conjugate the two chemical entities.  
  
The work described in Chapter four describes the characterisation of novel 
ferrocene containing compounds based upon the MNK1/2 inhibitor, compound 
1. Structural modelling of compound 1 in the active site of MNK kinase revealed 
a large hydrophobic pocket that could be exploited with a bulkier group such as 
a ferrocene. Although the ferrocene derivatives showed no activity against 
MNK1/2, their potency in cancer cell lines was promising. Cell viability was 
determined using the Cell Titer Blue assay and the ferrocene-containing 
compounds exhibited low micromolar IC50 values in several cancer cell lines 
(Table 4-1). MDA-MB-231 cells were particularly sensitive to these ferrocene 
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compounds and were used to assess these compounds when cells were grown 
in 3D culture (spheroids). It is generally believed that tumour spheroids provide 
a more biologically relevant environment to screen potential compounds (Lv, Hu 
et al., 2017). The work described here indicated that the more potent of the two 
ferrocene derivatives was found to significantly reduce spheroid diameter in 
conjunction with a decrease in cell viability. It is possible that the ferrocene itself 
was responsible for these effects and the production of ROS in the Fenton 
reaction has been proposed as a mechanism of cytotoxicity in other ferrocene 
derivatives (Tabbiet et al., 2002). Future work would aim to determine if the 
reduction in cell viability is due to the generation of ROS. This would be 
investigated by the use of a commercial assay, which utilises fluorogenic probes 
to measure generalised oxidative stress in cells in a 96-well plate format. 
 
Finally, the work described in Chapter five was focussed on an alternative 
translational target, an RNA helicase, termed DDX3X. Firstly, it was shown that 
genetic knockdown of DDX3X in MRC5 cells led to a reduction in cell migration. 
These data concurred with previous work by Chen et al (2015) who found that 
DDX3X depletion suppressed cell motility in HeLa cells in a scratch assay. In 
my work described here, prostate cancer cells (PC-3) with an intrinsically low 
level of DDX3X were treated with RK-33, an inhibitor of the ATP-dependent 
helicase function of DDX3X. Surprisingly, these data revealed that RK-33 
actually increased migration in these cells over a period of 6 hours, when 
assayed using the wound healing “bung” assay. These conflicting data highlight 
the limitations of performing cell migration assays over varying time periods. 
The traditional scratch/wound healing assays require controls to account for cell 
proliferation and visual analysis of data is often subjective. The trans-well cell 
migration assay using the xCELLigence DP device tracks cells in real-time as 
they migrate towards a chemo-attractant. The latter assay is very sensitive and 
produces quantitative data; however, it measures individual cell migration as 
opposed to cells migrating on mass to close a wound. Recent advances in 
technology have revolutionised the wound healing assay. An automated wound 
healing assay has been developed by Acea Biosciences®, which generates a 
uniform “scratch” in each well of a 96-well plate. Wound healing can then be 
measured in real-time, providing a reproducible quantitative measure of cell 
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migration. It would be pertinent to repeat these assays with the DDX3X 
knockdown cells and RK-33 treated cells using such a system. 
 
In addition to effects on cell migration, knockdown of DDX3X has been reported 
to result in reduced a reduced level of NHEJ activity (Bol et al., 2015a). This 
prompted us to investigate DDX3X inhibitor, RK-33, in combination with 
olaparib, a PARP inhibitor. Olaparib is approved for the treatment of germline 
BRCA mutated (gBRCAm) HER2-negative metastatic breast cancer and is 
currently in phase I clinical trials for the treatment of glioblastoma in 
combination with radiotherapy +/-temozolomide (Fulton et al., 2018). The 
combination of both RK-33 and olaparib may induce synthetic lethality by 
targeting both NHEJ and homologous recombination (HR) pathways. There is 
also potential for DDX3X inhibitors to be used as a second-line therapy to 
combat olaparib resistance in treatment of breast cancer. 
 
6.2 Future Perspectives 
 
In summary, targeting the translational machinery remains an exciting option for 
the treatment of cancers. In the last few years there has been an explosion in 
the development of MNK1/2 inhibitors, both in academia and in industry (Reich 
et al., 2018, Yang et al., 2018). This further provides evidence for the role 
MNK1/2 plays in chemoresistance and the potential of using MNK1/2 inhibitors 
in combination with other chemotherapeutic agents in the treatment of 
aggressive cancers. A CRISPR-Cas9 screen run in parallel with a siRNA screen 
of MNK in combination with other proteins would be useful to identify synergy 
between targets, and aid the development of novel hybrids. 
 
As discussed in the section above, further work analysing the compounds 
synthesised in this study would clarify their mode of action in cells. In particular, 
apoptosis assays and eIF2α assays may provide more information on the data 
obtained from migration and cell viability experiments. Mass spectrometry could 
also be performed to analyse the cellular uptake of compounds and indicate 
hybrid molecule solubility. 
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Recent work has further elucidated the role of DDX3X in medulloblastoma. To 
date, all DDX3X mutations reported in medulloblastoma occur in the helicase 
domain. A study aimed to identify the RNA targets and binding ability of wildtype 
DDX3X compared to the medulloblastoma-related DDX3R534H variant, with 
impaired catalytic activity, in HEK293 cells. Data showed that the mutant form 
bound less avidly to RNA than the wildtype form, although the transcriptome 
targets were similar. Although a reduction in translation initiation efficiency was 
observed, mutant DDX3X maintained extensive protein-protein interactions (Oh 
et al., 2016). A seperate study found that cancer-related DDX3X mutations 
promoted the assembly of stress granules and impaired mRNA translation. 
Missense mutations in DDX3X were found to impair global protein synthesis by 
several mechanisms (Valentin-Vega et al., 2016). These data suggest that 
drugs that limit the formation of stress granules may reverse the translation 
impairment caused by cancer-related DDX3X mutations and offer a potential 
treatment option for tumours containing mutant DDX3X. 
 
6.3 Published Work 
 
1. Copsey AC, Cooper S, Parker R, Lineham E, Lapworth C, Jallad D, et al. 
The helicase, DDX3X, interacts with poly(A)-binding protein 1 (PABP1) and 
caprin-1 at the leading edge of migrating fibroblasts and is required for 
efficient cell spreading. Biochem J. 2017;474(18):3109-20. 
 
2. Lineham E, Spencer J, Morley SJ. Dual abrogation of MNK and mTOR: a 
novel therapeutic approach for the treatment of aggressive cancers. Future 
Med Chem. 2017;9(13):1539-55.  
 
3. Lineham E, Tizzard GJ, Coles SJ, Spencer J, Morley SJ. Synergistic effects 
of inhibiting the MNK-eIF4E and PI3K/AKT/mTOR pathways on cell 
migration in MDA-MB-231 cells. Oncotarget. 2018;9:14148-59. 
 
4. Sansook S, Lineham E, Hassell-Hart S, Tizzard G, Coles S, Spencer J et al. 
Probing the Anticancer Action of Novel Ferrocene Analogues of MNK 
Inhibitors. Molecules. 2018;23(9):2126. 
194 
 
References 
 
Abekhoukh S, Bardoni B (2014) CYFIP family proteins between autism and 
intellectual disability: links with Fragile X syndrome. Front Cell Neurosci 8: 81 
Alain T, Morita M, Fonseca BD, Yanagiya A, Siddiqui N, Bhat M, Zammit D, 
Marcus V, Metrakos P, Voyer LA, Gandin V, Liu Y, Topisirovic I, Sonenberg N 
(2012) eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies. 
Cancer Res 72: 6468-76 
Allemand E, Guil S, Myers M, Moscat J, Caceres JF, Krainer AR (2005) 
Regulation of heterogenous nuclear ribonucleoprotein A1 transport by 
phosphorylation in cells stressed by osmotic shock. Proceedings of the National 
Academy of Sciences of the United States of America 102: 3605-10 
Altman JK, Szilard A, Konicek BW, Iversen PW, Kroczynska B, Glaser H, 
Sassano A, Vakana E, Graff JR, Platanias LC (2013) Inhibition of Mnk kinase 
activity by cercosporamide and suppressive effects on acute myeloid leukemia 
precursors. Blood 121: 3675-81 
Amin J, Chuckowree IS, Wang M, Tizzard G, J., Coles SJ, Spencer J (2013) 
Synthesis of Oxindole-Based Bioorganometallic Kinase Inhibitors Incorporating 
One or More Ferrocene Groups. Organometallics 32: 5818-5825 
Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, Hoffman 
R, Williams RL, Shokat KM, Knight ZA (2008) Targeted polypharmacology: 
discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem 
Biol 4: 691-9 
Asimomytis A, Karanikou M, Rodolakis A, Vaiopoulou A, Tsetsa P, Creatsas G, 
Stefos T, Antsaklis A, Patsouris E, Rassidakis GZ (2016) mTOR downstream 
effectors, 4EBP1 and eIF4E, are overexpressed and associated with HPV 
status in precancerous lesions and carcinomas of the uterine cervix. Oncol Lett 
12: 3234-3240 
Astanehe A, Finkbeiner MR, Krzywinski M, Fotovati A, Dhillon J, Berquin IM, 
Mills GB, Marra MA, Dunn SE (2012) MKNK1 is a YB-1 target gene responsible 
for imparting trastuzumab resistance and can be blocked by RSK inhibition. 
Oncogene 31: 4434-46 
Avdulov S, Li S, Michalek V, Burrichter D, Peterson M, Perlman DM, Manivel 
JC, Sonenberg N, Yee D, Bitterman PB, Polunovsky VA (2004) Activation of 
translation complex eIF4F is essential for the genesis and maintenance of the 
malignant phenotype in human mammary epithelial cells. Cancer Cell 5: 553-63 
Aylett CH, Sauer E, Imseng S, Boehringer D, Hall MN, Ban N, Maier T (2016) 
Architecture of human mTOR complex 1. Science 351: 48-52 
Bagrodia S, Derijard B, Davis RJ, Cerione RA (1995) Cdc42 and PAK-mediated 
signaling leads to Jun kinase and p38 mitogen-activated protein kinase 
activation. The Journal of biological chemistry 270: 27995-8 
Basnet SK, Diab S, Schmid R, Yu M, Yang Y, Gillam TA, Teo T, Li P, Peat T, 
Albrecht H, Wang S (2015) Identification of a Highly Conserved Allosteric 
Binding Site on Mnk1 and Mnk2. Mol Pharmacol 88: 935-48 
195 
 
Bayat Mokhtari R, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, 
Yeger H (2017) Combination therapy in combating cancer. Oncotarget 8: 
38022-38043 
Beggs JE, Tian S, Jones GG, Xie J, Iadevaia V, Jenei V, Thomas G, Proud CG 
(2015) The MAP kinase-interacting kinases regulate cell migration, vimentin 
expression and eIF4E/CYFIP1 binding. Biochem J 467: 63-76 
Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, Marotz C, 
Giannopoulou E, Chakravarthi BV, Varambally S, Tomlins SA, Nanus DM, 
Tagawa ST, Van Allen EM, Elemento O, Sboner A, Garraway LA, Rubin MA, 
Demichelis F (2016) Divergent clonal evolution of castration-resistant 
neuroendocrine prostate cancer. Nat Med 22: 298-305 
Berti DA, Seger R (2017) The Nuclear Translocation of ERK. Methods Mol Biol 
1487: 175-194 
Berube G (2016) An overview of molecular hybrids in drug discovery. Expert 
Opin Drug Discov 11: 281-305 
Beugnet A, Wang X, Proud CG (2003) Target of rapamycin (TOR)-signaling and 
RAIP motifs play distinct roles in the mammalian TOR-dependent 
phosphorylation of initiation factor 4E-binding protein 1. The Journal of 
biological chemistry 278: 40717-22 
Bhat M, Robichaud N, Hulea L, Sonenberg N, Pelletier J, Topisirovic I (2015) 
Targeting the translation machinery in cancer. Nat Rev Drug Discov 14: 261-
278 
Bhullar KS, Lagaron NO, McGowan EM, Parmar I, Jha A, Hubbard BP, 
Rupasinghe HPV (2018) Kinase-targeted cancer therapies: progress, 
challenges and future directions. Mol Cancer 17: 48 
Bianchini A, Loiarro M, Bielli P, Busa R, Paronetto MP, Loreni F, Geremia R, 
Sette C (2008) Phosphorylation of eIF4E by MNKs supports protein synthesis, 
cell cycle progression and proliferation in prostate cancer cells. Carcinogenesis 
29: 2279-88 
Blagosklonny MV (2004) Analysis of FDA approved anticancer drugs reveals 
the future of cancer therapy. Cell Cycle 3: 1035-42 
Bol GM, Vesuna F, Xie M, Zeng J, Aziz K, Gandhi N, Levine A, Irving A, Korz D, 
Tantravedi S, Heerma van Voss MR, Gabrielson K, Bordt EA, Polster BM, Cope 
L, van der Groep P, Kondaskar A, Rudek MA, Hosmane RS, van der Wall E et 
al. (2015) Targeting DDX3 with a small molecule inhibitor for lung cancer 
therapy. EMBO Mol Med 7: 648-69 
Bolton JL (2014) Quinone Methide Bioactivation Pathway: Contribution to 
Toxicity and/or Cytoprotection? Curr Org Chem 18: 61-69 
Botlagunta M, Vesuna F, Mironchik Y, Raman A, Lisok A, Winnard P, Jr., 
Mukadam S, Van Diest P, Chen JH, Farabaugh P, Patel AH, Raman V (2008) 
Oncogenic role of DDX3 in breast cancer biogenesis. Oncogene 27: 3912-22 
Brai A, Fazi R, Tintori C, Zamperini C, Bugli F, Sanguinetti M, Stigliano E, Este 
J, Badia R, Franco S, Martinez MA, Martinez JP, Meyerhans A, Saladini F, 
Zazzi M, Garbelli A, Maga G, Botta M (2016) Human DDX3 protein is a valuable 
196 
 
target to develop broad spectrum antiviral agents. Proceedings of the National 
Academy of Sciences of the United States of America 113: 5388-93 
Bramham CR, Jensen KB, Proud CG (2016) Tuning Specific Translation in 
Cancer Metastasis and Synaptic Memory: Control at the MNK-eIF4E Axis. 
Trends Biochem Sci 41: 847-58 
Brown MC, Gromeier M (2017) MNK inversely regulates TELO2 vs. DEPTOR to 
control mTORC1 signaling. Mol Cell Oncol 4: e1306010 
Bushell M, Wood W, Carpenter G, Pain VM, Morley SJ, Clemens MJ (2001) 
Disruption of the interaction of mammalian protein synthesis eukaryotic initiation 
factor 4B with the poly(A)-binding protein by caspase- and viral protease-
mediated cleavages. The Journal of biological chemistry 276: 23922-8 
Buxade M, Morrice N, Krebs DL, Proud CG (2008) The PSF.p54nrb complex is 
a novel Mnk substrate that binds the mRNA for tumor necrosis factor alpha. The 
Journal of biological chemistry 283: 57-65 
Buxade M, Parra JL, Rousseau S, Shpiro N, Marquez R, Morrice N, Bain J, 
Espel E, Proud CG (2005) The Mnks are novel components in the control of 
TNF alpha biosynthesis and phosphorylate and regulate hnRNP A1. Immunity 
23: 177-89 
Buxade M, Parra-Palau JL, Proud CG (2008) The Mnks: MAP kinase-interacting 
kinases (MAP kinase signal-integrating kinases). Front Biosci 13: 5359-73 
Cai X, Zhai HX, Wang J, Forrester J, Qu H, Yin L, Lai CJ, Bao R, Qian C (2010) 
Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-
hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and 
HER2 inhibitor for the treatment of cancer. J Med Chem 53: 2000-9 
Cargnello M, Roux PP (2011) Activation and function of the MAPKs and their 
substrates, the MAPK-activated protein kinases. Microbiology and molecular 
biology reviews : MMBR 75: 50-83 
Carriere A, Cargnello M, Julien LA, Gao H, Bonneil E, Thibault P, Roux PP 
(2008) Oncogenic MAPK signaling stimulates mTORC1 activity by promoting 
RSK-mediated raptor phosphorylation. Curr Biol 18: 1269-77 
Cate JH (2017) Human eIF3: from 'blobology' to biological insight. Philos Trans 
R Soc Lond B Biol Sci 372 
Chan CC, Dostie J, Diem MD, Feng W, Mann M, Rappsilber J, Dreyfuss G 
(2004) eIF4A3 is a novel component of the exon junction complex. RNA 10: 
200-9 
Chang PC, Chi CW, Chau GY, Li FY, Tsai YH, Wu JC, Wu Lee YH (2006) 
DDX3, a DEAD box RNA helicase, is deregulated in hepatitis virus-associated 
hepatocellular carcinoma and is involved in cell growth control. Oncogene 25: 
1991-2003 
Chen CY, Chan CH, Chen CM, Tsai YS, Tsai TY, Wu Lee YH, You LR (2016) 
Targeted inactivation of murine Ddx3x: essential roles of Ddx3x in placentation 
and embryogenesis. Hum Mol Genet 25: 2905-2922 
197 
 
Chen HH, Yu HI, Cho WC, Tarn WY (2015) DDX3 modulates cell adhesion and 
motility and cancer cell metastasis via Rac1-mediated signaling pathway. 
Oncogene 34: 2790-800 
Chen LS, Redkar S, Taverna P, Cortes JE, Gandhi V (2011) Mechanisms of 
cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood 
118: 693-702 
Chiarini F, Evangelisti C, McCubrey JA, Martelli AM (2015) Current treatment 
strategies for inhibiting mTOR in cancer. Trends Pharmacol Sci 36: 124-35 
Cho S, Kim JH, Back SH, Jang SK (2005) Polypyrimidine tract-binding protein 
enhances the internal ribosomal entry site-dependent translation of p27Kip1 
mRNA and modulates transition from G1 to S phase. Molecular and cellular 
biology 25: 1283-97 
Chrestensen CA, Shuman JK, Eschenroeder A, Worthington M, Gram H, 
Sturgill TW (2007) MNK1 and MNK2 regulation in HER2-overexpressing breast 
cancer lines. The Journal of biological chemistry 282: 4243-52 
Clancy S, Brown W (2008) Translation: DNA to mRNA to Protein. 1: 101 
Cobbold LC, Spriggs KA, Haines SJ, Dobbyn HC, Hayes C, de Moor CH, Lilley 
KS, Bushell M, Willis AE (2008) Identification of internal ribosome entry 
segment (IRES)-trans-acting factors for the Myc family of IRESs. Molecular and 
cellular biology 28: 40-9 
Cobbold LC, Wilson LA, Sawicka K, King HA, Kondrashov AV, Spriggs KA, 
Bushell M, Willis AE (2010) Upregulated c-myc expression in multiple myeloma 
by internal ribosome entry results from increased interactions with and 
expression of PTB-1 and YB-1. Oncogene 29: 2884-91 
Coles SJG, P. A (2012) Changing and challenging times for service 
crystallography. Chem Sci 3: 683-689 
Cope CL, Gilley R, Balmanno K, Sale MJ, Howarth KD, Hampson M, Smith PD, 
Guichard SM, Cook SJ (2014) Adaptation to mTOR kinase inhibitors by 
amplification of eIF4E to maintain cap-dependent translation. J Cell Sci 127: 
788-800 
Cowan-Jacob SW (2006) Structural biology of protein tyrosine kinases. Cell Mol 
Life Sci 63: 2608-25 
Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ (2014) Drugging the 
undruggable RAS: Mission possible? Nat Rev Drug Discov 13: 828-51 
Cuadrado A, Nebreda AR (2010) Mechanisms and functions of p38 MAPK 
signalling. Biochem J 429: 403-17 
Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierrez M, Borden KL (2006) 
eIF4E is a central node of an RNA regulon that governs cellular proliferation. J 
Cell Biol 175: 415-26 
Dai X, Chen A, Bai Z (2014) Integrative investigation on breast cancer in ER, 
PR and HER2-defined subgroups using mRNA and miRNA expression profiling. 
Sci Rep 4: 6566 
198 
 
Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate 
pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small 
molecules. Sci Rep 7: 42717 
Das S, Maitra U (2001) Functional significance and mechanism of eIF5-
promoted GTP hydrolysis in eukaryotic translation initiation. Progress in nucleic 
acid research and molecular biology 70: 207-31 
DaSilva J, Xu L, Kim HJ, Miller WT, Bar-Sagi D (2006) Regulation of sprouty 
stability by Mnk1-dependent phosphorylation. Molecular and cellular biology 26: 
1898-907 
Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, 
Treiber DK, Zarrinkar PP (2011) Comprehensive analysis of kinase inhibitor 
selectivity. Nature biotechnology 29: 1046-51 
de Lera AR, Ganesan A (2016) Epigenetic polypharmacology: from combination 
therapy to multitargeted drugs. Clin Epigenetics 8: 105 
de Oliveira AC, Hillard EA, Pigeon P, Rocha DD, Rodrigues FA, Montenegro 
RC, Costa-Lotufo LV, Goulart MO, Jaouen G (2011) Biological evaluation of 
twenty-eight ferrocenyl tetrasubstituted olefins: cancer cell growth inhibition, 
ROS production and hemolytic activity. Eur J Med Chem 46: 3778-87 
Di Tommaso P, Moretti S, Xenarios I, Orobitg M, Montanyola A, Chang JM, Taly 
JF, Notredame C (2011) T-Coffee: a web server for the multiple sequence 
alignment of protein and RNA sequences using structural information and 
homology extension. Nucleic acids research 39: W13-7 
Diab S, Kumarasiri M, Yu M, Teo T, Proud C, Milne R, Wang S (2014) MAP 
kinase-interacting kinases--emerging targets against cancer. Chem Biol 21: 
441-52 
Diab S, Li P, Basnet SK, Lu J, Yu M, Albrecht H, Milne RW, Wang S (2016) 
Unveiling new chemical scaffolds as Mnk inhibitors. Future Med Chem 8: 271-
85 
Diab S, Teo T, Kumarasiri M, Li P, Yu M, Lam F, Basnet SK, Sykes MJ, 
Albrecht H, Milne R, Wang S (2014) Discovery of 5-(2-(phenylamino)pyrimidin-
4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR 
analysis and biological evaluation. ChemMedChem 9: 962-72 
Ditton HJ, Zimmer J, Kamp C, Rajpert-De Meyts E, Vogt PH (2004) The AZFa 
gene DBY (DDX3Y) is widely transcribed but the protein is limited to the male 
germ cells by translation control. Hum Mol Genet 13: 2333-41 
Eddy J, Maizels N (2006) Gene function correlates with potential for G4 DNA 
formation in the human genome. Nucleic acids research 34: 3887-96 
Edwin F, Anderson K, Patel TB (2010) HECT domain-containing E3 ubiquitin 
ligase Nedd4 interacts with and ubiquitinates Sprouty2. The Journal of 
biological chemistry 285: 255-64 
Efeyan A, Sabatini DM (2010) mTOR and cancer: many loops in one pathway. 
Current opinion in cell biology 22: 169-76 
Eulalio A, Huntzinger E, Izaurralde E (2008) Getting to the root of miRNA-
mediated gene silencing. Cell 132: 9-14 
199 
 
Fabbro D, Cowan-Jacob SW, Moebitz H (2015) Ten things you should know 
about protein kinases: IUPHAR Review 14. Br J Pharmacol 172: 2675-700 
Fabian JR, Vojtek AB, Cooper JA, Morrison DK (1994) A single amino acid 
change in Raf-1 inhibits Ras binding and alters Raf-1 function. Proceedings of 
the National Academy of Sciences of the United States of America 91: 5982-6 
Fairman-Williams ME, Guenther UP, Jankowsky E (2010) SF1 and SF2 
helicases: family matters. Curr Opin Struct Biol 20: 313-24 
Faller WJ, Jackson TJ, Knight JR, Ridgway RA, Jamieson T, Karim SA, Jones 
C, Radulescu S, Huels DJ, Myant KB, Dudek KM, Casey HA, Scopelliti A, 
Cordero JB, Vidal M, Pende M, Ryazanov AG, Sonenberg N, Meyuhas O, Hall 
MN et al. (2015) mTORC1-mediated translational elongation limits intestinal 
tumour initiation and growth. Nature 517: 497-500 
Fan W, Wang W, Mao X, Chu S, Feng J, Xiao D, Zhou J, Fan S (2016) 
Elevated levels of p-Mnk1, p-eIF4E and p-p70S6K proteins are associated with 
tumor recurrence and poor prognosis in astrocytomas. J Neurooncol  
Feng Z, Hu W, de Stanchina E, Teresky AK, Jin S, Lowe S, Levine AJ (2007) 
The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell 
and tissue specificity, and the role of these gene products in modulating the 
IGF-1-AKT-mTOR pathways. Cancer Res 67: 3043-53 
Feoktistova K, Tuvshintogs E, Do A, Fraser CS (2013) Human eIF4E promotes 
mRNA restructuring by stimulating eIF4A helicase activity. Proceedings of the 
National Academy of Sciences of the United States of America 110: 13339-44 
Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi 
M, Chen I, Fowst C, Los G, Slamon DJ (2009) PD 0332991, a selective cyclin D 
kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen 
receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 11: 
R77 
Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, 
Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, 
Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson 
GH et al. (2008) The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-
piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as 
a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the 
treatment of cancer. J Med Chem 51: 5522-32 
Fortin S, Berube G (2013) Advances in the development of hybrid anticancer 
drugs. Expert Opin Drug Discov 8: 1029-47 
Friday BB, Adjei AA (2008) Advances in targeting the Ras/Raf/MEK/Erk 
mitogen-activated protein kinase cascade with MEK inhibitors for cancer 
therapy. Clin Cancer Res 14: 342-6 
Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, 
Zheng X, Leopold WR, Pryer NK, Toogood PL (2004) Specific inhibition of 
cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in 
human tumor xenografts. Mol Cancer Ther 3: 1427-38 
Fulton B, Short SC, James A, Nowicki S, McBain C, Jefferies S, Kelly C, Stobo 
J, Morris A, Williamson A, Chalmers AJ (2018) PARADIGM-2: Two parallel 
200 
 
phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus 
temozolomide in patients with newly diagnosed glioblastoma, with treatment 
stratified by MGMT status. Clin Transl Radiat Oncol 8: 12-16 
Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida K, Brueschke A, 
Petroulakis E, Robichaud N, Pollak M, Gaboury LA, Pandolfi PP, Saad F, 
Sonenberg N (2010) eIF4E phosphorylation promotes tumorigenesis and is 
associated with prostate cancer progression. Proceedings of the National 
Academy of Sciences of the United States of America 107: 14134-9 
Gandin V, Masvidal L, Cargnello M, Gyenis L, McLaughlan S, Cai Y, Tenkerian 
C, Morita M, Balanathan P, Jean-Jean O, Stambolic V, Trost M, Furic L, Larose 
L, Koromilas AE, Asano K, Litchfield D, Larsson O, Topisirovic I (2016a) 
mTORC1 and CK2 coordinate ternary and eIF4F complex assembly. Nat 
Commun 7: 11127 
Gandin V, Masvidal L, Hulea L, Gravel SP, Cargnello M, McLaughlan S, Cai Y, 
Balanathan P, Morita M, Rajakumar A, Furic L, Pollak M, Porco JA, Jr., St-
Pierre J, Pelletier J, Larsson O, Topisirovic I (2016b) nanoCAGE reveals 5' UTR 
features that define specific modes of translation of functionally related MTOR-
sensitive mRNAs. Genome Res 26: 636-48 
Gao M, Zhang X, Li D, He P, Tian W, Zeng B (2016) Expression analysis and 
clinical significance of eIF4E, VEGF-C, E-cadherin and MMP-2 in colorectal 
adenocarcinoma. Oncotarget  
Garbelli A, Beermann S, Di Cicco G, Dietrich U, Maga G (2011) A motif unique 
to the human DEAD-box protein DDX3 is important for nucleic acid binding, 
ATP hydrolysis, RNA/DNA unwinding and HIV-1 replication. PLoS One 6: 
e19810 
Garbelli A, Radi M, Falchi F, Beermann S, Zanoli S, Manetti F, Dietrich U, Botta 
M, Maga G (2011) Targeting the human DEAD-box polypeptide 3 (DDX3) RNA 
helicase as a novel strategy to inhibit viral replication. Curr Med Chem 18: 
3015-27 
Garcia-Aranda M, Redondo M (2017) Protein Kinase Targets in Breast Cancer. 
International journal of molecular sciences 18 
Garcia-Jimenez C, Goding CR (2019) Starvation and Pseudo-Starvation as 
Drivers of Cancer Metastasis through Translation Reprogramming. Cell Metab 
29: 254-267 
Garcia-Recio EM, Pinto-Diez C, Perez-Morgado MI, Garcia-Hernandez M, 
Fernandez G, Martin ME, Gonzalez VM (2016) Characterization of MNK1b DNA 
Aptamers That Inhibit Proliferation in MDA-MB231 Breast Cancer Cells. Mol 
Ther Nucleic Acids 5: e275 
Garuti L, Roberti M, Bottegoni G (2010) Non-ATP competitive protein kinase 
inhibitors. Curr Med Chem 17: 2804-21 
Gavrin LK, Saiah E (2013) Approaches to discover non-ATP site kinase 
inhibitors. MedChemComm  
Gediya LK, Khandelwal A, Patel J, Belosay A, Sabnis G, Mehta J, 
Purushottamachar P, Njar VC (2008) Design, synthesis, and evaluation of novel 
mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase 
201 
 
inhibitors with enhanced anticancer activities in breast and prostate cancer cells 
in vitro. J Med Chem 51: 3895-904 
Genheden M, Kenney JW, Johnston HE, Manousopoulou A, Garbis SD, Proud 
CG (2015) BDNF stimulation of protein synthesis in cortical neurons requires 
the MAP kinase-interacting kinase MNK1. J Neurosci 35: 972-84 
Gingras AC, Raught B, Gygi SP, Niedzwiecka A, Miron M, Burley SK, 
Polakiewicz RD, Wyslouch-Cieszynska A, Aebersold R, Sonenberg N (2001) 
Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes & 
development 15: 2852-64 
Glauser DA, Schlegel W (2007) Sequential actions of ERK1/2 on the AP-1 
transcription factor allow temporal integration of metabolic signals in pancreatic 
beta cells. FASEB J 21: 3240-9 
Glick D, Barth S, Macleod KF (2010) Autophagy: cellular and molecular 
mechanisms. J Pathol 221: 3-12 
Gormen M, Pigeon P, Top S, Hillard EA, Huche M, Hartinger CG, de Montigny 
F, Plamont MA, Vessieres A, Jaouen G (2010) Synthesis, cytotoxicity, and 
COMPARE analysis of ferrocene and [3]ferrocenophane tetrasubstituted olefin 
derivatives against human cancer cells. ChemMedChem 5: 2039-50 
Gottardis MM, Jordan VC (1987) Antitumor actions of keoxifene and tamoxifen 
in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer 
Res 47: 4020-4 
Graff JR, Konicek BW, Carter JH, Marcusson EG (2008) Targeting the 
eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 68: 
631-4 
Graff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D, Weir SN, Schwier P, 
Capen A, Goode RL, Dowless MS, Chen Y, Zhang H, Sissons S, Cox K, 
McNulty AM, Parsons SH, Wang T, Sams L, Geeganage S, Douglass LE et al. 
(2007) Therapeutic suppression of translation initiation factor eIF4E expression 
reduces tumor growth without toxicity. J Clin Invest 117: 2638-48 
Grifo JA, Abramson RD, Satler CA, Merrick WC (1984) RNA-stimulated ATPase 
activity of eukaryotic initiation factors. The Journal of biological chemistry 259: 
8648-54 
Gruner S, Peter D, Weber R, Wohlbold L, Chung MY, Weichenrieder O, Valkov 
E, Igreja C, Izaurralde E (2016) The Structures of eIF4E-eIF4G Complexes 
Reveal an Extended Interface to Regulate Translation Initiation. Mol Cell 64: 
467-479 
Grzmil M, Huber RM, Hess D, Frank S, Hynx D, Moncayo G, Klein D, Merlo A, 
Hemmings BA (2014) MNK1 pathway activity maintains protein synthesis in 
rapalog-treated gliomas. J Clin Invest 124: 742-54 
Grzmil M, Morin P, Jr., Lino MM, Merlo A, Frank S, Wang Y, Moncayo G, 
Hemmings BA (2011) MAP kinase-interacting kinase 1 regulates SMAD2-
dependent TGF-beta signaling pathway in human glioblastoma. Cancer Res 71: 
2392-402 
Gu J, Ruppen ME, Cai P (2005) lipase-catalyzed regioselective esterification of 
rapamycin: synthesis of temsirolimus (CCI-779). Org Lett 7: 3945-8 
202 
 
Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer 
Cell 12: 9-22 
Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen JH, Mullholland 
DJ, Magnuson MA, Wu H, Sabatini DM (2009) mTOR complex 2 is required for 
the development of prostate cancer induced by Pten loss in mice. Cancer Cell 
15: 148-59 
Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, Brown 
M, Fitzgerald KJ, Sabatini DM (2006) Ablation in mice of the mTORC 
components raptor, rictor, or mLST8 reveals that mTORC2 is required for 
signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 11: 859-71 
Guil S, Long JC, Caceres JF (2006) hnRNP A1 relocalization to the stress 
granules reflects a role in the stress response. Molecular and cellular biology 
26: 5744-58 
Gulhati P, Bowen KA, Liu J, Stevens PD, Rychahou PG, Chen M, Lee EY, 
Weiss HL, O'Connor KL, Gao T, Evers BM (2011) mTORC1 and mTORC2 
regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 
signaling pathways. Cancer Res 71: 3246-56 
Gumireddy K, Baker SJ, Cosenza SC, John P, Kang AD, Robell KA, Reddy MV, 
Reddy EP (2005) A non-ATP-competitive inhibitor of BCR-ABL overrides 
imatinib resistance. Proceedings of the National Academy of Sciences of the 
United States of America 102: 1992-7 
Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, 
Turk BE, Shaw RJ (2008) AMPK phosphorylation of raptor mediates a 
metabolic checkpoint. Mol Cell 30: 214-26 
Hallberg B, Rayter SI, Downward J (1994) Interaction of Ras and Raf in intact 
mammalian cells upon extracellular stimulation. The Journal of biological 
chemistry 269: 3913-6 
Harding HP, Novoa I, Zhang Y, Zeng H, Wek R, Schapira M, Ron D (2000) 
Regulated translation initiation controls stress-induced gene expression in 
mammalian cells. Mol Cell 6: 1099-108 
Hay N (2010) Mnk earmarks eIF4E for cancer therapy. Proceedings of the 
National Academy of Sciences of the United States of America 107: 13975-6 
Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. Genes & 
development 18: 1926-45 
Heerma van Voss MR, van Diest PJ, Raman V (2017) Targeting RNA helicases 
in cancer: The translation trap. Biochim Biophys Acta 1868: 510-520 
Hefner Y, Borsch-Haubold AG, Murakami M, Wilde JI, Pasquet S, Schieltz D, 
Ghomashchi F, Yates JR, 3rd, Armstrong CG, Paterson A, Cohen P, Fukunaga 
R, Hunter T, Kudo I, Watson SP, Gelb MH (2000) Serine 727 phosphorylation 
and activation of cytosolic phospholipase A2 by MNK1-related protein kinases. 
The Journal of biological chemistry 275: 37542-51 
Hemmings BA, Restuccia DF (2015) The PI3K-PKB/Akt pathway. Cold Spring 
Harb Perspect Biol 7 
203 
 
Hietakangas V, Cohen SM (2008) TOR complex 2 is needed for cell cycle 
progression and anchorage-independent growth of MCF7 and PC3 tumor cells. 
BMC Cancer 8: 282 
Higa GM, Abraham J (2007) Lapatinib in the treatment of breast cancer. Expert 
Rev Anticancer Ther 7: 1183-92 
Hinnebusch AG (2005) Translational regulation of GCN4 and the general amino 
acid control of yeast. Annu Rev Microbiol 59: 407-50 
Hinnebusch AG, Lorsch JR (2012) The mechanism of eukaryotic translation 
initiation: new insights and challenges. Cold Spring Harb Perspect Biol 4 
Hogbom M, Collins R, van den Berg S, Jenvert RM, Karlberg T, Kotenyova T, 
Flores A, Karlsson Hedestam GB, Schiavone LH (2007) Crystal structure of 
conserved domains 1 and 2 of the human DEAD-box helicase DDX3X in 
complex with the mononucleotide AMP. Journal of molecular biology 372: 150-9 
Holz MK, Ballif BA, Gygi SP, Blenis J (2005) mTOR and S6K1 mediate 
assembly of the translation preinitiation complex through dynamic protein 
interchange and ordered phosphorylation events. Cell 123: 569-80 
Hou J, Lam F, Proud C, Wang S (2012) Targeting Mnks for cancer therapy. 
Oncotarget 3: 118-31 
Hou J, Teo T, Sykes MJ, Wang S (2013) Insights into the Importance of DFD-
Motif and Insertion I1 in Stabilizing the DFD-Out Conformation of Mnk2 Kinase. 
ACS Med Chem Lett 4: 736-41 
Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, 
Christensen C, Bonham MJ, Wang S, Ren P, Martin M, Jessen K, Feldman ME, 
Weissman JS, Shokat KM, Rommel C, Ruggero D (2012) The translational 
landscape of mTOR signalling steers cancer initiation and metastasis. Nature 
485: 55-61 
Hsieh AC, Ruggero D (2010) Targeting eukaryotic translation initiation factor 4E 
(eIF4E) in cancer. Clin Cancer Res 16: 4914-20 
Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D, Peterson TR, 
Choi Y, Gray NS, Yaffe MB, Marto JA, Sabatini DM (2011) The mTOR-
regulated phosphoproteome reveals a mechanism of mTORC1-mediated 
inhibition of growth factor signaling. Science 332: 1317-22 
Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, 
Harada Y, Stankunas K, Wang CY, He X, MacDougald OA, You M, Williams 
BO, Guan KL (2006) TSC2 integrates Wnt and energy signals via a coordinated 
phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126: 955-68 
Inoki K, Zhu T, Guan KL (2003) TSC2 mediates cellular energy response to 
control cell growth and survival. Cell 115: 577-90 
Iqbal N, Iqbal N (2014) Imatinib: a breakthrough of targeted therapy in cancer. 
Chemother Res Pract 2014: 357027 
Ishida T, Doi M, Ueda H, Inoue M, Scheldrick GM (1988) Specific ring stacking 
interaction on the tryptophan-7-methylguanine system: Comparative 
crystallographic studies of indole derivatives-7-methylguanine base, nucleoside, 
204 
 
and nucleotide complexes. . Journal of the American Chemical Society 110: 
2286-2294 
Ishida T, Iyo H, Ueda H, Doi M, Inoue M, Nishimura S, Kitamura K (1991) 
Importance of simultaneous co-operation of hydrogen bond pairing and stacking 
interactions for recognition of guanine base of a peptide: X-ray crystal analysis 
of 7-methylguanosine-5' -phosphate-tryptophanylglutamic acid complex. Journal 
of the Chemical Society, Perkin Transactions 1: 1847-1853 
Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, 
Pirun M, Sander C, Socci ND, Ostrovnaya I, Viale A, Heguy A, Peng L, Chan 
TA, Bochner B, Bajorin DF, Berger MF, Taylor BS, Solit DB (2012) Genome 
sequencing identifies a basis for everolimus sensitivity. Science 338: 221 
Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, Hall MN (2004) 
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin 
insensitive. Nat Cell Biol 6: 1122-8 
Jackson RJ (2013) The current status of vertebrate cellular mRNA IRESs. Cold 
Spring Harb Perspect Biol 5 
Jackson RJ, Hellen CU, Pestova TV (2010) The mechanism of eukaryotic 
translation initiation and principles of its regulation. Nature reviews Molecular 
cell biology 11: 113-27 
Jaouen G, Vessieres A, Top S (2015) Ferrocifen type anti cancer drugs. Chem 
Soc Rev 44: 8802-17 
Jauch R, Cho MK, Jakel S, Netter C, Schreiter K, Aicher B, Zweckstetter M, 
Jackle H, Wahl MC (2006) Mitogen-activated protein kinases interacting kinases 
are autoinhibited by a reprogrammed activation segment. The EMBO journal 
25: 4020-32 
Jauch R, Jakel S, Netter C, Schreiter K, Aicher B, Jackle H, Wahl MC (2005) 
Crystal structures of the Mnk2 kinase domain reveal an inhibitory conformation 
and a zinc binding site. Structure 13: 1559-68 
Jhanwar-Uniyal M, Amin AG, Cooper JB, Das K, Schmidt MH, Murali R (2017) 
Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart 
in cellular and molecular aspects. Adv Biol Regul  
Jiang L, Gu ZH, Yan ZX, Zhao X, Xie YY, Zhang ZG, Pan CM, Hu Y, Cai CP, 
Dong Y, Huang JY, Wang L, Shen Y, Meng G, Zhou JF, Hu JD, Wang JF, Liu 
YH, Yang LH, Zhang F et al. (2015) Exome sequencing identifies somatic 
mutations of DDX3X in natural killer/T-cell lymphoma. Nat Genet 47: 1061-6 
Johnson RW (2002) Sirolimus (Rapamune) in renal transplantation. Curr Opin 
Nephrol Hypertens 11: 603-7 
Johnston S, Pippen J, Jr., Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez 
HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, 
O'Rourke L, Oliva C, Stein S, Pegram M (2009) Lapatinib combined with 
letrozole versus letrozole and placebo as first-line therapy for postmenopausal 
hormone receptor-positive metastatic breast cancer. J Clin Oncol 27: 5538-46 
Jordan VC, Allen KE, Dix CJ (1980) Pharmacology of tamoxifen in laboratory 
animals. Cancer Treat Rep 64: 745-59 
205 
 
Joshi S, Platanias LC (2014) Mnk kinase pathway: Cellular functions and 
biological outcomes. World J Biol Chem 5: 321-33 
Kannan S, Poulsen A, Yang HY, Ho M, Ang SH, Eldwin TS, Jeyaraj DA, 
Chennamaneni LR, Liu B, Hill J, Verma CS, Nacro K (2015) Probing the binding 
mechanism of Mnk inhibitors by docking and molecular dynamics simulations. 
Biochemistry 54: 32-46 
Keating GM (2016) Afatinib: A Review in Advanced Non-Small Cell Lung 
Cancer. Target Oncol 11: 825-835 
Kim YK, Hahm B, Jang SK (2000) Polypyrimidine tract-binding protein inhibits 
translation of bip mRNA. Journal of molecular biology 304: 119-33 
Kittler H, Tschandl P (2018) Driver mutations in the mitogen-activated protein 
kinase pathway: the seeds of good and evil. Br J Dermatol 178: 26-27 
Klann E, Dever TE (2004) Biochemical mechanisms for translational regulation 
in synaptic plasticity. Nat Rev Neurosci 5: 931-42 
Knauf U, Tschopp C, Gram H (2001) Negative regulation of protein translation 
by mitogen-activated protein kinase-interacting kinases 1 and 2. Molecular and 
cellular biology 21: 5500-11 
Komar AA, Hatzoglou M (2011) Cellular IRES-mediated translation: the war of 
ITAFs in pathophysiological states. Cell Cycle 10: 229-40 
Konicek BW, Stephens JR, McNulty AM, Robichaud N, Peery RB, Dumstorf CA, 
Dowless MS, Iversen PW, Parsons S, Ellis KE, McCann DJ, Pelletier J, Furic L, 
Yingling JM, Stancato LF, Sonenberg N, Graff JR (2011) Therapeutic inhibition 
of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E 
phosphorylation and suppresses outgrowth of experimental lung metastases. 
Cancer Res 71: 1849-57 
Kosciuczuk EM, Saleiro D, Kroczynska B, Beauchamp EM, Eckerdt F, Blyth GT, 
Abedin SM, Giles FJ, Altman JK, Platanias LC (2016) Merestinib blocks Mnk 
kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic 
effects in vitro and in vivo. Blood 128: 410-4 
Kozak M (1987) At least six nucleotides preceding the AUG initiator codon 
enhance translation in mammalian cells. Journal of molecular biology 196: 947-
50 
Kozak M (1989) The scanning model for translation: an update. J Cell Biol 108: 
229-41 
Kozak M (1995) Adherence to the first-AUG rule when a second AUG codon 
follows closely upon the first. Proceedings of the National Academy of Sciences 
of the United States of America 92: 2662-6 
Kufareva I, Abagyan R (2008) Type-II kinase inhibitor docking, screening, and 
profiling using modified structures of active kinase states. J Med Chem 51: 
7921-32 
Lai FP, Szczodrak M, Block J, Faix J, Breitsprecher D, Mannherz HG, Stradal 
TE, Dunn GA, Small JV, Rottner K (2008) Arp2/3 complex interactions and actin 
network turnover in lamellipodia. The EMBO journal 27: 982-92 
206 
 
Lai MC, Chang WC, Shieh SY, Tarn WY (2010) DDX3 regulates cell growth 
through translational control of cyclin E1. Molecular and cellular biology 30: 
5444-53 
Lama D, Pradhan MR, Brown CJ, Eapen RS, Joseph TL, Kwoh CK, Lane DP, 
Verma CS (2017) Water-Bridge Mediates Recognition of mRNA Cap in eIF4E. 
Structure 25: 188-194 
Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. 
Cell 149: 274-93 
Lazaris-Karatzas A, Montine KS, Sonenberg N (1990) Malignant transformation 
by a eukaryotic initiation factor subunit that binds to mRNA 5' cap. Nature 345: 
544-7 
Lee AS, Kranzusch PJ, Cate JH (2015) eIF3 targets cell-proliferation 
messenger RNAs for translational activation or repression. Nature 522: 111-4 
Lee AS, Kranzusch PJ, Doudna JA, Cate JH (2016) eIF3d is an mRNA cap-
binding protein that is required for specialized translation initiation. Nature 536: 
96-9 
Lee DF, Kuo HP, Chen CT, Hsu JM, Chou CK, Wei Y, Sun HL, Li LY, Ping B, 
Huang WC, He X, Hung JY, Lai CC, Ding Q, Su JL, Yang JY, Sahin AA, 
Hortobagyi GN, Tsai FJ, Tsai CH et al. (2007) IKK beta suppression of TSC1 
links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130: 
440-55 
Lee JH, Nan A (2012) Combination drug delivery approaches in metastatic 
breast cancer. J Drug Deliv 2012: 915375 
Leeson PD, Springthorpe B (2007) The influence of drug-like concepts on 
decision-making in medicinal chemistry. Nat Rev Drug Discov 6: 881-90 
Levin EG (2005) Cancer therapy through control of cell migration. Curr Cancer 
Drug Targets 5: 505-18 
Li Y, Wang H, Wang Z, Makhija S, Buchsbaum D, LoBuglio A, Kimberly R, Zhou 
T (2006) Inducible resistance of tumor cells to tumor necrosis factor-related 
apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a 
blockade at the death domain function. Cancer Res 66: 8520-8 
Li Z, Sun Y, Qu M, Wan H, Cai F, Zhang P (2017) Inhibiting the MNK-eIF4E-
beta-catenin axis increases the responsiveness of aggressive breast cancer 
cells to chemotherapy. Oncotarget 8: 2906-2915 
Librizzi M, Longo A, Chiarelli R, Amin J, Spencer J, Luparello C (2012) 
Cytotoxic effects of Jay Amin hydroxamic acid (JAHA), a ferrocene-based class 
I histone deacetylase inhibitor, on triple-negative MDA-MB231 breast cancer 
cells. Chem Res Toxicol 25: 2608-16 
Linder P, Jankowsky E (2011) From unwinding to clamping - the DEAD box 
RNA helicase family. Nature reviews Molecular cell biology 12: 505-16 
Lineham E, Spencer J, Morley SJ (2017) Dual abrogation of MNK and mTOR: a 
novel therapeutic approach for the treatment of aggressive cancers. Future Med 
Chem 9: 1539-1555 
207 
 
Lineham E, Tizzard GJ, Coles SJ, Spencer J, Morley S (2018) Synergistic 
effects of inhibiting the MNK-eIF4E and PI3K/AKT/mTOR pathways on cell 
migration in MDA-MB-231 cells. Oncotarget  
Liu B, Liu F (2014) Feedback regulation of mTORC1 by Grb10 in metabolism 
and beyond. Cell Cycle 13: 2643-4 
Liu P, Gan W, Chin YR, Ogura K, Guo J, Zhang J, Wang B, Blenis J, Cantley 
LC, Toker A, Su B, Wei W (2015) PtdIns(3,4,5)P3-Dependent Activation of the 
mTORC2 Kinase Complex. Cancer Discov 5: 1194-209 
Liu P, Gan W, Inuzuka H, Lazorchak AS, Gao D, Arojo O, Liu D, Wan L, Zhai B, 
Yu Y, Yuan M, Kim BM, Shaik S, Menon S, Gygi SP, Lee TH, Asara JM, 
Manning BD, Blenis J, Su B et al. (2013) Sin1 phosphorylation impairs 
mTORC2 complex integrity and inhibits downstream Akt signalling to suppress 
tumorigenesis. Nat Cell Biol 15: 1340-50 
Liu Q, Kirubakaran S, Hur W, Niepel M, Westover K, Thoreen CC, Wang J, Ni J, 
Patricelli MP, Vogel K, Riddle S, Waller DL, Traynor R, Sanda T, Zhao Z, Kang 
SA, Zhao J, Look AT, Sorger PK, Sabatini DM et al. (2012) Kinome-wide 
selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) 
inhibitors and characterization of their binding kinetics. The Journal of biological 
chemistry 287: 9742-52 
Liu Q, Wang J, Kang SA, Thoreen CC, Hur W, Ahmed T, Sabatini DM, Gray NS 
(2011) Discovery of 9-(6-aminopyridin-3-yl)-1-(3-
(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2( 1H)-one (Torin2) as a 
potent, selective, and orally available mammalian target of rapamycin (mTOR) 
inhibitor for treatment of cancer. J Med Chem 54: 1473-80 
Liu T, Li R, Zhao H, Deng J, Long Y, Shuai MT, Li Q, Gu H, Chen YQ, Leng AM 
(2016) eIF4E promotes tumorigenesis and modulates chemosensitivity to 
cisplatin in esophageal squamous cell carcinoma. Oncotarget  
Liu Y, Sun L, Su X, Guo S (2016) Inhibition of eukaryotic initiation factor 4E 
phosphorylation by cercosporamide selectively suppresses angiogenesis, 
growth and survival of human hepatocellular carcinoma. Biomed Pharmacother 
84: 237-243 
Lu C, Makala L, Wu D, Cai Y (2016) Targeting translation: eIF4E as an 
emerging anticancer drug target. Expert Rev Mol Med 18: e2 
Lugowska I, Kosela-Paterczyk H, Kozak K, Rutkowski P (2015) Trametinib: a 
MEK inhibitor for management of metastatic melanoma. Onco Targets Ther 8: 
2251-9 
Lv D, Hu Z, Lu L, Lu H, Xu X (2017) Three-dimensional cell culture: A powerful 
tool in tumor research and drug discovery. Oncol Lett 14: 6999-7010 
Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP (2005) 
Phosphorylation and functional inactivation of TSC2 by Erk implications for 
tuberous sclerosis and cancer pathogenesis. Cell 121: 179-93 
Maag D, Fekete CA, Gryczynski Z, Lorsch JR (2005) A conformational change 
in the eukaryotic translation preinitiation complex and release of eIF1 signal 
recognition of the start codon. Mol Cell 17: 265-75 
208 
 
Maekawa T, Ashihara E, Kimura S (2007) The Bcr-Abl tyrosine kinase inhibitor 
imatinib and promising new agents against Philadelphia chromosome-positive 
leukemias. Int J Clin Oncol 12: 327-40 
Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, 
Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, 
Murphy L, Finan P, Sellers W, Garcia-Echeverria C (2008) Identification and 
characterization of NVP-BEZ235, a new orally available dual 
phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with 
potent in vivo antitumor activity. Mol Cancer Ther 7: 1851-63 
Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N (2006) mTOR, 
translation initiation and cancer. Oncogene 25: 6416-22 
Mamane Y, Petroulakis E, Martineau Y, Sato TA, Larsson O, Rajasekhar VK, 
Sonenberg N (2007) Epigenetic activation of a subset of mRNAs by eIF4E 
explains its effects on cell proliferation. PLoS One 2: e242 
Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC (2002) Identification of 
the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a 
target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 10: 151-62 
Marsden S, Nardelli M, Linder P, McCarthy JE (2006) Unwinding single RNA 
molecules using helicases involved in eukaryotic translation initiation. Journal of 
molecular biology 361: 327-35 
Masuda N, Nishimura R, Takahashi M, Inoue K, Ohno S, Iwata H, Mori Y, 
Hashigaki S, Muramatsu Y, Nagasawa T, Umeyama Y, Toi M (2018) Palbociclib 
in combination with letrozole as first-line treatment for advanced breast cancer: 
A Japanese phase II study. Cancer Sci 109: 803-813 
Maurer G, Tarkowski B, Baccarini M (2011) Raf kinases in cancer-roles and 
therapeutic opportunities. Oncogene 30: 3477-88 
McGranahan N, Swanton C (2015) Biological and therapeutic impact of 
intratumor heterogeneity in cancer evolution. Cancer Cell 27: 15-26 
Menon S, Dibble CC, Talbott G, Hoxhaj G, Valvezan AJ, Takahashi H, Cantley 
LC, Manning BD (2014) Spatial control of the TSC complex integrates insulin 
and nutrient regulation of mTORC1 at the lysosome. Cell 156: 771-85 
Merrick WC (2015) eIF4F: a retrospective. The Journal of biological chemistry 
290: 24091-9 
Meyer KD, Patil DP, Zhou J, Zinoviev A, Skabkin MA, Elemento O, Pestova TV, 
Qian SB, Jaffrey SR (2015) 5' UTR m(6)A Promotes Cap-Independent 
Translation. Cell 163: 999-1010 
Morita M, Gravel SP, Hulea L, Larsson O, Pollak M, St-Pierre J, Topisirovic I 
(2015) mTOR coordinates protein synthesis, mitochondrial activity and 
proliferation. Cell Cycle 14: 473-80 
Morley SJ, Coldwell MJ, Clemens MJ (2005) Initiation factor modifications in the 
preapoptotic phase. Cell Death Differ 12: 571-84 
Nanda JS, Cheung YN, Takacs JE, Martin-Marcos P, Saini AK, Hinnebusch 
AG, Lorsch JR (2009) eIF1 controls multiple steps in start codon recognition 
during eukaryotic translation initiation. Journal of molecular biology 394: 268-85 
209 
 
Napoli I, Mercaldo V, Boyl PP, Eleuteri B, Zalfa F, De Rubeis S, Di Marino D, 
Mohr E, Massimi M, Falconi M, Witke W, Costa-Mattioli M, Sonenberg N, 
Achsel T, Bagni C (2008) The fragile X syndrome protein represses activity-
dependent translation through CYFIP1, a new 4E-BP. Cell 134: 1042-54 
Nepali K, Sharma S, Kumar D, Budhiraja A, Dhar KL (2014) Anticancer hybrids-
-a patent survey. Recent Pat Anticancer Drug Discov 9: 303-39 
Nguyen A, Vessières A, Hillard E, Top S, Pigeon P, Jaouen G (2007) 
Ferrocifens and ferrocifenols as new potential weapons against breast cancer. 
CHIMIA International Journal for Chemistry 61: 716-724 
Niedzwiecka A, Marcotrigiano J, Stepinski J, Jankowska-Anyszka M, Wyslouch-
Cieszynska A, Dadlez M, Gingras AC, Mak P, Darzynkiewicz E, Sonenberg N, 
Burley SK, Stolarski R (2002) Biophysical studies of eIF4E cap-binding protein: 
recognition of mRNA 5' cap structure and synthetic fragments of eIF4G and 4E-
BP1 proteins. Journal of molecular biology 319: 615-35 
Niepmann M (2009) Internal translation initiation of picornaviruses and hepatitis 
C virus. Biochim Biophys Acta 1789: 529-41 
O'Loghlen A, Gonzalez VM, Pineiro D, Perez-Morgado MI, Salinas M, Martin 
ME (2004) Identification and molecular characterization of Mnk1b, a splice 
variant of human MAP kinase-interacting kinase Mnk1. Exp Cell Res 299: 343-
55 
Ocasio CJ, Sansook S, Jones R, Roberts JM, Scott TG, Tsoureas N, Coxhead 
P, Guille M, Tizzard GJ, Coles SJ, Hochegger H, Bradner JE, Spencer J (2017) 
Pojamide: An HDAC3-Selective Ferrocene Analogue with Remarkably 
Enhanced Redox-Triggered Ferrocenium Activity in Cells. Organometallics 36: 
3276-3283 
Oh S, Flynn RA, Floor SN, Purzner J, Martin L, Do BT, Schubert S, Vaka D, 
Morrissy S, Li Y, Kool M, Hovestadt V, Jones DT, Northcott PA, Risch T, 
Warnatz HJ, Yaspo ML, Adams CM, Leib RD, Breese M et al. (2016) 
Medulloblastoma-associated DDX3 variant selectively alters the translational 
response to stress. Oncotarget 7: 28169-82 
Ojha J, Secreto CR, Rabe KG, Van Dyke DL, Kortum KM, Slager SL, Shanafelt 
TD, Fonseca R, Kay NE, Braggio E (2015) Identification of recurrent truncated 
DDX3X mutations in chronic lymphocytic leukaemia. Br J Haematol 169: 445-8 
Orton KC, Ling J, Waskiewicz AJ, Cooper JA, Merrick WC, Korneeva NL, 
Rhoads RE, Sonenberg N, Traugh JA (2004) Phosphorylation of Mnk1 by 
caspase-activated Pak2/gamma-PAK inhibits phosphorylation and interaction of 
eIF4G with Mnk. The Journal of biological chemistry 279: 38649-57 
Oyarzabal J, Zarich N, Albarran MI, Palacios I, Urbano-Cuadrado M, Mateos G, 
Reymundo I, Rabal O, Salgado A, Corrionero A, Fominaya J, Pastor J, Bischoff 
JR (2010) Discovery of mitogen-activated protein kinase-interacting kinase 1 
inhibitors by a comprehensive fragment-oriented virtual screening approach. J 
Med Chem 53: 6618-28 
Palm W, Park Y, Wright K, Pavlova NN, Tuveson DA, Thompson CB (2015) 
The Utilization of Extracellular Proteins as Nutrients Is Suppressed by 
mTORC1. Cell 162: 259-270 
210 
 
Panja D, Kenney JW, D'Andrea L, Zalfa F, Vedeler A, Wibrand K, Fukunaga R, 
Bagni C, Proud CG, Bramham CR (2014) Two-stage translational control of 
dentate gyrus LTP consolidation is mediated by sustained BDNF-TrkB signaling 
to MNK. Cell Rep 9: 1430-45 
Parra-Palau JL, Scheper GC, Wilson ML, Proud CG (2003) Features in the N 
and C termini of the MAPK-interacting kinase Mnk1 mediate its 
nucleocytoplasmic shuttling. The Journal of biological chemistry 278: 44197-204 
Parsyan A, Svitkin Y, Shahbazian D, Gkogkas C, Lasko P, Merrick WC, 
Sonenberg N (2011) mRNA helicases: the tacticians of translational control. 
Nature reviews Molecular cell biology 12: 235-45 
Passmore LA, Schmeing TM, Maag D, Applefield DJ, Acker MG, Algire MA, 
Lorsch JR, Ramakrishnan V (2007) The eukaryotic translation initiation factors 
eIF1 and eIF1A induce an open conformation of the 40S ribosome. Mol Cell 26: 
41-50 
Patel H, Chuckowree I, Coxhead P, Guille M, Wang M, Zuckermann A, Williams 
RS, Librizzi M, Paranal RM, Bradner JE (2014) Synthesis of hybrid anticancer 
agents based on kinase and histone deacetylase inhibitors. MedChemComm 5: 
1829-1833 
Patra M, Gasser G (2017) The medicinal chemistry of ferrocene and its 
derivatives. Nature Reviews Chemistry 1: 0066 
Paul MK, Mukhopadhyay AK (2004) Tyrosine kinase - Role and significance in 
Cancer. Int J Med Sci 1: 101-115 
Pavitt GD, Ron D (2012) New insights into translational regulation in the 
endoplasmic reticulum unfolded protein response. Cold Spring Harb Perspect 
Biol 4 
Peabody DS, Berg P (1986) Termination-reinitiation occurs in the translation of 
mammalian cell mRNAs. Molecular and cellular biology 6: 2695-703 
Pestova TV, Kolupaeva VG, Lomakin IB, Pilipenko EV, Shatsky IN, Agol VI, 
Hellen CU (2001) Molecular mechanisms of translation initiation in eukaryotes. 
Proceedings of the National Academy of Sciences of the United States of 
America 98: 7029-36 
Pestova TV, Lomakin IB, Lee JH, Choi SK, Dever TE, Hellen CU (2000) The 
joining of ribosomal subunits in eukaryotes requires eIF5B. Nature 403: 332-5 
Peter D, Igreja C, Weber R, Wohlbold L, Weiler C, Ebertsch L, Weichenrieder 
O, Izaurralde E (2015) Molecular architecture of 4E-BP translational inhibitors 
bound to eIF4E. Mol Cell 57: 1074-1087 
Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, 
Ferrin TE (2004) UCSF Chimera--a visualization system for exploratory 
research and analysis. J Comput Chem 25: 1605-12 
Phillips A, Blaydes JP (2008) MNK1 and EIF4E are downstream effectors of 
MEKs in the regulation of the nuclear export of HDM2 mRNA. Oncogene 27: 
1645-9 
Pickering BM, Willis AE (2005) The implications of structured 5' untranslated 
regions on translation and disease. Semin Cell Dev Biol 16: 39-47 
211 
 
Podo F, Buydens LM, Degani H, Hilhorst R, Klipp E, Gribbestad IS, Van Huffel 
S, van Laarhoven HW, Luts J, Monleon D, Postma GJ, Schneiderhan-Marra N, 
Santoro F, Wouters H, Russnes HG, Sorlie T, Tagliabue E, Borresen-Dale AL, 
Consortium F (2010) Triple-negative breast cancer: present challenges and new 
perspectives. Mol Oncol 4: 209-29 
Pooggin MM, Ryabova LA (2018) Ribosome Shunting, Polycistronic 
Translation, and Evasion of Antiviral Defenses in Plant Pararetroviruses and 
Beyond. Front Microbiol 9: 644 
Powles T, Wheater M, Din O, Geldart T, Boleti E, Stockdale A, Sundar S, 
Robinson A, Ahmed I, Wimalasingham A, Burke W, Sarker SJ, Hussain S, 
Ralph C (2016) A Randomised Phase 2 Study of AZD2014 Versus Everolimus 
in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer. Eur Urol 
69: 450-6 
Pyronnet S, Imataka H, Gingras AC, Fukunaga R, Hunter T, Sonenberg N 
(1999) Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 
to phosphorylate eIF4E. The EMBO journal 18: 270-9 
Qin X, Jiang B, Zhang Y (2016) 4E-BP1, a multifactor regulated multifunctional 
protein. Cell Cycle 15: 781-6 
Querol-Audi J, Sun C, Vogan JM, Smith MD, Gu Y, Cate JH, Nogales E (2013) 
Architecture of human translation initiation factor 3. Structure 21: 920-8 
Ramon YCS, Castellvi J, Hummer S, Peg V, Pelletier J, Sonenberg N (2018) 
Beyond molecular tumor heterogeneity: protein synthesis takes control. 
Oncogene 37: 2490-2501 
Randall-Demllo S, Chieppa M, Eri R (2013) Intestinal epithelium and autophagy: 
partners in gut homeostasis. Front Immunol 4: 301 
Ray BK, Lawson TG, Kramer JC, Cladaras MH, Grifo JA, Abramson RD, 
Merrick WC, Thach RE (1985) ATP-dependent unwinding of messenger RNA 
structure by eukaryotic initiation factors. The Journal of biological chemistry 
260: 7651-8 
Reich SH, Sprengeler PA, Chiang GG, Appleman JR, Chen J, Clarine J, Eam 
B, Ernst JT, Han Q, Goel VK, Han EZR, Huang V, Hung INJ, Jemison A, 
Jessen KA, Molter J, Murphy D, Neal M, Parker GS, Shaghafi M et al. (2018) 
Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated 
Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 
and 2 (MNK1/2) Inhibition. J Med Chem 61: 3516-3540 
Renna M (2016) Commentary: Overcoming mTOR resistance mutations with a 
new-generation mTOR inhibitor. Front Pharmacol 7: 431 
Richter-Cook NJ, Dever TE, Hensold JO, Merrick WC (1998) Purification and 
characterization of a new eukaryotic protein translation factor. Eukaryotic 
initiation factor 4H. The Journal of biological chemistry 273: 7579-87 
Ring A, Dowsett M (2004) Mechanisms of tamoxifen resistance. Endocr Relat 
Cancer 11: 643-58 
Robichaud N, del Rincon SV, Huor B, Alain T, Petruccelli LA, Hearnden J, 
Goncalves C, Grotegut S, Spruck CH, Furic L, Larsson O, Muller WJ, Miller 
WH, Sonenberg N (2015) Phosphorylation of eIF4E promotes EMT and 
212 
 
metastasis via translational control of SNAIL and MMP-3. Oncogene 34: 2032-
42 
Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, Poulikakos PI, Scaltriti 
M, Moskatel E, Baselga J, Guichard S, Rosen N (2011) mTOR kinase inhibition 
causes feedback-dependent biphasic regulation of AKT signaling. Cancer 
Discov 1: 248-59 
Rodrik-Outmezguine VS, Okaniwa M, Yao Z, Novotny CJ, McWhirter C, Banaji 
A, Won H, Wong W, Berger M, de Stanchina E, Barratt DG, Cosulich S, 
Klinowska T, Rosen N, Shokat KM (2016) Overcoming mTOR resistance 
mutations with a new-generation mTOR inhibitor. Nature 534: 272-6 
Rogers GW, Jr., Lima WF, Merrick WC (2001) Further characterization of the 
helicase activity of eIF4A. Substrate specificity. The Journal of biological 
chemistry 276: 12598-608 
Rosenwald IB, Lazaris-Karatzas A, Sonenberg N, Schmidt EV (1993) Elevated 
levels of cyclin D1 protein in response to increased expression of eukaryotic 
initiation factor 4E. Molecular and cellular biology 13: 7358-63 
Roskoski R, Jr. (2016) Classification of small molecule protein kinase inhibitors 
based upon the structures of their drug-enzyme complexes. Pharmacol Res 
103: 26-48 
Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J (2004) Tumor-promoting 
phorbol esters and activated Ras inactivate the tuberous sclerosis tumor 
suppressor complex via p90 ribosomal S6 kinase. Proceedings of the National 
Academy of Sciences of the United States of America 101: 13489-94 
Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, Taunton J, Sonenberg N, 
Blenis J (2007) RAS/ERK signaling promotes site-specific ribosomal protein S6 
phosphorylation via RSK and stimulates cap-dependent translation. The Journal 
of biological chemistry 282: 14056-64 
Rozen F, Edery I, Meerovitch K, Dever TE, Merrick WC, Sonenberg N (1990) 
Bidirectional RNA helicase activity of eucaryotic translation initiation factors 4A 
and 4F. Molecular and cellular biology 10: 1134-44 
Rozengurt E, Soares HP, Sinnet-Smith J (2014) Suppression of feedback loops 
mediated by PI3K/mTOR induces multiple overactivation of compensatory 
pathways: an unintended consequence leading to drug resistance. Mol Cancer 
Ther 13: 2477-88 
Ruggero D (2013) Translational control in cancer etiology. Cold Spring Harb 
Perspect Biol 5 
Ruggero D, Montanaro L, Ma L, Xu W, Londei P, Cordon-Cardo C, Pandolfi PP 
(2004) The translation factor eIF-4E promotes tumor formation and cooperates 
with c-Myc in lymphomagenesis. Nat Med 10: 484-6 
Ryabova LA, Pooggin MM, Hohn T (2002) Viral strategies of translation 
initiation: ribosomal shunt and reinitiation. Progress in nucleic acid research and 
molecular biology 72: 1-39 
Sabatini DM (2017) Twenty-five years of mTOR: Uncovering the link from 
nutrients to growth. Proceedings of the National Academy of Sciences of the 
United States of America 114: 11818-11825 
213 
 
Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH (1994) 
RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent 
fashion and is homologous to yeast TORs. Cell 78: 35-43 
Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L, 
Sabatini DM (2008) The Rag GTPases bind raptor and mediate amino acid 
signaling to mTORC1. Science 320: 1496-501 
Santag S, Siegel F, Wengner AM, Lange C, Bomer U, Eis K, Puhler F, Lienau 
P, Bergemann L, Michels M, von Nussbaum F, Mumberg D, Petersen K (2017) 
BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression 
and shows potent anti-tumor activity. Cancer Lett 390: 21-29 
Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard 
AL, Sabatini DM (2006) Prolonged rapamycin treatment inhibits mTORC2 
assembly and Akt/PKB. Mol Cell 22: 159-68 
Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and 
regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-101 
Saxton RA, Sabatini DM (2017) mTOR Signaling in Growth, Metabolism, and 
Disease. Cell 169: 361-371 
Scheper GC, Morrice NA, Kleijn M, Proud CG (2001) The mitogen-activated 
protein kinase signal-integrating kinase Mnk2 is a eukaryotic initiation factor 4E 
kinase with high levels of basal activity in mammalian cells. Molecular and 
cellular biology 21: 743-54 
Scheper GC, Parra JL, Wilson M, Van Kollenburg B, Vertegaal AC, Han ZG, 
Proud CG (2003) The N and C termini of the splice variants of the human 
mitogen-activated protein kinase-interacting kinase Mnk2 determine activity and 
localization. Molecular and cellular biology 23: 5692-705 
Sebolt-Leopold JS, English JM (2006) Mechanisms of drug inhibition of 
signalling molecules. Nature 441: 457-62 
Sedrani R, Cottens S, Kallen J, Schuler W (1998) Chemical modification of 
rapamycin: the discovery of SDZ RAD. Transplant Proc 30: 2192-4 
Segovia-Mendoza M, Gonzalez-Gonzalez ME, Barrera D, Diaz L, Garcia-
Becerra R (2015) Efficacy and mechanism of action of the tyrosine kinase 
inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive 
breast cancer: preclinical and clinical evidence. Am J Cancer Res 5: 2531-61 
Sehgal SN, Baker H, Vezina C (1975) Rapamycin (AY-22,989), a new 
antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot 
(Tokyo) 28: 727-32 
Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, 
Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, 
Arribas J, Baselga J (2008) NVP-BEZ235, a dual PI3K/mTOR inhibitor, 
prevents PI3K signaling and inhibits the growth of cancer cells with activating 
PI3K mutations. Cancer Res 68: 8022-30 
Shah OJ, Wang Z, Hunter T (2004) Inappropriate activation of the 
TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, 
and cell survival deficiencies. Curr Biol 14: 1650-6 
214 
 
Shahbazian D, Roux PP, Mieulet V, Cohen MS, Raught B, Taunton J, Hershey 
JW, Blenis J, Pende M, Sonenberg N (2006) The mTOR/PI3K and MAPK 
pathways converge on eIF4B to control its phosphorylation and activity. The 
EMBO journal 25: 2781-91 
Sharma D, Jankowsky E (2014) The Ded1/DDX3 subfamily of DEAD-box RNA 
helicases. Critical reviews in biochemistry and molecular biology 49: 343-60 
Shih JW, Tsai TY, Chao CH, Wu Lee YH (2008) Candidate tumor suppressor 
DDX3 RNA helicase specifically represses cap-dependent translation by acting 
as an eIF4E inhibitory protein. Oncogene 27: 700-14 
Showkat M, Beigh MA, Andrabi KI (2014) mTOR Signaling in Protein 
Translation Regulation: Implications in Cancer Genesis and Therapeutic 
Interventions. Mol Biol Int 2014: 686984 
Shveygert M, Kaiser C, Bradrick SS, Gromeier M (2010) Regulation of 
eukaryotic initiation factor 4E (eIF4E) phosphorylation by mitogen-activated 
protein kinase occurs through modulation of Mnk1-eIF4G interaction. Molecular 
and cellular biology 30: 5160-7 
Siridechadilok B, Fraser CS, Hall RJ, Doudna JA, Nogales E (2005) Structural 
roles for human translation factor eIF3 in initiation of protein synthesis. Science 
310: 1513-5 
Six DA, Dennis EA (2000) The expanding superfamily of phospholipase A(2) 
enzymes: classification and characterization. Biochim Biophys Acta 1488: 1-19 
Slentz-Kesler K, Moore JT, Lombard M, Zhang J, Hollingsworth R, Weiner MP 
(2000) Identification of the human Mnk2 gene (MKNK2) through protein 
interaction with estrogen receptor beta. Genomics 69: 63-71 
Slotkin EK, Patwardhan PP, Vasudeva SD, de Stanchina E, Tap WD, Schwartz 
GK (2015) MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in 
vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue 
sarcoma. Mol Cancer Ther 14: 395-406 
Sonenberg N, Dever TE (2003) Eukaryotic translation initiation factors and 
regulators. Curr Opin Struct Biol 13: 56-63 
Sonenberg N, Hinnebusch AG (2009) Regulation of translation initiation in 
eukaryotes: mechanisms and biological targets. Cell 136: 731-45 
Song J, Takeda M, Morimoto RI (2001) Bag1-Hsp70 mediates a physiological 
stress signalling pathway that regulates Raf-1/ERK and cell growth. Nat Cell 
Biol 3: 276-82 
Soto-Rifo R, Ohlmann T (2013) The role of the DEAD-box RNA helicase DDX3 
in mRNA metabolism. Wiley Interdiscip Rev RNA 4: 369-85 
Soto-Rifo R, Rubilar PS, Limousin T, de Breyne S, Decimo D, Ohlmann T 
(2012) DEAD-box protein DDX3 associates with eIF4F to promote translation of 
selected mRNAs. The EMBO journal 31: 3745-56 
Soto-Rifo R, Rubilar PS, Ohlmann T (2013) The DEAD-box helicase DDX3 
substitutes for the cap-binding protein eIF4E to promote compartmentalized 
translation initiation of the HIV-1 genomic RNA. Nucleic acids research 41: 
6286-99 
215 
 
Spencer J, Mendham AP, Kotha AK, Richardson SC, Hillard EA, Jaouen G, 
Male L, Hursthouse MB (2009) Structural and biological investigation of 
ferrocene-substituted 3-methylidene-1,3-dihydro-2H-indol-2-ones. Dalton Trans: 
918-21 
Spriggs KA, Stoneley M, Bushell M, Willis AE (2008) Re-programming of 
translation following cell stress allows IRES-mediated translation to 
predominate. Biol Cell 100: 27-38 
Stead RL, Proud CG (2013) Rapamycin enhances eIF4E phosphorylation by 
activating MAP kinase-interacting kinase 2a (Mnk2a). FEBS Lett 587: 2623-8 
Stoneley M, Subkhankulova T, Le Quesne JP, Coldwell MJ, Jopling CL, 
Belsham GJ, Willis AE (2000) Analysis of the c-myc IRES; a potential role for 
cell-type specific trans-acting factors and the nuclear compartment. Nucleic 
acids research 28: 687-94 
Stoneley M, Willis AE (2004) Cellular internal ribosome entry segments: 
structures, trans-acting factors and regulation of gene expression. Oncogene 
23: 3200-7 
Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, 
Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, 
Stojanov P, Carter SL, Voet D, Cortes ML, Auclair D, Berger MF, Saksena G, 
Guiducci C et al. (2011) The mutational landscape of head and neck squamous 
cell carcinoma. Science 333: 1157-60 
Stratford JK, Bentrem DJ, Anderson JM, Fan C, Volmar KA, Marron JS, Routh 
ED, Caskey LS, Samuel JC, Der CJ, Thorne LB, Calvo BF, Kim HJ, Talamonti 
MS, Iacobuzio-Donahue CA, Hollingsworth MA, Perou CM, Yeh JJ (2010) A six-
gene signature predicts survival of patients with localized pancreatic ductal 
adenocarcinoma. PLoS Med 7: e1000307 
Stuttfeld E, Aylett CH, Imseng S, Boehringer D, Scaiola A, Sauer E, Hall MN, 
Maier T, Ban N (2018) Architecture of the human mTORC2 core complex. Elife 
7 
Sun M, Song L, Li Y, Zhou T, Jope RS (2008) Identification of an antiapoptotic 
protein complex at death receptors. Cell Death Differ 15: 1887-900 
Tabbi G, Cassino C, Cavigiolio G, Colangelo D, Ghiglia A, Viano I, Osella D 
(2002) Water stability and cytotoxic activity relationship of a series of 
ferrocenium derivatives. ESR insights on the radical production during the 
degradation process. J Med Chem 45: 5786-96 
Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, 
Yang H, De Jesus J, Amzajerdi AN, Zhang Y, Dibble CC, Dan H, Rinkenbaugh 
A, Yong WH, Vinters HV, Gera JF, Cavenee WK, Cloughesy TF et al. (2011) 
Oncogenic EGFR signaling activates an mTORC2-NF-kappaB pathway that 
promotes chemotherapy resistance. Cancer Discov 1: 524-38 
Tanida I, Ueno T, Kominami E (2008) LC3 and Autophagy. Methods Mol Biol 
445: 77-88 
Teo T, Yang Y, Yu M, Basnet SK, Gillam T, Hou J, Schmid RM, Kumarasiri M, 
Diab S, Albrecht H, Sykes MJ, Wang S (2015a) An integrated approach for 
216 
 
discovery of highly potent and selective Mnk inhibitors: Screening, synthesis 
and SAR analysis. Eur J Med Chem 103: 539-50 
Teo T, Yu M, Yang Y, Gillam T, Lam F, Sykes MJ, Wang S (2015b) 
Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses 
proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid 
leukemia cells. Cancer Lett 357: 612-23 
Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, 
Sabatini DM, Gray NS (2009) An ATP-competitive mammalian target of 
rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. The 
Journal of biological chemistry 284: 8023-32 
Thumma SC, Jacobson BA, Patel MR, Konicek BW, Franklin MJ, Jay-Dixon J, 
Sadiq A, De A, Graff JR, Kratzke RA (2015) Antisense oligonucleotide targeting 
eukaryotic translation initiation factor 4E reduces growth and enhances 
chemosensitivity of non-small-cell lung cancer cells. Cancer Gene Ther 22: 396-
401 
Tiwari N, Gheldof A, Tatari M, Christofori G (2012) EMT as the ultimate survival 
mechanism of cancer cells. Semin Cancer Biol 22: 194-207 
Tomoo K, Shen X, Okabe K, Nozoe Y, Fukuhara S, Morino S, Ishida T, 
Taniguchi T, Hasegawa H, Terashima A, Sasaki M, Katsuya Y, Kitamura K, 
Miyoshi H, Ishikawa M, Miura K (2002) Crystal structures of 7-methylguanosine 
5'-triphosphate (m(7)GTP)- and P(1)-7-methylguanosine-P(3)-adenosine-5',5'-
triphosphate (m(7)GpppA)-bound human full-length eukaryotic initiation factor 
4E: biological importance of the C-terminal flexible region. Biochem J 362: 539-
44 
Topisirovic I, Ruiz-Gutierrez M, Borden KL (2004) Phosphorylation of the 
eukaryotic translation initiation factor eIF4E contributes to its transformation and 
mRNA transport activities. Cancer Res 64: 8639-42 
Tothova Z, Kollipara R, Huntly BJ, Lee BH, Castrillon DH, Cullen DE, McDowell 
EP, Lazo-Kallanian S, Williams IR, Sears C, Armstrong SA, Passegue E, 
DePinho RA, Gilliland DG (2007) FoxOs are critical mediators of hematopoietic 
stem cell resistance to physiologic oxidative stress. Cell 128: 325-39 
Truitt ML, Conn CS, Shi Z, Pang X, Tokuyasu T, Coady AM, Seo Y, Barna M, 
Ruggero D (2015) Differential Requirements for eIF4E Dose in Normal 
Development and Cancer. Cell 162: 59-71 
Truitt ML, Ruggero D (2017) New frontiers in translational control of the cancer 
genome. Nat Rev Cancer 17: 332 
Tzivion G, Shen YH, Zhu J (2001) 14-3-3 proteins; bringing new definitions to 
scaffolding. Oncogene 20: 6331-8 
Ueda T, Sasaki M, Elia AJ, Chio, II, Hamada K, Fukunaga R, Mak TW (2010) 
Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and 
Mnk2) delays tumor development. Proceedings of the National Academy of 
Sciences of the United States of America 107: 13984-90 
Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, Fukunaga R (2004) 
Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of 
217 
 
eukaryotic initiation factor 4E but not for cell growth or development. Molecular 
and cellular biology 24: 6539-49 
Valentin-Vega YA, Wang YD, Parker M, Patmore DM, Kanagaraj A, Moore J, 
Rusch M, Finkelstein D, Ellison DW, Gilbertson RJ, Zhang J, Kim HJ, Taylor JP 
(2016) Cancer-associated DDX3X mutations drive stress granule assembly and 
impair global translation. Sci Rep 6: 25996 
Van Der Kelen K, Beyaert R, Inze D, De Veylder L (2009) Translational control 
of eukaryotic gene expression. Critical reviews in biochemistry and molecular 
biology 44: 143-68 
Vartanian R, Masri J, Martin J, Cloninger C, Holmes B, Artinian N, Funk A, 
Ruegg T, Gera J (2011) AP-1 regulates cyclin D1 and c-MYC transcription in an 
AKT-dependent manner in response to mTOR inhibition: role of AIP4/Itch-
mediated JUNB degradation. Mol Cancer Res 9: 115-30 
Vassilev LT (2006) Cell cycle synchronization at the G2/M phase border by 
reversible inhibition of CDK1. Cell Cycle 5: 2555-6 
Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD (2002) 
Molecular properties that influence the oral bioavailability of drug candidates. J 
Med Chem 45: 2615-23 
Vessieres A, Corbet C, Heldt JM, Lories N, Jouy N, Laios I, Leclercq G, Jaouen 
G, Toillon RA (2010) A ferrocenyl derivative of hydroxytamoxifen elicits an 
estrogen receptor-independent mechanism of action in breast cancer cell lines. 
J Inorg Biochem 104: 503-11 
Vezina C, Kudelski A, Sehgal SN (1975) Rapamycin (AY-22,989), a new 
antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation 
of the active principle. J Antibiot (Tokyo) 28: 721-6 
Villa N, Do A, Hershey JW, Fraser CS (2013) Human eukaryotic initiation factor 
4G (eIF4G) protein binds to eIF3c, -d, and -e to promote mRNA recruitment to 
the ribosome. The Journal of biological chemistry 288: 32932-40 
Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, Stewart 
M, Choueiri TK, Gandhi L, Cleary JM, Elfiky AA, Taplin ME, Stack EC, 
Signoretti S, Loda M, Shapiro GI, Sabatini DM, Lander ES, Gabriel SB, Kantoff 
PW et al. (2014) Activating mTOR mutations in a patient with an extraordinary 
response on a phase I trial of everolimus and pazopanib. Cancer Discov 4: 546-
53 
Walker AJ, Wedam S, Amiri-Kordestani L, Bloomquist E, Tang S, Sridhara R, 
Chen W, Palmby TR, Fourie Zirkelbach J, Fu W, Liu Q, Tilley A, Kim G, Kluetz 
PG, McKee AE, Pazdur R (2016) FDA Approval of Palbociclib in Combination 
with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-
Negative Metastatic Breast Cancer. Clin Cancer Res 22: 4968-4972 
Wang Q, Wei F, Li C, Lv G, Wang G, Liu T, Bellail AC, Hao C (2013) 
Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and 
mTORC2 kinase activity and suppresses the progression of colorectal 
carcinoma. PLoS One 8: e73175 
Wang T, Bray SM, Warren ST (2012) New perspectives on the biology of fragile 
X syndrome. Curr Opin Genet Dev 22: 256-63 
218 
 
Wang X, Li W, Williams M, Terada N, Alessi DR, Proud CG (2001) Regulation 
of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. The EMBO 
journal 20: 4370-9 
Waskiewicz AJ, Flynn A, Proud CG, Cooper JA (1997) Mitogen-activated 
protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. The 
EMBO journal 16: 1909-20 
Webb BL, Proud CG (1997) Eukaryotic initiation factor 2B (eIF2B). Int J 
Biochem Cell Biol 29: 1127-31 
Wek RC (2018) Role of eIF2alpha Kinases in Translational Control and 
Adaptation to Cellular Stress. Cold Spring Harb Perspect Biol  
Wells SE, Hillner PE, Vale RD, Sachs AB (1998) Circularization of mRNA by 
eukaryotic translation initiation factors. Mol Cell 2: 135-40 
Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-
Cardo C, Pelletier J, Lowe SW (2004) Survival signalling by Akt and eIF4E in 
oncogenesis and cancer therapy. Nature 428: 332-7 
Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, Watanabe-Fukunaga 
R, Fukunaga R, Teruya-Feldstein J, Pelletier J, Lowe SW (2007) Dissecting 
eIF4E action in tumorigenesis. Genes & development 21: 3232-7 
Wlassoff WA, Albright CD, Sivashinski MS, Ivanova A, Appelbaum JG, Salganik 
RI (2007) Hydrogen peroxide overproduced in breast cancer cells can serve as 
an anticancer prodrug generating apoptosis-stimulating hydroxyl radicals under 
the effect of tamoxifen-ferrocene conjugate. J Pharm Pharmacol 59: 1549-53 
Woo LW, Bubert C, Purohit A, Potter BV (2011) Hybrid dual aromatase-steroid 
sulfatase inhibitors with exquisite picomolar inhibitory activity. ACS Med Chem 
Lett 2: 243-7 
Wu P, Nielsen TE, Clausen MH (2016) Small-molecule kinase inhibitors: an 
analysis of FDA-approved drugs. Drug Discov Today 21: 5-10 
Xie M, Vesuna F, Botlagunta M, Bol GM, Irving A, Bergman Y, Hosmane RS, 
Kato Y, Winnard PT, Jr., Raman V (2015) NZ51, a ring-expanded nucleoside 
analog, inhibits motility and viability of breast cancer cells by targeting the RNA 
helicase DDX3. Oncotarget  
Xie M, Vesuna F, Tantravedi S, Bol GM, Heerma van Voss MR, Nugent K, 
Malek R, Gabrielson K, van Diest PJ, Tran PT, Raman V (2016) RK-33 
Radiosensitizes Prostate Cancer Cells by Blocking the RNA Helicase DDX3. 
Cancer Res 76: 6340-6350 
Yamazaki T, Zaal K, Hailey D, Presley J, Lippincott-Schwartz J, Samelson LE 
(2002) Role of Grb2 in EGF-stimulated EGFR internalization. J Cell Sci 115: 
1791-802 
Yanagiya A, Suyama E, Adachi H, Svitkin YV, Aza-Blanc P, Imataka H, Mikami 
S, Martineau Y, Ronai ZA, Sonenberg N (2012) Translational homeostasis via 
the mRNA cap-binding protein, eIF4E. Mol Cell 46: 847-58 
Yang H, Chennamaneni LR, Ho MWT, Ang SH, Tan ESW, Jeyaraj DA, Yeap 
YS, Liu B, Ong EH, Joy JK, Wee JLK, Kwek P, Retna P, Dinie N, Nguyen TTH, 
Tai SJ, Manoharan V, Pendharkar V, Low CB, Chew YS et al. (2018) 
219 
 
Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 
1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia. J Med Chem 61: 
4348-4369 
Yang H, Rudge DG, Koos JD, Vaidialingam B, Yang HJ, Pavletich NP (2013) 
mTOR kinase structure, mechanism and regulation. Nature 497: 217-23 
Yang HS, Jansen AP, Komar AA, Zheng X, Merrick WC, Costes S, Lockett SJ, 
Sonenberg N, Colburn NH (2003) The transformation suppressor Pdcd4 is a 
novel eukaryotic translation initiation factor 4A binding protein that inhibits 
translation. Molecular and cellular biology 23: 26-37 
Yap TA, Omlin A, de Bono JS (2013) Development of therapeutic combinations 
targeting major cancer signaling pathways. J Clin Oncol 31: 1592-605 
Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. 
Nature reviews Molecular cell biology 2: 127-37 
Zaytseva YY, Valentino JD, Gulhati P, Evers BM (2012) mTOR inhibitors in 
cancer therapy. Cancer Lett 319: 1-7 
Zhang H, Dou J, Yu Y, Zhao Y, Fan Y, Cheng J, Xu X, Liu W, Guan S, Chen Z, 
shi Y, Patel R, Vasudevan SA, Zage PE, Zhang H, Nuchtern JG, Kim ES, Fu S, 
Yang J (2015) mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma 
growth via blocking mTORC signaling. Apoptosis 20: 50-62 
Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J (2006) An allosteric 
mechanism for activation of the kinase domain of epidermal growth factor 
receptor. Cell 125: 1137-49 
Zhao J, Zhai B, Gygi SP, Goldberg AL (2015) mTOR inhibition activates overall 
protein degradation by the ubiquitin proteasome system as well as by 
autophagy. Proceedings of the National Academy of Sciences of the United 
States of America 112: 15790-7 
Zhao L, Mao Y, Zhou J, Zhao Y, Cao Y, Chen X (2016) Multifunctional DDX3: 
dual roles in various cancer development and its related signaling pathways. 
Am J Cancer Res 6: 387-402 
Zhao Z, Wu H, Wang L, Liu Y, Knapp S, Liu Q, Gray NS (2014) Exploration of 
type II binding mode: A privileged approach for kinase inhibitor focused drug 
discovery? ACS Chem Biol 9: 1230-41 
Zheng Y, Jiang Y (2015) mTOR Inhibitors at a Glance. Mol Cell Pharmacol 7: 
15-20 
 
